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Abstract 
Human herpesvirus (HHV) –6A and HHV-6B are unique among herpesviruses in their 
ability to integrate into the telomeres of human chromosomes and be inherited in 
a Mendelian fashion. Based on current data, inherited chromosomally integrated 
HHV-6 (iciHHV-6) is present in 0.5-2% of the UK population. 
There is increasing evidence to suggest that iciHHV-6 is not a dead-end for the 
virus, and that HHV-6 can be excised from the genomes of iciHHV-6-positive 
individuals. It is hypothesised that this excision occurs from the formation of T-
loops between the end of the telomere and the viral telomere like repeats (TLRs). 
T-loops form naturally in a cell as part of the complex that protects the end of 
the chromosomes; however, under certain circumstances these can be excised 
leading to a loss of telomeric repeats from the chromosome and the formation of 
circular, extra-chromosomal telomeric sequence. There is increasing evidence 
that excision can lead to reactivation of the virus and potentially cause disease. 
Our current understanding of the phenotypic associations of iciHHV-6 is based on 
case-reports and case-control studies of individual diseases. The work presented 
in this thesis set out to answer a number of questions regarding the phenotypic 
consequences, and genome dynamics of iciHHV-6. First, the association between 
both exogenously acquired HHV-6 and iciHHV-6 and classical Hodgkin lymphoma 
(cHL) was examined in a case-control study. Whilst exogenously acquired HHV-6 
was significantly associated with cHL the virus was present at low levels in DNA 
extracted from cHL tumours. Virus at such low level was concluded as not having 
a direct role in the pathogenesis of cHL. A case control study of iciHHV-6 and cHL 
revealed no difference in the prevalence of iciHHV-6 amongst cases and controls, 
but identified a single iciHHV-6-positive individual who appeared to have four 
integrated viral genomes. 
Secondly, iciHHV-6 was examined in the Generation Scotland: Scottish Family 
Health Study (GS:SFHS) cohort, in a hypothesis generating study. It was revealed 
the iciHHV-6 was present at a prevalence of 2.7%. Further analysis showed a 
statistically significant difference in the prevalence of iciHHV-6 between 
individuals born in Scotland (2.8%) and England (1.8%). Analysis of disease 
phenotypes revealed potential associations between iciHHV-6 and breast cancer 
in an unrelated subset of the GS:SFHS cohort. Also confirmed was the recent 
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report of an association between iciHHV-6 and angina pectoris. Analysis of other 
variables revealed iciHHV-6-positive females had a lower average Mill Hill 
vocabulary test score than iciHHV-6-negative females; and that iciHHV-6-positivity 
was associated with participation in fewer years of education. 
Thirdly, the iciHHV-6 genome in an LCL generated from an iciHHV-6A-positive 
individual was shown to be dynamic. The gross structure of the HHV-6 genome is 
a unique (U) region flanked by direct repeats (DR) (DR.U.DR).Analysis using droplet 
digital PCR (ddPCR), on DNA extracted at various time points of the LCL culture 
revealed that viral sub-genomic regions were lost in a proportion of cells, which 
coincided with a reduction in population doublings of the culture. At the point of 
reduction of viral copy number, an excess of HHV-6 DRs was noted suggesting that 
only a portion of the viral genome had been lost in these cells. Gradually the viral 
copy number returned to approximately one copy per cell. It is likely this was 
caused by an outgrowth of cells where excision had not occurred. This in vitro 
model demonstrated that whilst excision of iciHHV-6 genomes is possible, it may 
be accompanied by a reduction in cell viability. Loss of HHV-6 genomic regions 
was also examined in 59 iciHHV-6-positive individuals and was infrequent. Only six 
showed some degree of DR loss. Further to this, inheritance of single direct 
repeats was observed in six individuals and two families in the GS:SFHS cohort. A 
novel ddPCR and mathematical model was developed to predict the iciHHV-6 
genome configuration in samples where atypical U:DR ratios were observed. 
Through this, we hypothesise that an iciHHV-6-positive individual who had 4 U 
regions per cell and 5 DR regions per cell, had an integrated HHV-6A genome 
concatemer with the configuration (DR.U)4.DR, and hypothesised that this arose 
from integration of a replication intermediate. 
Finally, phylogenetic analysis of five regions of 26 iciHHV-6 genomes and their 
counterparts in exogenously acquired HHV-6 genomes was performed. There was 
a higher degree of divergence between iciHHV-6A and exogenous HHV-6, along 
with evidence of a common viral ancestor in four iciHHV-6-positive individuals. 
This divergence was not observed in iciHHV-6B were very little variation was 
observed between iciHHV-6B and exogenously acquired HHV-6B. 
These results shed light on the complex relationship between iciHHV-6 and the 
human host. 
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1.1 Herpesviruses 
Herpesviruses are a major group of double-stranded (ds) DNA viruses whose host range 
include mammals, birds, reptiles, amphibians, fish and molluscs. There are currently nine 
known herpesviruses of humans (Table 1-1). A feature of herpesviruses is the relatively 
limited host range of each species; however, host cross-species transmission can occur 
which can result in severe disease (Davison et al., 2009). 
Structurally, there is little variability amongst herpesviruses. The virion is approximately 
200 nm in diameter, and is made up of a T=16 icosahedral capsid, that contains the viral 
genome, surrounded by a proteinaceous tegument. These are further encapsulated in a 
lipid membrane that contains viral surface glycoproteins. The linear dsDNA genome is 
packaged in the capsid of the virion (Davison et al., 2009). A key similarity amongst 
herpesviruses is their ability to persist through the life of a host through means of a latent 
infection. After an initial productive primary infection almost all gene expression is 
suppressed and the viral genome is maintained in the cell nucleus, with replication 
occurring with the host DNA. Upon encountering appropriate stimuli, viral gene expression 
commences and a new productive life cycle can begin. 
 
1.1.1 Herpesvirus classification 
Herpesviruses are members of the viral order Herpesvirales, and belong to three families 
within this: Herpesviridae, Alloherpesviridae and Malacoherpesviridae. Herpesviridae 
includes those of mammals and birds and reptiles; Alloherpesviridae are those of fish and 
amphibians; and the family Malacoherpesviridae include those of bivalve molluscs. The 
family Herpesviridae is further broken down in to three sub-families based on biological 
and genome sequence properties: Alphaherpesvirinae, Betaherpesvirinae and 
Gammaherpesvirinae (Pellett and Roizman, 2013). 
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1.1.1.1 Alphaherpesvirinae 
The members of sub-family Alphaherpesvirinae have a variable host range. In tissue 
culture they are able to infect cells from a range of species but remain restricted in vivo. 
They have relatively short life cycles and in most cases latency occurs in sensory ganglia. 
Alphaherpesvirinae have four genera: Simplexvirus, Varicelloviruses, Iltoviruses, and 
Mardiviruses. Viruses in this sub-family include Herpes Simplex virus (HSV) -1 and HSV-2, 
Equid herpesvirus (EHV) -1 Varicella-zosta virus (VZV), and Gallid herpesvirus 2 and 3, or 
Marek’s disease virus (MDV) (Davison et al., 2009; Pellett and Roizman, 2013). 
 
1.1.1.2 Betaherpesvirinae 
Members of the Betaherpesvirinae sub-family have a restricted host range both in vitro 
and in vivo. Their productive life cycle is longer than that of Alphaherpesvirinae members 
(over seven days). In cell culture, their infection progresses slowly and results in 
enlargement of infected cells. Sites of latency are more variable than Alphaherpesvirinae 
members and, depending on the virus, can occur in secretary glands, lymphoreticular 
cells, kidney cells and various other tissue types. There are four genera in the 
Betaherpesvirinae sub-family: Cytomegalovirus, Muromegalovirus, Proboscivirus and 
Roseolovius. Members of this subfamily include Human cytomegalovirus (HCMV), Murid 
herpesvirus 1 and 2, Elephantid herpesvirus 1, Human herpesvirus (HHV) -6A and HHV-6B 
(which will be the focus of this thesis) and HHV-7 (Davison et al., 2009; Pellett and 
Roizman, 2013). 
 
1.1.1.3 Gammaherpesvirinae 
Members of the sub-family Gammaherpesvirinae have a highly restricted host range that 
is restricted to the family of their natural host. In tissue culture, primary infection can 
be established in lymphoblastoid, epithelial, and fibroblastic cells. In vivo infection is 
usually restricted to lymphocytes. The Gammaherpesvirinae sub-family has four genera: 
Lymphocryptovirus, Macavirus, Percavirus and Rhadinovirus. Members of this sub-family 
include Epstein-Barr virus (EBV), EHV-2, Bovine herpesvirus-6, Kaposi’s sarcoma-
associated virus (KSHV) and Herpesvirus saimiri (Davison et al., 2009; Pellett and Roizman, 
2013). 
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1.1.2 Herpesviruses and disease 
Primary infection with herpesviruses usually occurs early in life leading to no or relatively 
mild, self-limiting disease. Reactivation from latency can result in disease similar to the 
primary infection. Severe disease can result from either primary infection or reactivation 
particularly likely in immunocompromised individuals. Complex disease such as cancers 
are associated with active and latent infections (Davison et al., 2009). The nine HHVs and 
their associated disease are summarised in Table 1-1. 
 
Table 1-1: The nine Human herpesviruses and their most prominent disease associations 
Common 
Name 
Formal 
Name 
Sub-
Family 
Diseases 
HSV-1 HHV-1 
Alpha 
Cold sores, herpatic whitlow, keratitis, encephalitis 
HSV-2 HHV-2 Genital sores/ulceration 
VZV HHV-3 Chicken pox, shingles, encephalitis 
HCMV HHV-5 
Beta 
Mononucleosis, hepatitis, retinitis, colitis, 
pneumonitis, congenital abnormalities 
HHV-6A HHV-6A Encephalitis (others discussed later) 
HHV-6B HHV-6B Exanthema subitum (others discussed later) 
HHV-7 HHV-7 Exanthema subitum 
EBV HHV-4 
Gamma 
Infectious mononucleosis (glandular fever), 
Burkitt’s lymphoma, classical Hodgkin lymphoma, 
nasopharyngeal carcinoma 
KSHV HHV-8 Kaposi’s sarcoma 
 
1.2 Human Herpesvirus 6 - An introduction 
HHV-6 is a member of the Betaherpesvirinae and Roseolovius sub-family and genus of 
herpesviruses, respectively. It was first isolated in 1986 by Salahuddin et al, from 
peripheral blood mononuclear cells (PBMCs) of patients with acquired immune deficiency 
syndrome (AIDS) and lymphoproliferative disorders. It was initially termed human B-
lymphotropic virus (HBLV) due to its observed propensity to infect B-lymphocytes 
(Salahuddin et al., 1986). Further characterisation revealed its relatedness to HHVs as 
well as highlighting many more cells being permissive to infection in vitro, particularly 
those derived from T-lymphocytes, this led to a change in the nomenclature to HHV-6 
(Ablashi et al., 1987; Josephs et al., 1986; Lusso et al., 1987; Takahashi et al., 1989). 
Early studies revealed that the virus existed as two related but distinct variants, HHV-6A 
and HHV-6B (discussed in section 1.3), which have now been classified as two distinct 
herpesviruses (Ablashi et al., 2013; Ablashi et al., 1991; Schirmer et al., 1991; Thomson 
et al., 1994). The existence of HHV-6A and HHV-6B has been known for many years, but 
throughout the literature they are often referred to singularly as HHV-6 without further 
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specification, and this nomenclature will be used if the particular virus is not specified. 
Although it is important to describe which virus is present in a study, HHV-6A and HHV-
6B share many common feature; the viruses will therefore be referred to collectively as 
HHV-6. 
As with most human herpesviruses, infection usually occurs within the first few years of 
life, with the majority of individuals being positive by two years of age (Zerr et al., 2005). 
Positivity for either HHV-6A or HHV-6B is ubiquitous throughout the world; the proportions 
of each virus vary widely depending on the population observed. In the United Kingdom 
(UK) HHV-6B is the predominant variant seen in primary infection, accounting for 97% 
(Ward et al., 2005).  Other western and industrialised countries show a similar bias 
towards HHV-6B, which is observed in France (94%) (Boutolleau et al., 2006), USA (97%) 
(Dewhurst et al., 1993) and Japan (75-87%) (Tanaka-Taya et al., 1996; Yamamoto et al., 
1994). In a Tunisian study of HHV-6 and acute-leukaemia all typed HHV-6-positive samples 
(57/63) were HHV-6B-positive (Faten et al., 2012). Whilst it is important to note this was 
a study of disease, no association was observed and it is possible this represents the 
prevalence of HHV-6B in the underlying population. In contrast, HHV-6A is the 
predominant variant in sub-Saharan Africa. In a study of two paediatric cohorts HHV-6A 
was exclusively present in 86% of individuals. A further 13% of children asymptomatic for 
HHV-6-related disease were HHV-6A and HHV-6B co-infected, bringing the overall HHV-
6A prevalence to 99%. The overall prevalence of HHV-6B was 15% (13% co-infection) (Bates 
et al., 2009). 
A feature unique to both HHV-6A and HHV-6B among human herpesviruses is their ability 
to integrate into the telomeric regions of human chromosomes (Arbuckle et al., 2010; 
Morris et al., 1999). In approximately 0.5-2% of the population this integration is present 
in the germ-line (Geraudie et al., 2012; Huang et al., 2013; Hubacek et al., 2013; Leong 
et al., 2007; Ward et al., 2005). In these individuals the virus is inherited in a Mendelian 
fashion and is termed inherited chromosomally integrated HHV-6 (iciHHV-6) (Daibata et 
al., 1999; Kaufer and Flamand, 2014). Despite its initial description occurring more than 
20 years ago (Luppi et al., 1993), little is understood of the exact mechanism of 
integration into the germ-line or the consequences to the host or virus. The aim of this 
project was to investigate the phenotypic consequences of iciHHV-6 on the host, 
characterise the genomes of integrated viruses, and to develop assays to investigate the 
dynamics of HHV-6 infection in individuals with iciHHV-6. 
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1.3 Human Herpesvirus 6 - Genome structure 
Both HHV-6A and HHV-6B are large double stranded DNA viruses approximately 160 
kilobases (kb) in length. The genome consists of three major units: a unique (U) region of 
approximately 140 kb, flanked by the left and right hand direct repeat (DR) regions of 
approximately 8 kb (Dominguez et al., 1999; Gompels et al., 1995). At the extreme 5’ 
and 3’ ends of the DR region are packaging sequences termed pac1 and pac2, respectively 
(Gompels et al., 1995; Thomson et al., 1994). Between the pac sequences and the coding 
region of the DR are telomere-like repeats (TLRs); the 5’ TLRs are heterogeneous repeats 
of (TTAGGG)n and are designated T1, the 3’ TLRs are perfect repeats of the human 
telomeric repeat (TTAGGG)n and are designated T2 (Gompels and Macaulay, 1995; 
Gompels et al., 1995; Thomson et al., 1994) (Fig. 1-1). Many regions of HHV-6A and HHV-
6B genomes are conserved between the two viruses, with the entire genome having 90% 
sequence homology; however in some regions more divergence is seen (Dominguez et al., 
1999). 
 
 
Figure 1-1: Schematic representation of the HHV-6 genome. The U region is flanked by the DR 
regions. At the 5’ end of each DR is an imperfect repeat of TTAGGG, het(TTAGGG)n. At the 3’ end 
of each DR is the perfect TLR. At the outermost ends of each DR are the pac1 and pac2 sequences. 
The extreme pac1 and pac2 allow circularisation and packaging of the viral DNA during lytic 
infection but may be lost during integration. 
 
1.3.1 Unique region 
There are several characterised strains of HHV-6A and HHV-6B: U1102 (isolated in Uganda) 
and GS (isolated in the USA) are HHV-6A (Downing et al., 1987; Salahuddin et al., 1986), 
and Z29 (isolated from the Democratic Republic of Congo [formally Zaire]) and HST 
(Isolated in Japan) are HHV-6B (Kosuge et al., 1997; Lopez et al., 1988). The U region of 
the HHV-6A and HHV-6B genomes contain the majority of the possible open reading frames 
(ORFs) encoding structural and regulatory viral proteins. The guanine-cytosine (GC) 
content of the HHV-6A and HHV-6B U regions is approximately 40% (Dominguez et al., 
1999; Gompels et al., 1995). 
The complete genome of HHV-6A (U1102) includes 108 distinct ORFs, 100 of which are in 
the U region and are designated U1 to U100. It is unlikely that all encode individual 
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proteins, and the entire genome probably contains 102 protein-coding genes (Gompels et 
al., 1995). Six ORFs of the HHV-6A U region are not conserved in HHV-6B (U1, U61, U78, 
U88, U92 and U93) (Dominguez et al., 1999). The U region of HHV-6B (Z29) contains 119 
ORFs, which correspond to 97 genes; 110 of these have homologues in HHV-6A, with nine 
remaining unique to HHV-6B (named B1-B9) (Dominguez et al., 1999). 
As well as coding sequences, the U region of both HHV-6A and HHV-6B contains the 
minimal lytic origin of replication and internal repeat (IR) regions: R1-R3 in HHV-6A and 
R0, R1, R2A, R2B and R3 in HHV-6B. In HHV-6A R1 consist of repeats similar to the serine-
arginine (SR) domain of the HCMV IE gene; R2 consists of imperfect thymine-guanine (TG) 
dinucleotide repeats; and R3 contains repeated KpnI restriction enzyme recognition sites 
(Gompels et al., 1995; Nicholas and Martin, 1994). R0 is unique to HHV-6B and is located 
in the B4 region; R1 in HHV-6B is similar to that in HHV-6A though with greater sequence 
variability; R2B is analogous to R2 of HHV-6A but much shorter; R3 is similar to that of 
HHV-6A with regions of variability both between HHV-6A and HHV-6B, and between HHV-
6B strains (Dominguez et al., 1999). 
Although HHV-6A and HHV-6B have an overall nucleotide sequence homology of 90%, there 
are regions of markedly more or less variability. The ORF U38 which encodes the viral 
DNA polymerase has 96.2% homology between HHV-6A (U1102) and HHV-6B (Z29), whilst 
the first exon of U91 shares only 76.3% homology (Dominguez et al., 1999; Isegawa et al., 
1999). Phylogenetic analysis comparing more than just the reference strains has been 
conducted on relatively few regions; summaried here are those that have been 
investigated. The ORF U39 encodes glycoprotein B (gB) in both HHV-6A and HHV-6B, the 
coding region is 2,493 base pairs (bp) in length with an expected protein product of 830 
amino acids (Achour et al., 2008). The nucleotide sequence homology between HHV-6A 
and HHV-6B for U39 is 96.4%, with an amino acid sequence homology of 96.1% (Dominguez 
et al., 1999; Isegawa et al., 1999). Achour et al. (2008) showed that phylogenetically 
HHV-6A and HHV-6B could be easily distinguished by the nucleotide sequence of U39. 
Further to this, U39 of clinical isolates of HHV-6B was shown to group into two distinct 
clades (named gB-B1 and gB-B2). The existence of two distinct clades in HHV-6B was also 
supported by analysis of the amino acid sequence. 
ORF U46 codes for glycoprotein N (gN) and shares 96.9% nucleotide and 94.0% amino acid 
sequence homology between HHV-6A and HHV-6B (Isegawa et al., 1999). Bates et al. 
(2009) demonstrated that the nucleotide sequence of U46 could distinguish between HHV-
6A and HHV-6B. 
Glycoprotein O (gO) is encoded in ORF U47 and shares 93.4% nucleotide sequence 
homology between U1102 and Z29. The amino acid sequence homology is lower, only 
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69.8% between U1102 and HST. This is not divergence specific to the HHV-6B HST, as this 
strain has 99.9% homology with Z29 at the amino acid level (Dominguez et al., 1999; 
Isegawa et al., 1999). Bates et al. (2009) showed that nucleotide sequence of U47 can be 
used to distinguish between HHV-6A and HHV-6B; however, in a subset of viruses HHV-6A 
had some ‘HHV-6B like’ residues and vice-versa. The authors speculate that these residues 
may arise from recombination between HHV-6A and HHV-6B as is observed between 
variants of the HCMV. This adds to earlier work that presented evidence for HHV-6A:HHV-
6B U47 ‘chimeric sequence’ (Kasolo et al., 1997). It seems possible, however, that HHV-
6A with ‘HHV-6B-like’ sequences and HHV-6B with ‘HHV-6A-like’ sequences arise from 
random mutations which are maintained as they do not affect the function of gO. Since a 
lack of clear evidence for inter-variant recombination was used as one of many reasons 
to justify HHV-6A and HHV-6B being classified as two distinct viral species (Ablashi et al., 
2013), any evidence of recombination between HHV-6A and HHV-6B raises questions 
regarding this classification. This could be addressed by examining the prevalence of 
‘chimeric sequences’ in geographical regions with diverse HHV-6A and HHV-6B 
prevalence. One caveat to this is that our current understanding of HHV-6A and HHV-6B 
prevalence is based on studies of early primary infection and disease; it is possible HHV-
6A and HHV-6B co-infection could emerge more frequently in later life with increased 
exposure to these viruses. 
ORF U48 encodes glycoprotein H (gH) and has 95.5% and 94.4% nucleotide and amino acid 
sequence homology, respectively between HHV-6A and HHV-6B (Dominguez et al., 1999; 
Isegawa et al., 1999). Similar to U39, phylogenetic analysis demonstrated a clear 
distinction between HHV-6A and HHV-6B, and HHV-6B U48 nucleotide sequences grouped 
into two clades (named gH-B1 and gH-B2); although grouping in a similar pattern the 
variability within clades was reduced compared to U39. The two distinct clades of HHV-
6B were again supported by the gH amino acid sequence, but there was no significant 
commonality between the U39 and U48 groupings (Achour et al., 2008). 
The ORF U83 encodes a viral chemokine that in HHV-6B functions as a chemoattractant 
for monocytes. HHV-6A however, lacks the region which corresponds to the signalling 
peptide of this protein (Sjahril et al., 2009; Zou et al., 1999). The ORF has 92.4% 
nucleotide and 87.5% amino acid sequence homology between HHV-6A and HHV-6B 
(Dominguez et al., 1999; Isegawa et al., 1999). Sjahril et al. (2009) reported that all HHV-
6A U83 nucleotide sequences lacked an appropriate start codon or had incurred a frame 
shift mutation, which effectively removed the signalling peptide sequence. However, 
HHV-6B sequences existed in two forms, one that consisted of the complete, full-length 
sequence in strains Z29 and HST, and another with a shorter signalling peptide. This had 
a bearing on the function of the U83 protein product: the product with the shorter 
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signalling peptide was secreted less efficiently, whilst the product completely lacking the 
signalling peptide was not secreted at all (as was the case with HHV-6A). These 
differences make U83 a candidate ORF for distinguishing between HHV-6A and HHV-6B. 
Tweedy et al. (2014) examined U83 in exogenously acquired HHV-6 and iciHHV-6, and 
found that whilst all exogenous HHV-6A genomes encoded the shortest form of the U83 
protein, 50% of iciHHV-6A genomes encoded the full-length product. For exogenous HHV-
6B, 43% of genomes encoded the full-length U83 product compared to 100% of iciHHV-6B. 
This suggests that the full-length U83 product, or secreted product is not crucial for active 
HHV-6 infection. 
The ORF U90 is made up of three exons and, depending on the splicing pattern with ORFs 
U89 and U86, encodes the IE-1 and IE-2 proteins. Percentage nucleotide homology 
between HHV-6B and HHV-6A ranges from 80.0% to 85.8% whilst the amino acid homology 
of the third exon is 61.6% (Dominguez et al., 1999; Isegawa et al., 1999). Phylogenetic 
analysis of the third (longest) exon of U90 from isolates of HHV-6A and HHV-6B from the 
UK showed HHV-6B U90 sequences forming two distinct clades. One clade included the 
HST reference and the other included Z29, 13/15 grouping with HST and 2/15 with Z29 
(Stanton et al., 2003). All three exons of U90 have been identified as possible latency 
associated transcripts. Kondo et al. (2002) identified four transcripts in latently infected 
macrophages isolated from peripheral blood. Two of these transcripts included all three 
U90 exons plus either one or four extra upstream exons depending on the initial start site 
used. The remaining two transcripts included ORF U86, the first two exons of U90, and 
again either one or four extra exons depending on the start site used. Although all of 
these new transcripts included exons of U90, it was the inclusion of the upstream exons 
that was unique to latency. 
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1.3.2 Direct repeat region 
As mentioned earlier, the DR regions flank the U region of the HHV-6A and HHV-6B 
genomes. At each end of the DR coding region are the TLRs and at the extreme ends are 
the packaging sequences known as pac1 (5’ end) and pac2 (3’ end). The pac1 and pac2 
sequences were identified through their homology with sequences at the ends of HCMV 
and HSV-1, which are involved in packaging genomes into viral particles during the lytic 
stage of infection (Deng and Dewhurst, 1998). 
The coding region of the DR of HHV-6A contains eight ORFs, named DR1-8. Not all of these 
ORFs encode distinct protein products, some appear to be different exons of the same 
coding gene. DR1, DR2, DR6 and DR7 were designated as separate ORFs when first 
described but later DR2 was recognised as the second exon of the DR1 gene; similarly, 
DR7 was identified as the second exon of DR6 (though with some contention). Whilst 
structurally similar the DR region of HHV-6B lacks some of the ORFs observed in HHV-6A, 
namely DR4, DR5 and DR8. Of the ORFs that are unique to HHV-B6 (B1-9) B1, B2 and B3 
are located in the DR region. The nucleotide sequence homology of the shared regions is 
80% to 90%, whilst the amino acid homology is 42.4% to 86.4% with the lowest homology 
in the second exon of DR6 (DR7) (Dominguez et al., 1999; Isegawa et al., 1999). 
Putative functions have been attributed to some of the protein products of the DR region, 
for example DR6 of HHV-6B has been shown to form a complex with the product of the 
viral ORF U41 and together may be involved in viral DNA replication. Borenstein et al. 
(2010) reported a replicating culture of strain U1102 in the T-cell line Sup-T1 that, whilst 
maintaining the pac1 sequence, had lost the T1 TLR and the majority of the DR coding 
region up to and including the first exon of DR6. This suggests that the majority of the DR 
region is not required for efficient viral replication and propagation, at least in vitro. 
 
1.3.3 Telomere-like repeats 
Since the identification of telomere-like sequences flanking the coding sequence of the 
DR region, efforts have been made to determine their function. It has become clear that 
the viral TLRs are crucial for HHV-6A and HHV-6B integration. The importance and 
proposed mechanisms of integration is discussed in section 1.7. 
At the 5’ end of the DRs are the imperfect TLRs, designated het(TTAGGG)n due to their 
heterogeneous nature or the T1 region (nomenclature used in this thesis). The T1 region 
of the 5’ strand of the viral genome is in the opposite orientation to the human telomeric 
repeats. Thomson et al. (1994) found that the imperfect repeats consisted of the motif 
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(TAG/ACC)n.TAGGTC.(TAG/ACCC)n, whilst Gompels & Macaulay (1995) found the 
sequence to be closer to (TAACCC)3.TAGGTC.(TAACCC)3 followed by imperfect repeats of 
the AATCCC telomere repeat. This region in HHV-6A U1102 spans 335 bp. The T1 region in 
HHV-6A strain GS, and HHV-6B strains HST and Z29 are of a similar size (Dominguez et al., 
1999; Gravel et al., 2013a; Isegawa et al., 1999). 
Whilst the T1 regions of the deposited exogenous HHV-6 genomes are short, this does not 
appear to be the case for iciHHV-6 genomes. Huang et al, (2013) examined the T1 region 
of 15 iciHHV-6 genomes and found that they ranged in length from 0.7 to 1.5 kb and 3 to 
9 kb in iciHHV-6A and iciHHV-6B, respectively. The perceived size difference in the T1 
region of integrated and exogenous HHV-6 could simply be due to a lack of accurately 
sized exogenous genomes; however, the full sequenced genome of the exogenous HHV-
6A AJ strain that was recently reported had equally short T1 regions (Tweedy et al., 
2015a). Several possible hypotheses could account for this size discrepancy. First, the 
expansion of the T1 region could facilitate homologous recombination between the 
imperfect TLRs of DRL and the perfect telomeric repeats of the human chromosome. 
Secondly, if iciHHV-6 is excised (see section 1.7.4) it is likely to bring human telomeric 
repeats with it, thus increasing the size of the T1 region. Thirdly, integration occurring 
through only homologous recombination with the perfect TLRs of DRR would result in the 
complete loss of the host telomere. The T1 region of the virus would therefore take on 
the role of the telomere, and there could be a selection pressure for longer T1 regions. 
At the 3’ end of the DR are perfect TLRs in the region termed T2; like the T1 region, the 
telomeric sequences in T2 are in the opposite orientation to the human telomeric repeats 
(Gompels and Macaulay, 1995). The T2 region of both HHV-6A and HHV-6B strains contain 
repeats of the hexanucleotide telomeric sequence (TAACCC)n (Gompels and Macaulay, 
1995; Thomson et al., 1994). Achour et al, (2009) expanded upon this by analysis of both 
laboratory strains and clinical isolates. HHV-6 laboratory strains had more repeating units, 
ranging from 58 to 63, than clinical isolates (15–25 repeats). HHV-6B laboratory strains 
had 27–57 repeats with strain MBE having in excess of 90 repeats (this was an estimate as 
the amplified fragment containing the T2 region was too large for conventional sequence 
analysis). Clinical isolates included 27 to 32 repeats. The significance of the difference 
between the number of repeats in HHV-6A and HHV-6B clinical isolates remains unclear. 
Laboratory strains showed on average higher repeat numbers than clinical isolates. If 
integration and subsequent genome excision is a required for latency and reactivation, 
TLR expansion could occur through the virus picking up human telomeric repeats. 
As mentioned earlier TRLs are crucial for HHV-6 integration into chromosomes, but they 
are not a feature exclusive to HHV-6 among herpesviruses. Better characterisation of TLRs 
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of both integrated and exogenous HHV-6 is required to fully understand the process of 
HHV-6 integration. 
 
1.3.4 Homology to other herpesviruses 
HHV-6A and HHV-6B are members of the herpesvirus genus Roseolovirus, in the subfamily 
Betaherpesvirus. Early after being discovered HHV-6 was described as closely related to 
HCMV (Efstathiou et al., 1988; Lawrence et al., 1990). Of the genes in HHV-6A strain 
U1102, 67% have homologues in HCMV including the major capsid protein, which has 43.8% 
amino acid sequence identity with the HCMV counterpart (Gompels et al., 1995; Littler 
et al., 1990). HHV-7 has an even greater degree of homology with HHV-6; however, 
divergent regions are present including the terminal repeats of HHV-7 and the DR regions 
of HHV-6. One gene missing from HCMV and HHV-7 is the U94 ORF, which encodes the 
putative HHV-6 integrase (Nicholas, 1996). 
The TLRs of HHV-6 are a crucial region for integration of the virus into human 
chromosomes; however, they are not unique to HHV-6. They are present in the terminal 
repeat regions of the avian herpesvirus, MDV, where they are also important for viral 
integration (discussed in section 1.7.5). TLRs are also found in numerous other 
herpesviruses that do not seem to integrate into host telomeres. Like HHV-6, HHV-7 
possesses DR regions flanking the U region. Both the 5’ and 3’ TLRs of the DR region of 
HHV-7 contain perfect repeats of (TAACCC)n interspersed with imperfect repeats. The 5’ 
TLRs are notably shorter than those of HHV-6 (Secchiero et al., 1995). TLRs have also 
been identified in equine herpesvirus genomes (Secchiero et al., 1995). TLRs are not 
confined to herpesviruses of mammals and birds and have been identified in members of 
the Alloherpesviridae. TLRs have been identified in Cyprinid herpesvirus (CyHV) -1, -2 
and -3 whose hosts include carp, Kio and goldfish. Like the above examples, the TLRs are 
located at the genomic termini, flanking repeat regions, and contain repeats of the 
hexamer (TTAGGG)n. Of these three viruses the TLRs of CyHV1 are the longest (Davison 
et al., 2013). 
 
1.4 Human Herpesvirus 6 - Cellular tropism 
Though initially described as a B-lymphocyte tropic virus, the main cell to be infected by 
HHV-6 are CD4 positive (CD4+) T-lymphocytes (Lusso et al., 1988; Lusso et al., 1987; 
Salahuddin et al., 1986; Takahashi et al., 1989). Both HHV-6A and HHV-6B are able to 
utilise the cellular complement receptor CD46 as a receptor for infection (Santoro et al., 
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1999); however, recently CD134 (also known as OX40) —a member of the tumour necrosis 
factor (TNF) family— was identified as a specific receptor for HHV-6B (Tang et al., 2013; 
Tang et al., 2014). 
HHV-6A and HHV-6B are able to infect a wide array of cells in vitro. As well as CD4+ T-
lymphocytes, HHV-6A is able to productively infect CD8+ T-lymphocytes (Grivel et al., 
2003). HHV-6A and HHV-6B are both able to infect JJHANS; HHV-6A is able to productively 
infect HSB-2 cells (CD4-), whilst HHV-6B can infect Molt-3 cells (CD4+); all of a T-cell 
origin. With varying degrees of efficiency, HHV-6A and HHV-6B are also able to infect 
Natural Killer (NK) cells (Lusso et al., 1993), gamma/delta T-Lymphocytes (Lusso et al., 
1995), dendritic cells (Kakimoto et al., 2002), oligodendrocytes and microglia (Ahlqvist 
et al., 2005; Albright et al., 1998), astrocytes (Ahlqvist et al., 2006; Donati et al., 2005; 
He et al., 1996), mesenchymal stroma stem cells (Avanzi et al., 2013), and umbilical vein 
endothelial cells (Wu and Shanley, 1998). In vitro latent infection has been demonstrated 
in monocytes and macrophages (Kondo et al., 1991), oligodendrocytes (Ahlqvist et al., 
2005), and latent infection has been detected ex vivo in early bone marrow progenitors 
(Luppi et al., 1999). 
Both HHV-6A and HHV-6B infection have a broad tissue range in vivo. HHV-6A is neuro-
tropic, an important difference between the two viruses. As well as the brain, other 
tissues that can be infected include tonsils, lymph nodes, kidneys and the liver (Donati et 
al., 2003; Harma et al., 2003; Merlino et al., 1992; Roush et al., 2001). 
  
1.5 Human Herpesvirus 6 - Natural history 
As has already been discussed infection with HHV-6A and HHV-6B usually occurs in early 
childhood with transmission occurring through the oral route. The natural history of HHV-
6 infection consists of primary acquisition and lytic infection, establishment of a non-
productive latent infection, reactivation, and dissemination of the virus to a new host.  
HHV-6 gains entry into a cell by the association of the viral-membrane glycoprotein 
complex and the cellular receptor. In the case of HHV-6A that receptor is CD46, and for 
HHV-6B CD134 (possibly in conjunction with CD46). Upon entry into the cytoplasm the 
viral membrane is lost and the capsid migrates to the nucleus where it is disassembled. 
HHV-6 gene expression occurs in a temporal manner. Immediate early (IE) gene products 
regulate gene expressions, early (E) genes encode products needed for genome 
replication such as the viral polymerase, and late (L) genes encode structural components 
of the viral particle (Yamanishi et al., 2013). 
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The viral genome replication begins during the phase of early gene expression. Replication 
is initiated from the origin of replication, oriLyt, and requires viral proteins such as the 
viral polymerase, its processivity factor, and a helicase-primase complex (Yamanishi et 
al., 2013). Replication of the viral genome generates head-to-tail concatemers of variable 
length and circular genomic monomers or oligomers. Only 5% of packaged viral genomes 
in infecting virions are circularised, and these are suggested to act as a template for 
replication through rolling-circle amplification. Unlike HSV-1 (the prototype example) the 
replication intermediates are not highly branched suggesting the mechanism may be 
different (Severini et al., 2003). The viral concatemers are separated into single genomic 
units by cleavage at the junction between the packaging sequences (pac1-x-pac2) (Deng 
and Dewhurst, 1998; Thomson et al., 1994). 
Replication, assembly of the viral capsid, and packaging of the viral genome monomers 
occur in the cell nucleus, and can be seen only three days after infection. The capsid 
migrates to the cytoplasm where it gains its associated tegument. Viral glyocoproteins 
accumulate in the annulate lamellae and it is here and at the golgi that the viral-envelope 
is presumed to be gained. Mature virions are released from the cell by exocytosis and 
through cell lysis (Yamanishi et al., 2013). 
As with all herpesviruses HHV-6 is able to enter a latent phase, persisting through the life 
of the host. With certain stimuli the virus is able to reactivate and re-enter a lytic phase 
marked by the production of infectious viral particles. During latency the majority of 
herpesviruses are maintained as a circular episome tethered to the host cell chromosomes 
by proteins such as EBNA-1 in the case of EBV, and LANA-1 in the case of KSHV (Rajcani 
and Kudelova, 2003). There is no formally defined latent state of HHV-6. It is possible 
that the virus is maintained as an integrated genome. Indeed Arbuckle et al. (2010), using 
pulse-field gel electrophoresis (PFGE) on DNA from iciHHV-6-positive PBMCs, were only 
able to identify viral DNA in the high molecular weight fraction, suggesting integrated 
virus but no viral episomes. PFGE has also been used to show that in cervical carcinoma 
cell lines latent HHV-6 is maintained as a circular episome (Chen et al., 1994). 
The major latency-associated viral factor is the protein product of ORF U94. This ORF, 
which encodes a 490 amino acid protein, is present in both HHV-6A and HHV-6B and shares 
96.5% DNA sequence and 98.4% amino acid sequence homology between U1102 and Z29 
strains (Dominguez et al., 1999; Isegawa et al., 1999). The RNA has been described as a 
latency associated transcript in PBMCs (Rotola et al., 1998). T-lymphocytes stably 
expressing U94 were permissive for HHV-6A infection but did not produce observable 
cytopathic effects, and reduced genome replication and viral transcription (Caselli et al., 
2006).  U94 also has further transcription regulatory functions (Thomson et al., 1994). 
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Other latency associated transcripts have been identified such as U90 (discussed in section 
1.3.1). 
 
1.6 Human Herpesvirus 6 - Disease Associations 
By two years of age most people are seropositive for either HHV-6A or HHV-6B, which is 
transmitted mainly through saliva from mother to child. Primary infection is usually 
subclinical; however, HHV-6B is the aetiological agent of exanthema subitum (ES) a 
disease usually observed in young children that presents with high fever followed by a 
rash (Yamanishi et al., 1988). In rare cases, primary infection with HHV-6A or HHV-B can 
lead to other, more severe symptoms including: seizures; meningoencephalitis and 
encephalitis; respiratory tract symptoms; gastrointestinal symptoms; hepatitis; infectious 
mononucleosis-like symptoms; and myocarditis (De Bolle et al., 2005). 
Symptomatic reactivation in immunocompetent individuals is rare; however, reactivation 
of HHV-6A or HHV-6B can result in similar outcomes to primary infection particularly in 
the immunocompromised. One such example is in transplant recipients. The frequency of 
reactivation of HHV-6 in transplant recipients varies widely in reports ranging from 20% 
to 80% (De Bolle et al., 2005; Kong et al., 2013). Clinical signs and symptoms such as those 
already mentioned above occur in an estimated 1% of transplant recipients (Cervera et 
al., 2006; Kong et al., 2013). HHV-6 reactivation is also associated with drug-induced 
hyposensitivity syndrome (DIHS). DIHS is a severe reaction occurring after administering 
a range of drugs which manifests as rash, fever, eosinophilia, and lymphadenopathy 
(Cacoub et al., 2011; Gentile et al., 2010; Shiohara et al., 2007; Tohyama et al., 1998). 
Though associated with HHV-6, the exact role of viral reactivation in DIHS remains 
unclear. Chronic fatigue syndrome, although a disease long suggested to be associated 
with HHV-6, in one recent study was shown to not be associated with HHV-6 antibody 
seropositivity (Burbelo et al., 2012). 
There is increasing evidence that HHV-6 may be involved in the pathogenesis of multiple 
sclerosis (MS), a demyelinating disease of the central nervous system (CNS). HHV-6 DNA 
and mRNA expression have been detected in MS lesions, but not the surrounding white 
matter (Cermelli et al., 2003; Leibovitch and Jacobson, 2014). There is also both an 
increased seroprevalence and titres of antibodies to HHV-6 U94, and HHV-6 specific 
antibodies have been identified in the CSF of MS patients (Caselli et al., 2002; Virtanen 
et al., 2011). Whilst there is evidence for an association between HHV-6 and MS the role 
of the virus in disease pathogenesis remains unclear. Another disease that has been 
hypothesised to be associated with HHV-6 is classical Hodgkin lymphoma, and this is one 
of the focuses of this thesis. 
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1.6.1 Hodgkin lymphoma 
Hodgkin Lymphoma (HL) is one of the most common lymphomas of humans (Roman and 
Smith, 2011). It is characterised by the presence of large multi-nucleated Reed-Sternberg 
(RS) cells, and mono-nuclear equivalents termed Hodgkin (H) cells. These cells are 
clonally related and derived from B-lymphocytes, and collectively referred to as H/RS 
cells. Whilst H/RS cells are the characteristic tumour cells, they account for only 1% of 
the cells present in a tumour, the remainder are infiltrating cells of the immune system 
including CD4+ T-lymphocytes and macrophages (Chan, 2001; Kuppers, 2009; Roman and 
Smith, 2011). HL can be divided into two groups: classical HL (cHL), which accounts for 
95% of cases, and nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL). Classical 
HL can be further divided into four types: nodular sclerosing (NS); mixed cellularity (MC); 
lymphocyte rich (LR); and lymphocyte depleted (LD). 
EBV is the causative agent of a subset of cHL cases (Glaser et al., 1997; Jarrett et al., 
1996; Jarrett et al., 1991). In these cases, the virus is present in every H/RS cell within a 
tumour and the latent membrane proteins (LMP) 1 and 2A are expressed and thought to 
play a direct role in pathogenesis. LMP2A mimics the activated form of the B-cell receptor 
and can provide survival and proliferation signals (Caldwell et al., 2000; Mancao and 
Hammerschmidt, 2007). LMP1 mimics CD40 and activates several signalling pathways 
including the NF-κB pathway, generating an anti-apototic effect (Devergne et al., 1998). 
EBV-positive cases account for only 33% of cases within the UK and have a peak incidence 
in late adult life (Jarrett et al., 2003). EBV-negative cases have a peak incidence between 
the ages of 15 and 34 years. This peak in young adults is seen only in industrialised 
countries and is associated with a high standard of living in early childhood. This has led 
to the hypothesis that these cases may be due to late exposure to a common infectious 
agent (Chang et al., 2004). One such hypothesised infectious agent is HHV-6. 
Clark et al. (1990) carried out one of the first investigations into HHV-6 and HL in 1990. 
They demonstrated that there is both an increased viral seroprevalence and HHV-6 
antibody titre in cases of HL compared to controls. Our unpublished data also show that 
there is an increase in seroprevalence and antibody titre in cases of EBV-negative cHL 
when compared to age-matched EBV-positive cases. Torelli et al. (1991) demonstrated 
an increased HHV-6 antibody titre in HL patients compared to controls and highlighted 3 
HL patients who had HHV-6 DNA identified in tumour samples by Southern blot analysis, 
compared to none of the non-HL cases. The frequency of detection of HHV-6 in tumour 
samples range from 0 to 79% (Armstrong et al., 1998; Collot et al., 2002; Gallagher et al., 
2002; Lacroix et al., 2010; Lacroix et al., 2007; Torelli et al., 1991; Valente et al., 1996). 
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If HHV-6 were to play a direct role in the pathogenesis of cHL, it would likely be found in 
all H/RS cells within a tumour, as is seen with EBV. In 1996 Valente et al. showed 73% of 
52 HL tumours were positive for HHV-6 DNA by PCR, although the viral genome was 
present at a low level, as Southern blot analysis of tumour DNA did not detect viral DNA. 
In situ hybridisation (ISH) for HHV-6 DNA found 82.4% of 57 HL samples were positive for 
the virus; however, the viral DNA was detected only in infiltrating cells and not H/RS 
cells. It was also noted that the presence of HHV-6 did not correlate with any clinical 
parameters, such as outcome (Valente et al., 1996). Immunohistochemistry (IHC) allows 
the detection of viral antigens within a tumour sample and provides another means of 
investigating viral localisation. IHC for p101K, gp106 and gp116 —all late viral antigens— 
found only a few cells positive for p101K and gp106 in each of 15 HL cases; again all of 
the positive cells were reactive infiltrating cells. IHC for the p41 early antigen showed 
rare staining of infiltrating cells; two HL cases, which had viral DNA detectable by 
Southern blot analysis, had HHV-6-positive ‘mummified’ H/RS cells, cells that have 
undergone apoptosis before the fixing and staining procedures (Valente et al., 1996). In 
2010 Lacroix et al. detected HHV-6B positive H/RS cells through IHC for the DR7B protein. 
They examined 38 cHL biopsies that were positive for HHV-6B by PCR, 28 of these 38 
(73.7%) had H/RS cells positive for DR7B by detection with a fluorescently labelled 
antibody. However, 39.3% (11/28) also had infiltrating cells positive for DR7B and 32.1% 
(9/28) of the H/RS-DR7-positive cases displayed ‘mummified’ DR7B-positive H/RS cells. 
In all 38 HHV-6B-positive cases, infiltrating cells were positive for the gp16/64/54 
complex of late antigens and 15 of the 38 samples had H/RS cells positive for this 
complex. Whilst this work suggested for the first time that H/RS cells can be positive for 
HHV-6B, these results should be interpreted cautiously. First, DR7 was detected using 
polyclonal antisera, produced by the group for this study, and antibody specificity was 
not verified. To ensure that these were not false positive results either ISH for the viral 
DNA or IHC for other viral antigens present at the same stage of infection as DR7B or 
single cell PCR on microdissected H/RS cells should have been performed to confirm the 
presence of the virus. Secondly, the presence of late viral antigens in the infiltrating cells 
of all samples, along with their presence in some H/RS cells and in ‘mummified’ H/RS 
cells, suggests that active infection is present in the tumours. This is unlikely to be 
involved in the development of cHL. Lacroix et al. also examined the possible function of 
DR7, and suggested it can interact with p53 and therefore contribute to the pathogenesis 
of cHL. Again this must be interpreted with caution given the use of the yeast-two-hybrid 
system and transfection based experiments. It is well documented in the literature that 
both of these techniques can produce false positive results. Although these data do not 
provide convincing evidence for a direct role for HHV-6 in cHL they do suggest that active 
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infection can occur in cHL tumours and that HHV-6B may be capable of infecting H/RS 
cells. 
More recently Siddon et al. (2012) found 87% (27/31) of biopsy samples of the NS subtype 
of cHL were positive for HHV-6, and though qPCR was not used, the virus load varied 
greatly. Whilst the percentage of HHV-6-positive cases was high, this frequency was not 
dissimilar to that observed in non-neoplastic lymphoid tissue (83%).  Siddon et al, also 
demonstrated HHV-6-positive IHC staining of H/RS cells, this time with an antibody raised 
to whole virus lysate (WVL). To further demonstrate the presence of HHV-6, laser 
microdissection (LMD) was used to isolate and pool H/RS cells. PCR targeting the viral U94 
gene showed a significant enrichment of HHV-6 DNA within the microdissected cells 
compared to whole tumour tissue. The authors clearly demonstrate the presence of HHV-
6 DNA and antigens in H/RS cells in several NS cHL biopsies, and conclude that HHV-6 may 
have a role in the pathogenesis of cHL. The lack of a difference in HHV-6 prevalence in 
NS cHL tissue and non-neoplastic controls could make a direct role unlikely, though the 
control sample set was small. As is the case with EBV, if HHV-6 is directly causative it 
would be expected to be present in all H/RS cells and be clonal. IHC staining targeted 
multiple viral antigens, including p41, p98, U94 and the antibody raised to WVL. The exact 
target of the latter antibody is unknown, but is likely to be one of the more abundant 
proteins present in the viral particle such as the capsid or tegument. The results are 
therefore consistent with a lytic infection of H/RS cells in some cases. 
Rather than being directly involved in the pathogenesis of cHL, HHV-6 could simply be 
present and possibly reactivated in cells in the tumour microenvironment. One possible 
mechanism is reactivation of HHV-6 in association with high levels of the chemokine, 
thymus, and activation regulated chemokine (TARC) or CCL17. TARC is up regulated in 
H/RS cells as well as being present at high levels in the serum of cHL patients (Kuppers 
et al., 2003; Niens et al., 2008; van den Berg et al., 1999). DIHS is also associated with 
high TARC levels and is associated with HHV-6 reactivation. Ogawa et al. (2014) found 
serum TARC levels were significantly up regulated in DIHS compared to other 
hypersensitivity diseases. Further to this, they demonstrated that serum TARC levels were 
significantly higher in DRESS/DIHS patients with HHV-6 reactivation compared to those 
without reactivation. If high TARC levels can influence HHV-6 reactivation it may lead to 
active replication of the virus in the tumour, and could lead to higher HHV-6 antibody 
titres. Active replication could also be facilitated by the immunosuppressive nature of 
the cHL tumour microenvironment (Scott and Steidl, 2014). 
The evidence for and against a role for HHV-6 in the pathogenesis of cHL remains 
contradictory. On the one hand the virus is present with relative frequency in cHL biopsies 
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and is present in H/RS cells. On the other, when tested the viral loads vary greatly, 
suggesting the virus cannot be present in all H/RS cells in all cases. 
 
1.7 Inherited chromosomally integrated Human Herpesvirus 6 
A unique characteristic of HHV-6 among human herpesviruses is targeted integration into 
the human genome, specifically into telomeres. When the first cases of chromosomally 
integrated HHV-6 were described it was thought that a targeting mechanism was unlikely 
and that the virus would integrate randomly into the genome, possibly resulting in clonal 
expansion (Luppi et al., 1993). However, it is now known that this is not the case and the 
virus is always present within the telomeres. It is likely that integration is achieved 
through homologous recombination with telomeric like repeats within the HHV-6A and 
HHV-6B genomes. 
The first suggestion that HHV-6 can integrate into the human genome came from Luppi 
et al. in 1993. They presented three cases where HHV-6 was found integrated into the 
DNA of PBMCs. Two of these cases had lymphoproliferative disorders, HL and non-HL of B 
cell lineage, and one case had MS. None of the cases had signs of an active HHV-6 infection 
and all were negative for IgM antibodies (Luppi et al., 1993). HHV-6 latently infected cells 
can be detected in PBMCs from an individual following primary infection, but these 
positive cells are usually detected at low level (Clark et al., 1996). However, in the three 
cases described by Luppi et al. (1993) a high viral genome load was seen in uncultured 
PBMCs. To investigate these cases further, PFGE was used to examine the state of the 
viral genomes and compare them to those in an infected cell line. In the cell-line, free 
viral genomes were seen persisting but this pattern was not observed in the three cases. 
Restriction enzyme digestion and Southern blot analysis revealed only fragments that 
were larger than the viral genome consistent with virus integrated into the human genome 
(Luppi et al., 1993). In 1995 the same group identified the chromosomal arm into which 
HHV-6 was integrated, and showed that the virus was variant B in the three cases. 
Fluorescent in situ hybridisation (FISH) analysis of metaphase chromosomes of PBMCs 
identified that the virus was integrated into the short arm of chromosome 17 (Torelli et 
al., 1995). Further to this, fine mapping of one of the non-HL cases suggested that the 
virus was integrated into the telomeric region of 17p (Morris et al., 1999). In 2010, 
Arbuckle et al reported both HHV-6 integration in human subjects and cell lines, and 
integration sites on several chromosomes. Crucially they were able to sequence the DRR 
and sub-telomeric junction of a 17p integration and this showed loss of the external 
packaging sequence, pac2 (Arbuckle et al., 2010). The importance of loss of pac2 will be 
discussed later. 
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1.7.1 Transmission 
In 1997, Bandobashi et al. described an EBV-negative case of Burkitt’s lymphoma (BL) in 
a Japanese female. The tumour cells were positive for HHV-6 and the virus persisted in a 
cell-line established from them (Bandobashi et al., 1997). Further investigation of this 
‘Katata’ cell-line revealed integrated HHV-6 at chromosome 22q13 (Daibata et al., 
1998c). When Diabata et al. (1999) investigated the BL patient and her family further, 
they identified HHV-6 in the blood of the BL patient and showed that HHV-6 was 
integrated in the PBMCs at 22q13. Next they examined the asymptomatic husband; 
surprisingly FISH analysis of PBMCs showed HHV-6 integrated at 1q44. When their daughter 
was examined she was positive for integrated HHV-6 at the same two loci. This was the 
first described case of inheritance of integrated HHV-6 (Daibata et al., 1999). The 
discovery of germ-line transmitted HHV-6 lead to the hypothesis that viral genomes must 
be present in all somatic and half of the germ cells of an individual who inherits it. 
Tanaka-Taya et al. (2004), further examined the inheritance of integrated HHV-6, 
identifying five individuals with a high viral copy number in DNA from PBMCs. They 
examined samples from family members of these individuals, and identified a further five 
with high viral loads in DNA samples from multiple locations. These five additional new 
individuals came from four of the examined families; four were parents of the original 
individuals, and one was a sibling, suggesting Mendelian-like autosomal inheritance. In 
addition, FISH was performed on two of these families and HHV-6 integration into the q-
arm of chromosome 22 was confirmed (22q13) (Tanaka-Taya et al., 2004). From these 
initial reports and subsequent investigations it has become clear that the integrated HHV-
6 is transmitted through the germ-line (Arbuckle et al., 2010; Huang et al., 2013). Large 
studies, investigating families across multiple generations are required to address 
whether iciHHV-6 inheritance is truly Mendelian or if there is selection pressure for or 
against integration, in general or on specific chromosomes. 
 
1.7.2 Prevalence 
Once the possibility of germ-line transmission of chromosomally integrated HHV-6 had 
been suggested several large scale studies of integration of HHV-6 and the prevalence of 
iciHHV-6 were performed. In a study of over 7,000 PBMC samples from over 2,000 
Japanese patients referred for HHV-6 screening, Tanaka-Taya et al. (2004) assessed the 
prevalence of iciHHV-6. The premise that germ-line transmission of integrated HHV-6 
would result in the presence of HHV-6 in all cells of the body and therefore a high viral 
load in PBMC samples taken on multiple occasions, was used as a marker of iciHHV-6. Of 
the cases with a viral load higher than 103 genome copies per 105 PMBCs, five had 
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constantly high levels. High viral loads were then also found in family members of these 
cases. Two of these families were found to have iciHHV-6 at 22q13. In this study the 
prevalence of iciHHV-6 was 0.21% (Tanaka-Taya et al., 2004). This proof of concept, i.e. 
that high viral load could be used as a marker for iciHHV-6, was crucial and provided a 
screening method. Studies that have used this method or that have included a 
quantitative analysis and/or a confirmatory analysis (such as FISH or droplet digital PCR) 
are summarised in Table 1-2 along with the reported prevalence. One notable study 
excluded from Table 1-2 is that of Hall et al, (2004); although this study included 5638 
cord blood samples with an HHV-6 prevalence of 1%, the screening method used was 
nested PCR. Due to the sensitivity and qualitative nature of nested PCR it is questionable 
if iciHHV-6 could be distinguished from other forms of HHV-6 infection. 
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Table 1-2: Studies investigating iciHHV-6 prevalence in various populations 
Study Location Key study features 
Sample 
size 
Prevalence 
(%) 
Torelli et al. (1995)    Italy 
Non-Hodgkin lymphoma, 
Hodgkin lmphoma and 
multiple sclerosis patients 
150 2.0 
Clark et al. (1996)    UK Healthy 25 4.0 
Griffiths et al. 
(1999)    
UK Liver transplant recipients 60 5.0 
Kidd et al. (2000)    UK Renal transplant recipients 52 1.9 
Tanaka-Taya et al. 
(2004)    
Japan 
Patients referred with 
suspected 
reactivation/primary infection 
of HHV-6 
2332 0.21 
Ward et al. (2005)    
UK & Ireland 
England & Wales 
Children’s encephalitis survey 
Serum bank 
184 
653 
3.3 
1.5 
Leong et al. (2006)    UK 
Blood donors 
Screened for transplant or 
related symptoms 
500 
449 
0.8 
2.9 
Ward et al. (2007)    UK 
Routine screens of 
neurological illnesses and 
those screened suspected 
HHV-6 infection or 
reactivation 
522 
2.0 (<2 
years) 
1.3 (>2 
years) 
Hall et al. (2008)    USA 
Infants tested for congenital 
infection 
254 14* 
Hubacek et al. 
(2009)     
Czech Republic Children with leukaemia 339 1.5 
Potenza et al. 
(2009)    
Italy 
Solid organ transplant 
recipients 
Allogeneic stem cell 
transplant recipients 
205 0.9 
Géraudie et al. 
(2011)    
France Blood donors 200 0.5 
Lee et al. (2011)    USA Renal transplant recipients 47 2.1 
Lee et al. (2011)    USA Liver transplant recipients 548 1.3 
Faten et al. (2012)    Tunisia 
Acute myeloid leukaemia 
patients 
34 2.9 
Huang et al. (2013)    
World Populations 
UK 
General Populations 3858 1.5 
Hubacek et al. 
(2013)    
Czech Republic 
Malignant disease 
Healthy Donors 
812 
421 
1.1 
1.2 
Pantry et al. (2013)    USA Neurological symptoms 337 2.1 
Gravel et al. 
(2013b)    
Canada 
Acute lymphoblastic 
leukaemia 
287 0.35 
Kainth et al. (2013) USA HIV-positive individuals 439 0.91 
Godet et al. (2014) France 
Sperm samples, individuals 
experiencing fertility 
problems 
179 1.1 
Hill et al. (2014) USA 
Haematopoeitic stem cell 
transplant recipients with CNS 
disfuntion 
37 2.7 
Kühl et al. (2014) Germany 
Patients with unexplained 
symptoms of heart failure 
1656 1.1 
*High prevalence is likely due to a bias for congenital infection in the study which iciHHV-6 is the 
primary cause of. 
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Screens of healthy individuals in the UK have reported a iciHHV-6 prevalence range of 
0.8-4% (Clark et al., 1996; Leong et al., 2007; Ward et al., 2005), and studies of healthy 
individuals in France and the Czech Republic report a prevalence range of 0.5-1.19% 
(Geraudie et al., 2012; Hubacek et al., 2013). Problematically the majority of prevalence 
studies have been performed in specific disease groups which may not reflect the 
prevalence in the general populations. In all studies presented here (with the exception 
of Hall et al, (2008)) the iciHHV-6 prevalence is anything between 0.21% and 5%. The 
reported prevalence (14%) of Hall et al, (2008) is likely biased as they focus on 
congenitally acquired HHV-6 of which up to 86% are accounted for by iciHHV-6. This 
relatively wide range in prevalence could be due to several reasons: first, studies 
including disease groups may not be reflective of the general population. Secondly, the 
highest prevalence values, are associated with studies with the smallest sample sizes and 
may reflect sampling error. Thirdly, it is possible that the prevalence of iciHHV-6 differs 
by geographical region, country or ethnicity. This third point is difficult to examine by 
comparing data from existing studies; given the relatively low prevalence of iciHHV-6 and 
the relatively small sample sizes such an exercise is likely to be ‘underpowered’ 
statistically. Comparison of prevalence require large studies with information on the 
geographical, ethnic and ideally genetic origin (such as is provided with genome wide 
association studies) on all participants. 
 
1.7.3 Integration and HHV-6 species 
In a review of studies up to 2008, Clark & Ward (2008) noted that between one-fifth and 
one-third of iciHHV-6 cases were HHV-6A . As the majority of reported iciHHV-6 cases are 
in Europe, USA and Japan the apparent disparity between the relative proportions of 
exogenous HHV-6A prevalence has led to speculation that HHV-6A integrates more readily 
into the germ-line than HHV-6B. Excluding studies with less than ten iciHHV-6-positive 
subjects, HHV-6A accounts for 6.8-40% of iciHHV-6 cases (Hall et al., 2004; Huang et al., 
2013; Ward et al., 2005).  Hubacek et al, (2013), whilst only having nine iciHHV-6-poisitive 
samples in one study group, demonstrated a HHV-6A prevalence of 70% among iciHHV-6-
positive samples. 
There are several possible explanations for the perceived skew towards iciHHV-6A. First, 
given the high prevalence of exogenous HHV-6A observed in some populations, such as 
those in sub-Saharan Africa, then these populations may have a high prevalence of iciHHV-
6A. Investigations which do not take ethnicity or geographical location into account may 
inadvertently bias for either HHV-6A or HHV-6B. Secondly, the prospect of early primary 
HHV-6B infection and delayed exposure to HHV-6A may mean the prevalence of exogenous 
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HHV-6A is higher in populations in industrialised countries than reported. It is clear that 
the predominant virus in primary infant infections in sub-Saharan Africa is HHV-6A; 
however, there is an increased prevalence of HHV-6A and HHV-6B co-infections between 
asymptomatic infants of six and eighteen months (Bates et al, 2009). Thäder-Voigt et al, 
(2011) showed, through serological evidence, that in a sample of the German population 
the level of co-infection of HHV-6B and HHV-6A increases from 10% in children under 2 
years to 81.7% in adults. If this is the case in industrialised countries, the majority of the 
population become co-infected with HHV-6A after a primary HHV-6B infection, then the 
prevalence of HHV-6A may be higher than thought. This would go some way to explain 
the discordance between the observed exogenous HHV-6A and iciHHV-6A prevalence. 
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1.7.4 Integration site 
To fully understand both the mechanisms behind HHV-6 integration and inheritance, and 
their consequences, the involved chromosome must be considered. If there is no selection 
pressure, either from the virus or the host, there are 48 possible sites of integration (both 
arms of the 22 autosomal chromosomes and both arms of the two sex chromosomes). 
Table 1-3 summarises all published integration sites for independent integration events; 
for example, if a family with an integration on chromosome 17 is present in a study, this 
is considered as one independent event regardless of the number of affected individuals 
in the family. 
 
Table 1-3: Summary of all published independent iciHHV-6 integration events, where 
chromosome is specified 
Study Country Species Site of 
Integration 
Individual 
Events 
Torelli et al. (1995)   Italy B 17p13.3 3 
Daibata et al. (1998a)   Japan B 22q13 1 
Daibata et al. (1998b)  Japan -a 1q44 1 
Tanaka-Taya et al. 
(2004)   
Japan B 22q13 2 
Clark et al. (2006)   UK B 
A 
11p15.5 
17p13.3 
1 
1 
Nacheva et al. (2008)   UK B 
A 
B 
B 
9q34.3 
10q26.3 
17p13.3 
19q13.4 
2b 
1 
2b 
2b 
Watanaba et al. (2008)   Japan -a 1q44 1 
Hubacek et al. (2009)   Czech 
Republic 
B 18p11.3 1 
Pagter et al. (2009)   Netherlands -a 9p 1 
Arbuckle et al. (2010)  USA A 
A 
B 
17p13.3 
18q23 
22q13 
1 
1 
1 
Lohi et al. (2010)   Finland -a 22q13 1 
Strenger et al. (2010)   Austria -a 17p13.3 1 
Strenger et al. (2011)   Austria B 
B 
9p 
19q 
1 
1 
Haung et al. (2013)   World wide 
UK 
A 
B 
9q34.3 
10q26.3 
2 
1 
Strenger et al. (2013)   Austria A 7p 1 
Endo et al. (2014) Japan A 22 1 
Ohye et al. (2014) Japan B 
B 
B 
6q 
22q 
Xp 
1 
3 
2 
Pinto et al. (2015) USA -a 11p 1 
a variant is not specified and cannot reliably be obtained from evidence presented. 
b cases presented without a specified site in Ward et al. 2006. 
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To date, chromosomal integration sites for 40 independent integration events have been 
reported. These are spread across 11 different chromosomes; only chromosomes 9 and 18 
have integration events reported on both the q and the p arms. Whilst it should only be 
considered speculative at the present time due to small numbers, 17p and 22q are the 
most frequently involved chromosome arms, accounting for 20% and 22% of events, 
respectively (Fig. 1-2). There may be geographical differences as all chromosome 1 and 
eight of nine chromosome 22 integrations were reported in Japan. In contrast, 
integrations on chromosomes 9 and 17 have only been reported in European and the USA 
populations. If real, this leads to two hypotheses: that there are different selection 
pressures from the virus or host in different populations, or that there are founder effects, 
neither of these being mutually exclusive. 
 
Figure 1-2: Proportion of integrations events by chromosome 
 
1.7.5 Integration mechanisms 
Whilst to date HHV-6A and HHV-6B are the only herpesviruses that are transmitted 
through the germ-line, they are not the only herpesviruses that can integrate into host 
DNA. An analogous model for HHV-6A and HHV-6B integration is the avian herpesvirus 
MDV. 
MDV, as mentioned earlier, possesses TLRs similar to those present in the DRs of HHV-6A 
and HHV-6B. The hypothesised route of integration for MDV and HHV-6 is homologous 
recombination between the host telomeres and the viral TLRs. Kaufer et al, (2011), found 
that the TLRs of MDV both facilitated the integration of the virus into the host genome, 
and subsequent viral reactivation. Deletion of the multiple TLR regions of the long 
terminal repeat restricted integration to only intrachromosomal regions. Since only the 
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TLRs were mutated in the experimental viruses, this difference is attributed to reduced 
levels of homologous recombination. Further to this, Greco et al, (2014) demonstrated 
that mutation of the short TLR region of the long terminal repeat reduced the number of 
integration events per cell; however, the presence of integrated virus at the chromosomal 
ends suggests the role of the short TLR region is less crucial for MDV integration than the 
longer, multiple TLR region. Evidence supports MDV integration through homologous 
recombination between viral TLRs and host telomeres, though the mechanism and 
mediating factors in this remain unconfirmed. 
Similar to MDV, HHV-6A and HHV-6B integration is hypothesised to occur through 
homologous recombination. Arbuckle et al, (2010) were the first to demonstrate the 
orientation of and integrated virus. They showed that DRR was closest to the sub-
telomere, consistent with integration by homologous recombination. PCR amplification 
and sequencing of the integration site showed only a relatively short sequence of perfect 
telomeric repeats between sub-telomeric and viral DR sequence. Crucially, the pac2 
sequence downstream of the DRR T2 region had been lost. Arbuckle & Medveczky (2011) 
further developed the hypothesis of integration through homologous recombination by 
theorising that human TRF1 and TRF2 (proteins that associate with human telomeric 
sequence) could associate with viral TLRs bringing viral and human sequence into close 
proximity. 
How and if a recombination event occurs at the DRL is more contentious. Any 
recombination event with DRL could utilise either the inner T2 region of perfect TLRs or 
the T1 region of imperfect TLRs. Recombination involving the T1 would result in a nearly 
complete integrated virus lacking only the outermost pac1 and pac2 sequences, whereas 
recombination with T1 would result in the loss of DRL (Fig 1-3). 
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Figure 1-3: Schematic representation of HHV-6A and HHV-6B integration utilising 
different TLRs. A) Homologous recombination occurs between the human telomeres and 
the T1 region of DRL and the T2 region of DRR resulting in the loss of the most 5’ pac1 and 
most 3’ pac2 sequences. B) Homologous recombination between human telomeres and 
the T2 regions (perfect TLRs) of both DRL and DRR. This results in the complete loss of DRL 
and the 3’ pac2 sequence of DRR. 
 
Due to the repetitive nature of the telomeres, PCR-based amplification of any DRL:Human 
telomere junction is difficult, but has recently been achieved through the technique of 
single telomere length analysis (STELA). STELA (Fig. 1-4) was originally designed to 
determine the length of a telomere through PCR amplification with primers targeting a 
specific sub-telomere and an oligonucleotide that hybridises to the 3’ overhang present 
at the end of telomeres (Baird et al., 2003). Rather than using a primer that targets a 
sub-telomere, STELA can be adapted to target the viral DRL, thus amplifying the sequence 
between DRL and the telomere end. This method has confirmed, in all cases examined to 
date, that the DRL sequence is present (Huang et al., 2013). Huang et al, (2013) also 
analysed their STELA products and shown that they lacks the pac1 sequence upstream of 
the DRL T1 region. 
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Figure 1-4: Schematic representation of STELA. 1) An adaptor sequence which includes 
a region homologous to the telomere 3’ overhang and a non-homologous primer region 
(green) is hybridised to the 3’ overhang. A PCR is next performed with primers P1 
(homologous to sub-telomere sequence) and P1 (the exact sequence of the non-
homologous region of the adaptor). 2) Initially polymerisation can only occur from P1 as 
the region homologous to P2 has yet to be synthesised. 3) After the initial round of PCR, 
polymerisation can occur from P2 generating a double-stranded product spanning the full 
length of the telomere. 
 
Due to the loss of the outermost pac1 and pac2 sequences it could be hypothesised that 
homologous recombination occurs between human telomeric sequences and the 
outermost T1 and T2 regions. This however is not the only possibility. In their review of 
iciHHV-6, Kaufer & Flamand (2014) put forward two other possible mechanisms. The first 
utilises a DNA repair mechanism termed break-induced replication (BIR). BIR is a form of 
homologous recombination that allows repair when only a single free end is available, 
such as at a telomere end or collapsed replication fork (Llorente et al., 2008). The authors 
hypothesise that the 3’ overhang of the human telomere invades the HHV-6 genome at 
the site of the DRR T2 region. Extension and strand displacement result in a HHV-6 genome 
at the end of the telomere. Subsequent cellular replications gradually erode the 
outermost pac1 sequence of DRL until the T1 region is met. The T1 region then acts as a 
template for telomerase leading to telomere extension and the formation of a new 3’ 
overhang (crucial for telomere maintenance) (Kaufer and Flamand, 2014). This leads to 
an integrated virus in the form we observe; however, this model is not without issue. The 
number of telomeric repeats between the sub-telomere and DRR is variable. Arbuckle et 
al, (2010) described a case with only five repeats in this region. This would imply the 
chromosome in which the virus integrated had an exceptionally short telomere at the 
time of integration, something that would perhaps not be expected in a germ-cell where 
this integration event must have occurred. 
The second model suggests involvement of several other factors, including the viral 
protein U94 and the telomere cap structure. The telomere cap is crucial for protecting 
the chromosomal ends from degradation and cellular mechanisms such as homologous end 
joining that would result in chromosomal fusion (Sfeir and de Lange, 2012). The formation 
of the cap structure is described in Figure 1-5. 
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Figure 1-5: Schematic representation of DNA formation in the telomere cap structure. 
The 3’ overhang at the telomere end folds back invading the dsDNA and displacing the 
top strand. This structure is termed the T-loop, whilst the displaced DNA is termed the 
D-loop. Proteins that associate along the looped DNA include TRF1 and TRF2 (double 
stranded DNA binding proteins) and POT1 (binding to the single stranded DNA in the D-
loop). The DNA loop and associated proteins form the protective cap structure known as 
the Shelterin complex (Oeseburg et al., 2010) 
 
 U94 is a putative latency inducing protein (as discussed earlier) and integrase. In their 
review Kaufer & Flamand state that U94 is able to bind human telomeres and possesses 
3’-5’ exonuclease activity, though these data remain unpublished. U94 shares 24% 
sequence homology with the latency associated gene rep68/78 of human adeno-
associated virus type 2 (AAV-2) (Thomson et al., 1991). AAV-2 rep68/78 has both 
transcriptional regulatory and targeted integrase activity (Linden et al., 1996). Despite 
the relatively low homology there are structural similarities between U94 and rep68/78, 
leading to the suggestion that this viral factor may be crucial for HHV-6 integration 
(Arbuckle and Medveczky, 2011; Kaufer and Flamand, 2014). 
The telomere cap and viral U94 proteins are crucial for the second integration model 
proposed by Kaufer and Flamand. In this model U94 attacks the D-loop region using 
exonuclease activity to degrade the invading strand, disrupting the T-loop and generating 
a 5’ overhang. At the same time, U94 degrades the ends of the viral genome generating 
a complementary overhang at the DRR end. The viral DNA then anneals to the end of the 
telomere and again, the DRL pac1 sequence could be eroded and a new 3’ overhang 
generated (Kaufer and Flamand, 2014). As with the first model the problem of small 
numbers of TLRs between the sub-telomere and DRR means that either a short telomere 
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was present when integration occurred or that the majority of the telomere was degraded 
prior to integration. It remains to be seen whether these models or homologous 
recombination occurring at both ends of the genome are the mechanism of HHV-6A and 
HHV-6B integration; experiments involving knockout and mutation of both U94 and the 
TLRs are likely required to answer these questions. 
 
1.7.6 Latency and reactivation 
The genome of the majority of herpesviruses are maintained as an episome tethered to 
the host cell chromosome by viral proteins. Whilst U94 of HHV-6A and HHV-6B has been 
shown to induce a latency-like phenotype, no such tethering protein has been identified 
for either virus. 
There have been few attempts to determine how the latent genomes of HHV-6A and HHV-
6B are maintained, though it has been shown that the presence of TLRs does not act to 
mimic the gross structure of human chromosomes (Bulboaca et al., 1998). It has recently 
been proposed that the latent HHV-6 genome is maintained through integration; evidence 
for this is provided by a single publication using PFGE to separate episomal from genomic 
DNA of PBMCs from iciHHV-6A-positive individuals. Southern blot analysis showed viral 
DNA was associated only with high molecular weight genomic DNA (Arbuckle et al., 2010). 
Although an attractive and viable model this cannot alone be taken as proof of integration 
as the true form HHV-6A and HHV-6B latency. It does however raise the question can 
iciHHV-6 be used as a model for HHV-6A and HHV-6B latency? 
There are several caveats to using iciHHV-6 as a model for latency through somatic 
integration. First, iciHHV-6 could be dead end for the virus, i.e. the virus is not able to 
reactivate. The presence of iciHHV-6 could mask episomal latency either through the 
abundance of integrated virus masking low levels of episomal DNA, or through prevention 
of super-infection with exogenously acquired virus. Whilst these cannot be discounted, 
there is mounting evidence to suggest that iciHHV-6 is not a dead-end for the virus. 
Arbuckle et al. (2010) showed that HHV-6A is capable of integrating into the JJHAN and 
HEK-293 cell lines demonstrating that integration is not confined to the germ-line. U94, 
U42 and U22 mRNA and protein components of the virus particle have been detected in 
PBMCs of iciHHV-6A and iciHHV-6B-positive individuals (Strenger et al., 2014). Although, 
with the exception of U94, these are not transcripts previously described as associated 
with latency, it does highlight the virus is not completely inactive. 
A necessity of any latent infection is the ability for a virus to re-enter a productive life 
cycle after appropriate stimuli. As discussed earlier, a common feature among 
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herpesviruses is genomic replication through rolling-circle type amplification, if this is 
the case with reactivated HHV-6A and HHV-6B then genome excision and re-circularisation 
would be required. Huang et al, (2013) proposed that the viral genome could be excised 
through standard telomere shortening mechanisms. Figure 1-6 describes telomere 
shortening through loss of T-loop structures. 
 
Figure 1-6: Telomere shortening through T-loop formation and excision. A T-loop 
forms as part of the cap structure. The 5’ end of the blue strand can migrate into the D-
loop forming a Holliday junction. Cleavage at the D-loop and Holliday Junction leaves a 
circle molecule derived from telomeric sequence and a shortened telomere (with a 3’ 
overhang). 
 
If a T-loop formed between the telomere end and the T1 region of DRR it could result in 
the excision of a DR and the complete U region (Fig. 1-7). Crucially the excision would 
reconstitute the DR which would contain both pac1 and pac2. 
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Figure 1-7: Excision of a HHV-6 episome that contains the complete U region and a 
reconstituted complete DR. Rolling circle amplification of this would result in a 
concatemer of (DR.U)n. 
 
Supporting this hypothesis, the authors identified extra-chromosomal telomeric circles 
containing viral DR sequence as well as viral genomes truncated at DRL T2. Further to this, 
one case was identified with extra-chromosomal circles containing DR and U region 
sequence (Huang et al., 2013). 
There have now been several incidences of inducible productive infection likely arising 
from an integrated genome in vitro and in vivo. As well as chemical induced reactivation 
(Arbuckle et al., 2010), Prusty et al, (2013) reported excision of iciHHV-6 genomes is 
inducible by the presence of Chlamydia trachomatis (Prusty et al., 2013). There are also 
two notable clinical presentations. Watanaba et al (2008) reported a case of a Japanese 
man suffering from anticonvulsant DIHS, a condition associated with HHV-6 reactivation. 
Six weeks after the onset of symptoms his HHV-6 IgG titre had increased 128-fold from 
the time of hospitalisation; however, HHV-6 IgM titres did not change. This difference in 
IgG and IgM levels is indicative of reactivation rather than a primary infection. When viral 
load was examined it was 10,000 copies ml-1 of serum and was higher in whole blood 
(value not provided). FISH analysis of PBMC showed iciHHV-6 at 1q44. Though reactivation 
of exogenously acquired HHV-6 was not ruled out, reactivation of iciHHV-6 is a possibility 
(Watanabe et al., 2008). The second case of likely iciHHV-6 reactivation was described in 
a 2-month old baby with X-linked severe combined immunodeficiency (X-SCID). The baby 
presented symptoms suggestive of a viral infection. Upon investigation, high levels of 
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HHV-6A DNA in peripheral blood, which did not decrease with antiviral treatment, were 
noted leading to the suspicion of iciHHV-6. HHV-6A was found integrated on chromosome 
22, and was transmitted from the father. No other pathogens were identified and 
discontinuation of antiviral treatment resulted in symptoms returning, suggesting HHV-6A 
was the likely cause. Sequence comparisons between virus isolated from the patient, the 
patient’s finger nails and the fathers hair follicles, the U1102 and Z29 isolates suggested 
that the isolated virus originated from re-activation of the integrated strain, and was 
unlikely to be from an exogenously acquired virus (Endo et al., 2014). 
There is therefore mounting evidence to support the hypothesis that iciHHV-6 can 
reactivate and under specific circumstances such as immunodeficiency lead to clinical 
symptoms. Reactivation is not the only means by which iciHHV-6 could cause disease, and 
the phenotypic consequences of a relatively large viral genome integrated into a 
functionally important region of the human genome is a crucial area of research. 
 
1.8 inherited chromosomally integrated Human Herpesvirus 6 - 
Disease associations 
Inherited chromosomally integrated HHV-6 could cause disease in one of several ways, 
none being mutually exclusive: reactivation; expression of viral genes and altering 
expression of sub-telomere genes; or disruption of normal telomere function through the 
act of integration or excision. Examples of diseases associated with reactivation have 
already been discussed, and any others may be similar to those associated with 
reactivation of exogenously acquired virus (section 1.5). Associations with the other two 
possibilities could be more variable in their pathogenicity and presentation. 
As part of this thesis an analysis of the current literature on disease and phenotypic 
associations was conducted (summarised in Figure 1-8). Seventy-eight publications were 
identified in the NCBI PubMed database, 37 were reviews or papers not directly related 
to disease aetiology. Though not all will be discussed here in detail, the remainder was 
comprised of case reports and descriptive publications, prevalence and case-control 
studies and functional studies. 
Chapter 1: Introduction 
52 
 
 
Figure 1-8: Analysis of English language publications related to iciHHV-6. Reviews and 
publications not directly related to disease aetiology are excluded from further literature 
review. 
 
1.8.1 Case reports and descriptive publications 
The identified case reports focus on haematopoietic stem cell transplant (HSCT) donors 
or recipients who were positive for iciHHV-6 and single descriptions of iciHHV-6 in 
numerous diseases. In transplant settings, the presence of iciHHV-6 can lead to 
administration of unnecessary anti-viral treatments and highlights the importance of 
excluding iciHHV-6 as a cause of high HHV-6 viral loads (Jeulin et al., 2009; Kamble et 
al., 2007). Other case reports included DIHS and X-SCID, as described previously (Endo et 
al., 2014; Watanabe et al., 2008), as well as cardiomyopathy (Das, 2015), respiratory 
infection (Oikawa et al., 2014), lupus erythematosus (Cavagna et al., 2013), cognitive 
dysfunction (Montoya et al., 2012) and encephalomyelitis (Troy et al., 2008). Since a 
proportion of the population is iciHHV-6-positive, these could be chance observations but 
some could result from reactivation of virus from iciHHV-6. 
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Descriptive studies and case reports can provide useful information and provide evidence 
for hypothesis testing; however, they are not proof of causality or an aetiological 
association. 
 
1.8.2 Functional studies 
Functional studies, whilst not providing evidence for an association with a particular 
disease, can identify potential mechanisms by which iciHHV-6 could lead to disease 
genesis. 
Some of these functional studies have already been mentioned, such as those pertaining 
to U83 (Tweedy et al., 2015b), C.trachomatis and excision of viral genomes (Prusty et 
al., 2013), mRNA profiles of iciHHV-6-positive PBMCs (Strenger et al., 2014), and the 
identification of extra-chromosomal telomere circles containing viral genomic regions 
(Huang et al., 2013). 
Further to their identification of excised viral genomes, Huang et al, (2013) demonstrated 
through STELA that in 50% of iciHHV-6-positive lymphoblastoid cell lines (LCLs) the virus-
associated telomere was shorter than those of XpYp, 12q and 17p. This finding was 
mirrored in 9/16 of examined blood samples from iciHHV-6A and iciHHV-6B positive 
individuals. It is also important to note that the telomere associated with 17p is regarded 
as being one of the shortest in a normal setting. Whilst being some of the shortest 
telomeres, the rate of attrition of viral telomeres was not dissimilar to that of other 
chromosomes in LCL culture. 
The apparent effect of HHV-6 integration on telomere length highlights possible means of 
influencing both acute and complex disease. Telomere length is an important factor in 
immune senescence, cancer, and age-related diseases. 
 
1.8.3 Prevalence and case-control studies 
Although case studies can provide speculative information as to disease associations and 
functional studies, provide mechanistic information, the gold standard for investigating 
disease associations is case-control studies. In this literature analysis (Fig. 1-8) and 
previous analyse throughout this project, 20 primary publications investigating a range of 
conditions from those associated with acute HHV-6 infection to malignant disease and 
cognitive function were identified (Table 1-2). Problematically, many studies addressing 
iciHHV-6 and disease do not state whether the virus is HHV-6A or HHV-6B, or include a 
well-matched control group for comparison. Instead, they tend to compare to an average 
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prevalence of 0.5-2% derived from studies of European and USA populations, or to the 
0.21% in the context of Japanese studies. 
To date, there have been six primary studies investigating iciHHV-6 prevalence in solid 
organ and HSCT transplant recipients. For renal and hepatic transplant recipients the 
iciHHV-6 prevalence range is 1.3-5% with a prevalence of 0.9% in a study with both solid 
organ and HSCT transplants (Griffiths et al., 1999a; Kidd et al., 2000; Lee et al., 2011a; 
Lee et al., 2011b). The high prevalence (5%) observed by Griffiths et al, (1999) appears 
to be an outlier among these studies. A major consideration is the sample size used in 
each (Table 1-2), for Griffiths et al, (1999) only 60 individuals were screened; in fact with 
the exception of Lee et al, (1999) all studies investigating iciHHV-6 in transplant 
recipients without secondary sequelae have less than 100 participants each. Reactivation 
from iciHHV-6 could be a major burden in a transplant setting. Hill et al, (2014) identified 
37 HSCT recipients who presented with HHV-6-associated CNS dysfunction. Only one case 
was found to be iciHHV-6A positive. Whilst not supporting iciHHV-6 increasing the chances 
of HHV-6-associated CNS dysfunction post-transplant, the authors note the small sample 
size of the study.  
Diseases associated with primary HHV-6 infection or reactivation are prime candidates for 
possible associations with iciHHV-6. In Japan a large study (2,332 participants) found a 
0.21% prevalence of iciHHV-6 in patients referred with potential primary or reactivated 
HHV-6. Of the five identified cases, four were iciHHV-6B and one was iciHHV-6A. This low 
prevalence could suggest no association with iciHHV-6 and symptoms associated with 
acute and reactivated HHV-6, however with no control group or other large studies on the 
Japanese population this remains unclear (Tanaka-Taya et al., 2004). Inherited 
chromosomally integrated HHV-6 was found to have no bearing on the progression of 
Human immunodeficiency virus (HIV) to AIDS or the severity of the disease in a study of 
439 HIV-positive individuals, with an iciHHV-6 prevalence of 0.91% (Kainth et al., 2013). 
A study of 1,656 individuals with persistent unexplained symptoms of heart failure found 
an iciHHV-6 prevalence of 1.1% (19/1,656), 36.8% (7/19) of which were iciHHV-6A. 
Although the prevalence did not differ from that in healthy individuals, symptoms were 
attributed to HHV-6 reactivation. HHV-6 mRNA and antigens were identified in cardiac 
tissue, herpesvirus-like particles were observed in vascular endothelial cells and antiviral 
therapy reduced mRNA levels and improved symptoms (Kuhl et al., 2015). Given previous 
examples, it is possible that iciHHV-6 was reactivated; but sequence analysis was not 
conducted to confirm this and not reactivation of an exogenously acquired strain. The 
fact that iciHHV-6 prevalence is not increased in these individuals, but could reactivate 
and cause disease when present, suggests that some as yet undetermined factor is also 
involved. 
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Three studies from the UK and one from the USA examined iciHHV-6 in neurological and 
HHV-6-associated illnesses. In the USA, Pantry et al, (2013) screened 337 individuals with 
a wide range of neurological symptoms and observed an iciHHV-6 prevalence of 2.1% 
(7/337). They compared this to an estimated US population prevalence of 0.8% and 
reported that the difference was statistically significant (p = 0.03) (Pantry et al., 2013). 
This ‘significant’ finding is problematic, however, as there is no documented publication 
describing an iciHHV-6 prevalence of 0.8% in the US population; the referenced papers 
suggest a higher prevalence of 1% and 14% (Hall et al., 2008; Hall et al., 2004). In the UK, 
Ward et al, (2007) screened 510 immunocompetent patients with neurological conditions 
and 12 who had been specifically referred for HHV-6 testing. One aim of this study was 
to distinguish primary exogenous infection from iciHHV-6 in young children and 
reactivation in older individuals. In children under two years of age the iciHHV-6 
prevalence was 2%, whilst in individuals older than two years, the prevalence was 1.3%. 
Of the iciHHV-6-positive individuals four carried HHV-6A whilst 17 carried HHV-6B (Ward 
et al., 2007). A matched control group was not analysed but the data do not support an 
association with iciHHV-6 and neurological disorders. The remaining two UK-based studies 
were case-control studies. The first compared 184 children from the UK and Ireland 
encephalitis survey and 653 from a serum bank. The serum bank samples comprised 
samples remaining from diagnostic testing, so may not have been representative of the 
general population, but immunocompromised individuals were excluded. The iciHHV-6 
prevalence in the survey children was 3.3% (6/184); two being HHV-6A-positive and four 
HHV-6B-positive. The prevalence in the serum bank was 1.5% (10/653). Although the 
prevalence in the two groups differed, the difference was not statistically significant (p 
= 0.13) (Ward et al., 2005). The final study compared blood donors from the general 
population to hospitalised patients (either transplant recipients or those with symptoms 
consistent with HHV-6 infection). The iciHHV-6 prevalence was 0.8% and 2.9% for blood 
donors and hospital patients, respectively (Leong et al., 2007). The differences between 
disease and control groups in these studies has led some to suggest that this supports 
iciHHV-6 having a role in HHV-6 neurological and other diseases (Arbuckle and Medveczky, 
2011). Whilst this may be the case, the lack of statistical significance in the study by Ward 
et al, (2005) and the lack of well-matched control suggests these results should be 
interpreted with caution. It must be noted that due to the sample sizes used, both studies 
lack statistical power to determine the significance of such differences. 
Some of the first descriptions of iciHHV-6 were in malignant disease; Torelli et al, (1995) 
identified two (one cHL and one non-HL) such cases which were later confirmed as iciHHV-
6. The prevalence in that study was 2%, since then there have been numerous other 
studies (including one presented in this thesis) investigating iciHHV-6 and malignant 
disease. Hubacek et al, (2009) investigated the association between iciHHV-6 and 
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childhood acute lymphoblastic leukaemia (ALL) and myeloid leukaemia (AML) in the Czech 
Republic. Of the 339 examined individuals, 318 had ALL and 21 had AML. The prevalence 
of iciHHV-6 in the full study was 1.4% (5/339); all five identified individuals were in the 
ALL group and the prevalence in ALL alone was 1.6% (5/318). Four out of five of the 
iciHHV-6 individuals carried HHV-6A. A further study in the Czech Republic in 2013 
compared 812 patients with malignant disease to 421 healthy donors. The malignant 
disease group comprised 267 cHL cases and 345 cases with adult leukaemias or 
myelodysplastic syndrome (MDS), 111 childhood leukaemias and MDS, and 89 childhood 
solid tumours. The iciHHV-6 prevalence was 1.11% (9/812) and 1.19% (5/421) in the case 
and control groups, respectively. Of the 9 cases in the disease group 7 were HHV-6A-
positive; in the control group three were HHV-6B-positive, one HHV-6A and one was 
undetermined (Hubacek et al., 2013). Both these publications do not support iciHHV-6 
having a role in the pathogenesis of the malignant disease in general; however, whilst 
large studies they are limited in the sample sizes used for the individual diseases. An 
investigation of HHV-6 and acute leukaemias in Tunisia found an iciHHV-6 prevalence of 
2.9% (1/34); the sole identified iciHHV-6-positive individual being a case of AML (Faten et 
al., 2012). Finally, a study of 293 ALL and 288 healthy individuals in Canada found only 1 
(0.35%) ALL case positive for iciHHV-6A whilst no controls were positive. None of the 
publications discussed here support a role for iciHHV-6 in the investigated malignant 
diseases, particularly leukaemias. However, as with other studies sample sizes of specific 
disease means the studies lack statistical power to identify small effect sizes. 
Evidence from case reports and Kühl et al, (2014) suggest that, under certain 
circumstances, the virus can reactivate and cause acute disease. Studies investigating 
malignant disease do not reveal any strong association, but in most cases sample sizes 
are relatively small leaving the studies statistically underpowered. The range of observed 
iciHHV-6 prevalence values highlights the importance of study design and the use of well-
matched controls. Case-control studies are a good way of investigating a single disease or 
symptom, but it is for this same reason they are limited. Since there is not enough 
available information to generate hypotheses, well characterised population based 
studies are needed. Evidence from these studies could then be used to target case control 
studies to confirm any observed associations. 
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1.9 Summary 
There is mounting evidence that HHV-6A and HHV-6B genomes can be excised from the 
telomeres and possibly reactivate; however, the frequency and the dynamics of such a 
process remain unclear. Since the consequences to the host and virus could be numerous 
a comprehensive understanding of the dynamics of iciHHV-6 genome excision is needed. 
Whilst it has been known for some time that HHV-6A and HHV-6B are able to integrate 
into the telomeres of human chromosomes it remains a relatively poorly understood 
phenomenon. Work is needed to establish if there are any phenotypic associations with 
iciHHV-6. It is relatively simple to screen for the presence of iciHHV-6; however, owing 
to its relatively low prevalence large studies are required. Case-control studies are 
appropriate for examining likely associations but hypotheses are required for their design. 
A more systematic approach is needed which allows the examination of multiple diseases 
and phenotypes in a single study, as well as examining HHV-6 through multiple generations 
for a full understanding of the consequences of iciHHV-6 on the individual and population 
 
1.10 Aims and objectives 
This project aimed to address several objectives regarding iciHHV-6 in health and disease, 
specifically: 
Is iciHHV-6 and/or exogenously acquired HHV-6 associated with cHL? (Chapter 4) 
What is the prevalence of iciHHV-6 in the Scottish and British Isles populations, and are 
there social, physical or disease phenotypes associated with it? (Chapter 5) 
What are the possible iciHHV-6 genome configurations and does iciHHV-6 remain stable 
following integrations? (Chapter 6) 
Do iciHHV-6 genomes form a distinct phylogenetic group? (Chapter 7) 
In order to address the above aims, a series of assays were designed and optimised for 
iciHHV-6 detection and analysis and there are described in Chapter 3. 
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2.1 Materials 
Materials and reagents for each method are described in the relevant sections. Suppliers 
and their addresses are presented in full in Appendix 1. A list of plastic ware is provided 
in Table 2-1. 
 
Table 2-1: Plastic ware 
Item Abbreviated name 
(where used) 
Supplier 
1.5 ml sterile screw-cap 
polypropylene 
microcentrifuge tube 
1.5 ml screw-cap tube Elkay 
PCR tube, 0.2 ml 200 µl tube Eppendorf 
NUNC™ 1.8 ml cryotubes  Fisher Scientific Inc. 
ABgene 0.2 ml 96-well plate 96-well plate Thermo Scientific 
Twin.tec® 96-well plate, 
semi-skirted 
Eppendorf 96-well plate Eppendorf 
MicroAMp® Optical 96-Well 
Reaction Plate 
96-well optical plate Life Technologies 
MicroAmp® Fast Optical 96-
Well Reaction Plate 
96-well Fast optical 
plate 
Life Technologies 
MicroAmp® Optical 8-cap 
Strips 
Optical caps Life Technologies 
Non-optical caps Caps  
DG8TM Cartridges for 
QX200TM/QX100TM Droplet 
Generator 
DG8 cartridges Bio-Rad Laboratories 
DG8TM Gaskets for 
QX200TM/QX100TM Droplet 
Generator 
DG8 gaskets Bio-Rad Laboratories 
Pierceable Foil Heat Seal Foil seal Bio-Rad Laboratories 
Corning® CentriStarTM 15 ml 
conical polypropylene tube 
15 ml tube Sigma-Aldrich 
Corning® CentriStarTM 50 ml 
conical polypropylene tube 
50 ml tube Sigma-Aldrich 
Corning® Small culture flask 25 cm2 culture flask Sigma-Aldrich 
Corning® Medium culture 
flask 
75 cm2 culture flask Sigma-Aldrich 
Corning® Large culture flask 175 cm2  culture flask Sigma-Aldrich 
Pastette  Fisher Scientific Inc. 
Magnetic Stand-96  Life Technologies 
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2.1.1 Culture media and solutions 
Table 2-2 provides a list of tissue culture media, buffers and solutions used. 
 
Table 2-2: Culture media, buffers and solutions 
Culture media, 
buffer or 
solution 
Abbreviation Purpose Recipe 
Complete 
culture medium, 
10% FBS* 
10% CCM Cell culture 
500 ml RPMI 1640 
50 ml FBS 
20 ml Penicillin/Streptomycin 
5 ml L-glutamine 
(All Life Technologies) 
575 ml Total volume 
Freezing medium  Cell freezing 
9.2 ml FBS (Life Technologies) 
0.8 ml DMSO (Fisher Scientific Inc.) 
Dulbecco’s 
Phosphate 
buffered saline 
PBS Isotonic buffer 
90 ml Sterile water 
10 ml 10 x Dulbecco’s phosphate 
buffered saline 
(Both Life Technologies) 
50 x Tris 
Acetate, EDTA 
Buffer 
50 x TAE 
Agarose gel 
electrophoresis 
242 g Tris base (Promega) 
57 ml glacial acetic acid (Sigma) 
100 ml 0.5 M EDTA (pH 8.0) (Sigma) 
Water up to 1 L 
1 x Tris Acetate, 
EDTA Buffer 
1 x TAE 
Agarose gel 
electrophoresis 
20 ml 50 x TAE 
980 ml water 
* 10% CCM was made by adding components to 500 ml of RPMI, which resulted in a slightly 
lower FBS percentage. The medium was filtered through a 0.45 µm Corning filter flask 
(Sigma), dispensed into 50 ml aliquots and stored at 4oC. 
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2.1.2 Equipment 
Items of equipment and their suppliers, are listed in Table 2-3, as well as the described 
methods. 
 
Table 2-3: Equipment 
  Item Supplier 
Pipetterboy-acu Integra Biosciences 
Pipettes Gilson Scientific 
Pipette Light XLS+ 8 channel 5-50 µl 
LTS (described in text as P50 
multichannel pipette) 
Rainin 
Pipette tips – 10 µl, 20 µl, 200 µl, 1000 
µl 
Rainin 
5 – 250 µl Filter Racked Tips LTS Rainin 
Heraeus Pico 17 microcentrifige Thermo Scientific 
Inc. 
Coulter mixer (rotator mixer)  Coulter Electronics 
Ltd. 
Heraeus Multifuge 3 S-R Thermos Scientific 
Inc. 
CS-15 centrifuge Beckman 
MS2 Minishaker IKA® Thermo Fisher 
FORMA Series II water Jacket CO2 
Incubator 
Thermo Scientific 
Inc. 
NanoDrop ND-1000 spectrophotometer Thermo Scientific 
CountessTM Life Technologies 
Qubit Reader Life Technologies 
24 well plate PCR machine Life Technologies 
GeneAmp PCR system 9700 Life Technologies 
GeneAmp PCR system 2400 Life Technologies 
C1000 TouchTM Thermal Cycler Bio-Rad Laboratories 
7500 Real-Time PCR system Life Technologies 
7500 Fast Real-Time PCR system Life Technologies 
QX200TM Droplet Generator Bio-Rad Laboratories 
PX1TM PCR Plate Sealer Bio-Rad Laboratories 
QX200TM Droplet Reader Bio-Rad Laboratories 
1500 series freezer -70oC MVE System 
Freezer -20oC Haier 
Vapour-phase nitrogen freezer New Brunswick 
Sciences 
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2.1.3 Software 
A list of software used for data interpretation and analysis is presented in Table 2-4. 
 
Table 2-4: Software 
Software Purpose Supplier 
7500 Software V2.0.6 Real-Time PCR data collection and 
analysis 
Life Technologies 
QuantStudio 12K Flex 
Software 
Real-Time PCR data analysis Life Technologies 
Primer Express® V3.0 Design of TaqMan® assays Life Technologies 
QuantaSoftTM V1.4.0 Droplet digital PCR data collection 
and analysis 
Bio-Rad Laboratories 
MEGA6 Phylogenetic analysis (Tamura et al., 2013) 
CLC Genomic Workbench V7.0 Sequence analysis CLC Bio 
SPSS V20.0 Statistical analysis IBM 
 
 
2.2 Safety Measures 
All work conducted herein was performed in accordance with the relevant appropriate 
health and safety legislation. Control of substances hazardous to health (COSHH) 
assessments were conducted for all reagents used. All work was carried out in either a 
standard containment level (CL) 2 laboratory or a CL 2 laboratory operating under strict 
managerial conditions. Cell and virus cultures were handled in a Class 2 Microbiological 
Safety Cabinet (MSC) and gowns were worn over laboratory coats when working in MSCs. 
All surfaces were sprayed with 70% ethanol (Fisher Scientific Inc.) both before and after 
use. Liquids that contained biological material were discarded into 2% Virkon (Fisher 
Scientific Inc.) to a final Virkon concentration of 1%. All waste material, including 
disposable plastic ware, was autoclaved at 120oC and 100 KiloPascal above atmospheric 
pressure for 20 minutes prior to disposal as clinical waste. 
 
2.3 Cell and Virus Culture 
Where possible uninfected, virally infected, and LCL cultures were handled on different 
days to prevent cross contamination. When this was not possible, uninfected cells were 
handled at the start of the day before any virally infected or LCL cultures had been 
handled. HHV-6A and HHV-6B cultures were not handled on the same day. 
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2.3.1 Cell thawing, counting and freezing 
The required aliquot of uninfected, virally infected, or LCL cells was removed from liquid 
following appropriate safety precautions. The vial of cells was removed into a metal flask 
and transported to a water bath at 37oC  were cells were thawed. Post thawing vials were 
submerged in 70% ethanol. The cell culture was then transferred to 10ml of pre-warmed 
(37oC) 10% CCM in a 15 ml tube. Cells were pelleted by centrifugation at 1200 x g for 5 
minutes in a Heraeus Multifuge 3 S-R centrifuge. The supernatant was discarded and cells 
re-suspended in the remaining media by tapping the bottom of the tube. Five millilitres 
of PBS (Life Technologies) was added and centrifugation repeated. The PBS was aspirated 
and the cells re-suspended in 3 ml of 10% CCM and added to a 25 cm2 culture flask. Three 
to five days later 7 ml of 10% CCM was added. A week later cultures were transferred to 
a 75 cm2 culture flask and 20 ml of 10% CCM was added. Cultures were maintained by 
splitting cells 1:3 every four to five days in a final volume of 30 ml. 
Cells were counted with a CountessTM automated cell counter as per the manufacturer’s 
instructions. Briefly, 10 µl of the cell suspension was mixed with 10 µl of trypan blue 
(0.4%) by gentle pipetting. Ten microliters of this mix was added to the CountessTM cell 
counter chamber slide, and the slide was places in the CountessTM. A magnified image of 
the cell-suspension was visible on screen and the focus was adjusted until cells could be 
seen with defined edges. The Countess was then instructed to count cells, which provided 
a total cell count and a live cell count per microliter. 
Cells were frozen in aliquots of 5 x 106 cells. The appropriate amount of cell culture 
suspension was spun at 1200 x g for 5 minutes. The media was discarded and the cell 
pellet was re-suspended in the appropriate amount of freezing medium (1 ml per aliquot). 
Cells were frozen in 1 ml volumes in NUMC™ 1.8 ml cryotubes (Fisher Scientific Inc.). Cells 
were then taken down to -70oC using NALGENE (Fisher Scientific Inc.) system for 
controlling the freezing rate. Briefly, this involves the use of a container, the base of 
which is filled with isopropyl alcohol, allowing for a freezing rate of -1oC min-1. The 
following day vials were transferred from this container into liquid nitrogen for long term 
storage at -200oC. 
 
2.3.2 Uninfected cell lines 
Uninfected cells were cultured for the propagation of HHV-6A, HHV-6B and for a source 
of viral negative DNA. Cell lines culture for work in this thesis were JJHANs and Sub-T1, 
both of a T-lymphocyte lineage. Cells were thawed and cultures established as described 
in section 2.3.1. 
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2.3.3 HHV-6A and HHV-6B culture 
HHV-6A and HHV-6B were cultured in JJHAN and Sub-T1 cell lines, respectively. HHV-6B 
infected Sup-T1 cells were provided by the HHV-6 Foundation repository of regents (Santa 
Barbara, CA, USA) whilst HHV-6A infected JJHANS had been cultured previously and stored 
in liquid nitrogen. 
Cells cultures were established from vials stored in liquid nitrogen as described in section 
2.3.1. After approximately one week the established culture was added to 10 ml of a 
culture of the appropriate uninfected cells. HHV-6A and HHV-6B-cultures were 
maintained by adding of 10 ml of an infected culture to 20 ml of an uninfected one. 
Depending on the progression of the infection within a culture, cells were pelleted by 
centrifugation at 1200 x g for 5 minutes, and half the culture medium was removed and 
replaced with fresh 10% CCM 3-4 days post mixing cells. Virally infected cultures were 
monitored for the visual appearance of cells displaying HHV-6 infection. When the 
majority of examined cells presented with cytopathic effects such as enlargement, 
formation of vacuoles and the formation of syncytia uninfected cells were seeded into 
the culture as described. 
 
2.3.4 Lymphoblastoid cell lines 
Lymphoblastoid cell lines established from individuals with iciHHV-6 were kindly donated 
by Dr Duncan Clark (Barts and London NHS Trust, London, UK) and are summarised in 
Table 2-5. Cultures were established and maintained as described in section 2.3.1. 
 
Table 2-5: iciHHV-6-positive LCLs used in this project 
LCL Name HHV-6 type HHV-6 integration 
site 
7-17p13.3 A 17p13.3 
3-10q23.3 A 10q23.3 
4-11p15.5 B 11p15.5 
2-9q34.3 B 9q34.3 
1-9q34.3 B 9q34.3 
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2.4 DNA Extraction 
DNA extractions were performed using either Illustra Nucleon genomic DNA extraction kit 
(GE Healthcare, Buckinghamshire, UK) or the Qiagen AllPrep DNA/RNA kit (Qiagen, 
Crawly, West Sussex, UK). 
 
2.4.1 Illustra nucleon genomic DNA extraction kit 
DNA extractions with Illustra Nucleon genomic DNA extraction kit (GE Healthcare) were 
performed as per the manufacturer’s instructions using the BACC2 protocol. Briefly, 5 x 
106 – 1 x 107 cells were pelleted by centrifugation at 1200 x g for 5 minutes in a 15 ml 
tube. Cell pellets were washed with 1 – 5 ml PBS and pelleted as before. Cells were re-
suspended in 1 ml of ‘reagent A’, incubated on ice for 5 minutes, and pelleted by 
centrifugation at 1300 x g for 5 minutes and the supernatant discarded. Two millilitres of 
‘reagent B’ was added to the pellet and vortexed briefly. Five-hundred microliters of 
sodium perchlorate were added and the lysate mixed by inverting the tube seven times. 
Two millilitres of chloroform was added, mixed by inverting seven times, before 300 µl 
of nucleon resin was added down the side of the tube. Without disturbing the phases, the 
tube was then spun at 1300 x g for 3 minutes. Without disturbing the resin, the top phase 
was transferred to a new 15 ml tube using a Pastette. Two volumes of -20oC ethanol were 
then added. The tube was gently inverted several times and precipitated DNA spooled on 
a pipette tip. The spooled DNA was transferred to a 1.5 ml screw-cap tube. One millilitre 
of 70% ethanol was added to the DNA. The tube was spun at 8000 x g for 3 minutes, and 
the ethanol removed. The precipitated DNA was air dried for 10 minutes, 100 – 200 µl of 
water was added, and the DNA re-suspended overnight on a rotator mixer. 
 
2.4.2 Qiagen AllPrep DNA/RNA kit 
DNA and RNA were extracted from tumour biopsy samples using the Qiagen AllPrep 
DNA/RNA kit (Qiagen), and RNA was stored for use in other studies. Extractions were 
performed as per the manufacturer’s instructions. Briefly, a maximum of 1 x 107 cells 
were pelleted by centrifugation at 300 x g for 5 minutes in a 15 ml tube, and the medium 
aspirated. Cells were re-suspended in 600 µl of Buffer RLT Plus by mixing using a vortex. 
The lysate was transferred to an AllPrep DNA spin column in a 2 ml collection tube and 
spun in a microcentrifuge for 30 s at 8000 x g. The column was placed in a fresh collection 
tube, and stored at 4oC whilst RNA extraction was performed. 
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DNA extraction was continued by the addition of 500 µl of buffer AW1 to the column 
before centrifugation at 8000 x g in a microcentrifuge. The column was placed in a fresh 
collection tube and 500 µl of buffer AW2 was added to the column which was then spun 
in a microcentrifuge at 13,000 x g for 2 minutes. The flow-through was discarded and the 
column was placed in a fresh 1.5 ml collection tube, 100 µl of buffer EB was added to the 
column membrane and incubated at room temperature for 1 minute and then spun in a 
microcentrifuge for 1 minute at 8000 x g to elute the DNA. The eluate was then added 
back to the membrane and incubated for a further minute and spun again, to elute more 
DNA. DNA concentration was determined using either the Qubit® BR assay (Life 
Technologies) or NanoDrop reading (Thermo Scientific) as described below, and the 
sample stored at -80oC until required. 
 
2.5 DNA Concentrations 
DNA was quantified using one of three methods: NanoDrop 1000 Spectrophotometer 
(Thermo Scientific), the Qubit® Broad Range (BR) or High Sensitivity (HS) double-stranded 
DNA (dsDNA) assays (Life Technologies). 
 
2.5.1 NanoDrop 
The NanoDrop ND-1000 spectrophotometer measures the concentration and purity of a 
DNA sample through the absorption of light at wavelengths of 260 and 280 nm, which 
measures the concentration of double- and single-stranded DNA. Upon start-up of the 
device, 1 µl of water was loaded onto the sample stage, the arm closed, and the device 
initiated. The stage and arm were wiped clean and 1 µl of the appropriate eluent (e.g. 
water or elution buffer) was placed on the sample stage, the arm closed, and absorption 
measured to determine a blank reading. This process was repeated using the test DNA 
samples of which the concentration was to be measured. 
 
2.5.2 Qubit® BR and HS dsDNA quantification assays 
Both the Qubit® BR and HS dsDNA assays utilise a fluorescent DNA intercalating agent to 
quantify dsDNA. The range of quantification of the two assays are 2-1000 ng µl-1 (BR) and 
0.2-100 ng µl-1 (HS). The protocol for both was as follows: 199 µl of the supplied buffer 
was mixed with 1 µl of the fluorescing agent for each DNA sample to be tested, and for a 
set of two standards. Ten microlitres of each standard was mixed with 190 µl of the assay 
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mix in a Qubit® assay tube, and incubated for 2 minutes at room temperature. Each 
standard was placed in the Qubit® reader in the appropriate order and their fluorescence 
read. Two microlitres of each sample was mixed with 198 µl of the appropriate assay mix 
in Qubit® assay tubes, and the concentration read in the Qubit® reader. The concentration 
was then determined by multiplying by the appropriate dilution factor. 
The HS assay was used to quantify samples after a reading could not be obtained with the 
BR assay, and on DNA extracted from an agarose gel. 
 
2.6 PCR Methods 
Several polymerase chain reaction (PCR) based techniques were used in this project and 
the basic methods for each are described below. All primer and probe sequences for qPCR 
assays were designed with Primer ExpressTM V3.0 unless specified otherwise. Primers and 
probes were manufactured by either Life Technologies or Integrated DNA Technologies 
(IDT). Upon arrival, lyophilised primers were suspended to 1 µg µl-1 with double distilled 
water (Microzone) and stored at -80oC as stocks. Subsequently primers were diluted to 10 
µM, combined with the partner primer, aliquoted and stored at -20oC. Probes were 
treated in two ways; those that arrived lyophilised were re-suspended as for primers and 
diluted to a final concentration of either 5 or 10 µM. Those that arrived in solution were 
diluted straight to either 5 or 10 µM. Probes were aliquoted and stored at -20oC. 
 
2.6.1 TaqMan® real-time quantitative PCR 
TaqMan® qPCR is a means of quantifying target DNA molecules and utilises primers and a 
fluorescently labelled probe. There are two types of TaqMan® qPCR probes; one utilising 
probes labelled with the fluorophore TAMRA as a quencher molecule and the other 
utilising major grove binders (MGB) and dark quenchers. Each chapter includes a list of 
primer and probes used therein, fluorophores used as reporter and quencher dyes, and 
the system used. Sequences of all primers and probes are provided in Table A2-1. 
All TaqMan® reactions included 1 x TaqMan® Universal MasterMix without UNG (Life 
Technologies) and primers and probes in the specified concentrations in a final volume of 
25 µl. Super-mixes of mastermix, primers, probe, and water were made before each 
experiment and appropriate amount placed in the wells of either a 96-well optical plate 
or a 96-well fast optical plate. Sample or control DNA and water for no template controls 
(NTCs) were then added and optical caps used to seal the wells. Sealed plates were 
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agitated briefly on a vortex mixer and contents spun down using a CS-15 centrifuge (plate 
centrifuge). 
Thermal cycling and data collection were conducted on either a 7500 Real-Time PCR 
System or a 7500 Fast Real-Time PCR System. Although both systems were used for reasons 
of availability, standard cycling conditions of 50oC for 2 minutes, 95oC for 10 minutes 
followed by 40 cycles of 95oC for 15 s and 60oC for 1 minute, were used on both 
instruments. Data were collected and analysed using 7500 Software V2.0.6. 
 
2.6.2 Droplet Digital PCR 
Droplet digital PCR (ddPCR), like TaqMan®, uses primers and fluorescently labelled probes 
(in this 3’ dark quanchers) to quantify DNA. Unlike TaqMan®, in ddPCR a reaction is 
partitioned into approximately 20,000 oil droplets; this partitioning effectively increases 
the efficiency of a qPCR assay by reducing competition between target molecules and 
confining the reaction into a much smaller, finite area. In addition ddPCR measures 
fluorescence at the end of a reaction scoring droplets of oil as either positive or negative 
for amplification (Hindson et al., 2011). 
To confirm iciHHV-6 status and investigated iciHHV-6 configuration copy number variant 
(CNV) analyses using multiple viral specific assays in duplex with ones specific to human 
genes were performed. Optimisation of these assays is described in detail in Chapter 3. 
All ddPCR reactions consisted of 1x ddPCR supermix for probes without dUTP (Bio-Rad 
Laboratories), primers and probes at specified concentrations, and endogenous control 
assay components (specified when used) and 10-100 ng of template DNA in a final volume 
of 20 or 25 µl. Some reactions had an additional 1 µl of ‘digest mix’ and this is specified 
when included. 
The ddPCR protocol was as follows: a mastermix including all reaction components except 
DNA was prepared with an excess (one reaction volume per eight reactions). Twenty 
microlitres of this mastermix was added to wells of a 96-well plate, and 5 µl of DNA was 
added, before used wells were capped and reactions mixed by vortexing. Agitated 
reactions were spun down in a centrifuge. Either 20 or 21 µl of the reactions were loaded 
into the sample wells of a DG8 cartridge followed by 70 µl of droplet generating oil into 
each oil well, and droplets were generated in a QX200 droplet generator (all Bio-Rad 
Laboratories). Droplets were transferred to a 96-well Eppendorf plate using a p50 multi-
channel pipette. Droplets were aspirated over an approximate 10 s interval, and ejected 
at a similar rate. Care was taken to ensure a steady and constant movement of droplets. 
Wells were then heat-sealed with a foil seal using a PX1TM PCR Plate Sealer. 
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Thermal cycling was performed on a C1000 Touch Thermo Cycler (Bio-Rad Laboratories) 
using the following conditions (unless specified otherwise): 95oC for 10 minutes followed 
by 40 cycles of 94oC for 30 s and 60oC for 1 minute, and a final extension at 98oC for 10 
minutes. After amplification, results were analysed on a QX200 Droplet reader using 
QuantaSoft analysis software C1.4.0. 
 
2.6.2.1 DNA digestion for ddPCR 
DNA was digested with restriction enzymes either prior to ddPCR or using an ‘in-reaction’ 
digestion technique. 
Restriction enzyme (RE) digestion prior to ddPCR was performed as follows: 1-3 µg of DNA 
was digested with 10-20 U of the specified restriction enzyme with 1 x RE buffer in a final 
volume of 10-30 µl. Reactions were incubated at the appropriate temperature for 2 hours 
followed by heat inactivation where appropriate. The reaction was then diluted five-fold 
using double distilled water. 
For ‘in-reaction’ digests a mix of 5 U µl-1 of the appropriate enzyme in 1 x RE buffer was 
prepared immediately before ddPCR reactions were set up and 1 µl per reaction was 
added to the mastermix. After the addition of DNA reactions were incubated for 5 
minutes, before proceeding to droplet generation and ddPCR, as described in section 
2.6.2.  
 
2.6.3 Amplification with AccuPrimeTM Taq High Fidelity DNA 
Polymerase 
Standard Taq DNA polymerase lacks both the fidelity and processivity for-long range PCR 
or to generate PCR products for sequencing. For these reasons AccuPrimeTM Taq High 
Fidelity DNA Polymerase (AccuPrime Taq) was used (Life Technologies). AccuPrime Taq 
has 9-fold increased fidelity over standard Taq DNA polymerase and an increased yield 
compared to other long range enzymes. 
PCRs contained 1x AccuPrimeTM PCR Buffer 1, 300 nM primers, 1 unit AccuPrime Taq and 
template DNA, in a final volume of 25 µl. Thermal cycling conditions varied depending on 
the product being generated, but all reactions had an initial denaturation step at 94oC, 
followed by a variable number of appropriate denaturation, annealing and extension, and 
a final extension step. 
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2.7 PCR product purification 
PCR products were purified in one of two ways. If no non-specific products were present, 
Agencourt AMPure XP beads (GE Healthcare, UK) were used; if non-specific products were 
present the appropriately sized band was cut from a 0.8% agarose Tris-Acetate-EDTA 
(TAE) gel and product extracted using the PureLink® Quick Gel Extraction kit (Life 
Technologies). 
 
2.7.1 Agencourt AMPure XP Beads 
Product purification was performed as per the manufactures instructions for a 96-well 
plate format. Briefly, 0.5 x (7.5 µl) AMPure XP bead solution was added to 15 µl of PCR 
reaction, and pipetted up and down a minimum of ten times until homogeneous, and then 
incubated at room temperature for 5 minutes. To separate the beads from the solution, 
the 96-well plate was then placed onto a Magnetic Stand-96 (life Technologies) for 2 
minutes. Well contents were aspirated leaving 2-4 µl at the bottom of the well, before 
the addition of 200 µl of 70% ethanol and incubation at room temperature for 30 s. All 
ethanol was then aspirated, and a further 200 µl added and incubated for a further 30 s 
at room temperature. All ethanol was again aspirated and the 96-well plate removed from 
the magnet and allowed to air dry for several minutes. Forty microlitres of 10 mM Tris 
(pH 7-8) was added to the wells and the beads were re-suspended by pipetting at least 
ten times until an homogenous mix was seen, and incubated at room temperature for 2 
minutes to elute DNA. The 96-well plate was placed back on the magnet and incubated 
for 1 minute to separate the beads from the solution. Thirty-seven microlitres of the 
elution was then transferred to a new plate and DNA was quantified as discussed in section 
2.5.2. 
 
2.7.2 PureLink® Quick Gel Extraction Kit 
PCRs generating multiple products were subjected to agarose gel electrophoresis in a 
0.8% agarose TAE gel at 8.6 V cm-2. Appropriate fragments were chosen based on the 
expected size of the amplicon, and bands were cut from the gel using a scalpel and placed 
in individual 1.5 ml screw-cap tubes. 
Agarose was removed as per the PureLink® Quick Gel Extraction kit instructions. Briefly, 
gel slices were weighed and three volumes of buffer L3 per gel weight were added. Tubes 
containing the gel and buffer L3 were incubated at 50oC for 10 minutes, with periodic 
vortex mixing. Once all the agarose had dissolved, one gel volume of isopropanol was 
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added and mixed by vortexing. The solution was then added to Quick Gel Extraction 
Columns, spun in a microcentrifuge at 12,000 x g for 1 minute, and the flow-through 
discarded. Five hundred microlitres of buffer W1 was added to the column, spun as in the 
previous step and the flow through discarded. The column was spun for a further 2 
minutes at 12000 x g to ensure complete removal of buffer W1. Next, 50 µl of buffer E5 
was added directly to the centre of the column membrane and incubated at room 
temperature for 1 minute to elute DNA. The column was spun in a microcentrifuge at 
12000 x g for 1 minute and the eluate was quantified as described in section 2.5.2. 
 
2.8 Study participants 
DNA samples, disease data, and patient parameters from serval studies were utilised in 
this project. Each participant sample set is discussed in the appropriate chapter. 
Summarised here is ethical approval for the use of each. 
 
2.8.1 Ethical approval and accessing participant information 
For participants involved in cHL case and control studies ethical approval was obtained 
from research ethics committees (REC) for each of the four contributing studies as 
follows: SNEHD, NHS Research Ethics Committee for Wales, REC reference number 
08/MRE09/72; YHHCCS, NHS Greater Glasgow and Clyde West of Scotland Research Ethics 
Committee 4, REC reference number 09/S0704/73; ELCCS, NHS England Northern and 
Yorkshire Research Ethics Committee, REC reference number MREC/97/3/33; local case 
series, NHS Scotland Multi-Centre Research Ethics Committee for Scotland, REC reference 
number 06MRE00/83. All participants provided written informed consent. 
Each participant had been allocated a unique identifier number that enabled data storage 
and retrieval of pertinent clinical information that was stored on the LRF Virus Centre 
Database. This computer database stored recorded details of each participant and the 
samples held. Linked to this are separate databases storing participant information, 
associated clinical events, diagnoses, samples held, and their freezer location. This 
database allowed for timely retrieval of information and samples. Participant names are 
not held on this database; instead information is retrieved through the unique identifying 
number. 
Application for use of the Generation Scotland cohort was first made for a pilot study of 
approximately 2000 samples followed by an application for use of the full cohort. 
Generation Scotland Collaboration Proposal form numbers were GS12094 (pilot study) and 
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GS14204 (full study). Ethical approval for use of samples from the Generation Scotland 
cohort was covered through the Generation Scotland: Scottish Family Health Study Tissue 
Bank, REC reference number 10/S1402/20. 
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Chapter 3.  Optimisation of PCR-based methods for detecting 
inherited chromosomally integrated HHV-6 
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3.1 Introduction 
Both HHV-6A and HHV-6B can be acquired horizontally (exogenous virus), or vertically 
through inheritance of iciHHV-6, as mentioned previously. It is important to distinguish 
between these two forms of the virus when investigating possible disease and phenotypic 
associations. Furthermore exogenously-acquired virus can be present as either a latent or 
an actively replicating virus. 
The gold standard for confirming iciHHV-6 is FISH, where the virus can be localised to the 
telomeres of chromosomes in all observed cells. FISH has the added benefit of not only 
confirming the presence of iciHHV-6 but also identifying the chromosome on which 
integration has occurred; however, the technique is difficult, time consuming and 
requires access to metaphase cells. Molecular techniques to replace or complement this 
method would be beneficial. 
PCR based methods offer a fast and reliable means of distinguishing these two forms of 
HHV-6. Initially these focused on qualitative detection of a particularly high viral load. 
Previously publications have utilised nested PCR as a means of screening for iciHHV-6 
(Hall et al., 2004). Though highly sensitive, the fact this method is not quantitative means 
it cannot distinguish between forms of the virus, and techniques such as TaqMan® qPCR 
are more reliable. 
TaqMan® qPCR assays utilise target specific primers and probes, the latter being labelled 
with a reporter dye at the 5’ end and a quencher dye at the 3’ end. The change in 
fluorescence is measured over time allowing for the number of initial target molecules to 
be quantified. TaqMan® qPCR can be used to screen individuals for iciHHV-6, through 
determining the viral load of a sample. Due to the presence of a viral genome in every 
nucleated, somatic cell of the body in iciHHV-6, viral loads in excess of 106 – 107 copies 
ml-1 of whole blood can be observed (Leong et al., 2007). Such high viral loads mean 
iciHHV-6 is easily distinguishable from latent forms of the virus, where the viral load can 
be as low as 60 copies per million cells (Geraudie et al., 2012). Actively replicating virus 
can produce viral loads of approximately 105 copies ml-1 of whole blood (Griffiths et al., 
1999a). Use of TaqMan® qPCR allows for both absolute and relative quantification of a 
target. Relative quantification can be performed by using two assays in a single reaction 
(duplex assay). In the context of iciHHV-6 duplex assays have been used which target a 
single copy human gene, and a region of the virus providing an approximation of the virus 
copies per cell. Quantitative PCR is ideal for screening for iciHHV-6 but lacks the 
precession, and in a clinical setting where treatment decisions are necessary, or when 
studying iciHHV-6, more accurate means of confirming iciHHV-6 are required. 
Chapter 3: Assay Optimisation 
75 
 
A further technique that has recently been used to confirm the presence of iciHHV-6 is 
ddPCR. Droplet digital PCR partitions a single PCR reaction into approximately 20,000 oil 
droplets. This effectively increases the efficiency of a qPCR assay by reducing competition 
between targets and confining the reaction to a smaller area. In two recent studies ddPCR 
duplex assays targeting single copy human genes and viral regions have shown the 
technique can provide highly accurate HHV-6 copy numbers per cell (Leibovitch et al., 
2014; Sedlak et al., 2014). 
Since much of the work described in this thesis involved detection of iciHHV-6, the design 
and optimisation of duplex TaqMan qPCR assays used to screen for iciHHV-6 and ddPCR 
duplex assays used to confirm and further analyse iciHHV-6 are described here. 
 
3.2 Β-globin/U7 duplex assay 
To develop a robust means of screening for iciHHV-6 a duplex TaqMan® qPCR assay that 
could detect both HHV-6A and HHV-6B with similar efficiencies was developed. A review 
of the literature identified an assay designed to the U6/U7 region of HHV-6 (Tavakoli et 
al., 2007). The U6/U7 region has 95.1% sequence identity between HHV-6A (U1102) and 
HHV-6B (Z29) (Dominguez et al., 1999). The assay primer and probe sequences span a 95 
base pair region which contains four nucleotide changes between U1102 and Z29; 
however, none of these changes are in the primer and probe regions (Fig 3-1). Tavakoli 
et al. (2007) used primers and probe (Appendix 2) at concentrations of 1.1 µM and 200 
nM, respectively and were able to detect and quantify HHV-6 genomes over a range of 5- 
5x106 genome copies per reaction. The assay was found to have an efficiency of 100%, a 
standard curve slope (m value) of -3.32 and R2 = 0.99. 
 
 
Figure 3-1: U6/U7 assay amplicon sequences in HHV-6A and HHV-6B. Arrows indicate 
the primer and probe sequences. 
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3.2.1 U7 singleplex assay optimisation 
To develop a screening assay for iciHHV-6 the efficiency and sensitivity of this assay 
(designated U7 from here on) was evaluated. For optimisation experiments, and use as 
controls, the HHV-6A and HHV-6B amplicon sequences were synthesised and cloned into 
plasmids (pBS-U7A and pBS-U7B, respectively). To avoid contamination this was 
performed by Dundee Cell Products Ltd (Dundee, UK). Assay efficiency and sensitivity 
were assessed using duplicate 1 in 10 serial dilutions of each plasmid (1-1x105 copies per 
reaction). Reactions were prepared and performed as described in section 2.6.1, with 
primers and probe at 150 nM and 200 nM respectively (sequences in Appendix 2). A NTC 
was included every two reactions. 
For HHV-6A (Fig 3-2 A and B) the assay efficiency was 90.15% with an m value of -3.58 
and R2 = 0.998. For HHV-6B (Fig 3-2C and D) the assay efficiency was 85.21% with an m 
value of -3.74. The detection limit for HHV-6A and HHV-6B was 10 copies per reaction 
each. 
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Figure 3-2: Amplification plots of the U7 assay performed on a 10-fold dilution series 
of plasmids pBS-U7A (A) and pBS-U7B (C). In both, plasmid copy numbers of 100,000 
(red), 10,000 (orange), 1000 (light green), 100 (dark green), 10 (cyan) and 1 copy per 
reaction (dark blue) were used. B) Standard curve for pBS-U7A (generated from 100-
100,000 copies per reaction). D) Standard curve for pBS-U7B (generated from 100-100,000 
copies per reaction). Replicates with CT values less than 34 were omitted when generating 
the standard curve. 
 
Next the efficiency of the U7 assay in a background of genomic DNA was assessed. Ten-
fold serial dilutions (1-1000 copies per reaction) of each plasmid were spiked into a 
background of 100 ng of human genomic DNA. Reactions were prepared and conducted as 
in section 2.6.1 with primers at 150 nM, probe at 200 nM and template DNA in a final 
volume of 25 µl. Ten replicates were performed at each dilution. For both plasmids the 
assay was able to detect all replicates at 1000 and 100 copies per reaction 7 out of 10 
replicates at 10 copies per reaction and none at 1 copy per reaction (Fig 3-3).  
 
A B 
C D 
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Figure 3-3: Amplification plots of the U7 assay conduced on 10-fold dilution series of 
plasmids pBS-U7A (A) and pBS-U7B (B) spiked into a 100 ng genomic DNA background. 
A) Amplification of 1000 copies per reaction (red), 100 copies per reaction (yellow) and 
10 copies per reaction (green). B) Amplification of 1000 copies per reaction (cyan), 100 
copies per reaction (blue) and 10 copies per reaction (purple). 
 
Although not as efficient as described previously, the U7 assay was found to be a robust 
and sensitive assay when amplifying plasmids contained the amplicon regions from HHV-
6A and HHV-6B, with little difference in efficiency between the two. 
 
3.2.2 Duplex assay: β-globin component optimisation 
To develop this assay for iciHHV-6 screening it was combined with an assay for the human 
β-globin gene, a single copy human gene (Appendix 2). The β-globin component of this 
duplex assay acts as an endogenous control and a reference for comparisons to the U7 
assay. When using duplex assays containing an endogenous control, limiting the control 
primer concentration is recommended. This limitation prevents the control assay target 
out-competing the test target for reaction components. When run on its own, the β-globin 
assay performed in our laboratory has a primer concentration of only 50 nM (Gallagher et 
al., 2003). To obtain the lowest possible β-globin primer concentration that could be used 
when in duplex with the U7 assay, β-globin primer concentrations of 50 nM, 25 nM and 
12.5 nM were compared. Reactions were run and prepared as described in section 2.6.1 
with appropriate primer concentration 200 nM probe and template DNA. Template DNA 
consisted of duplicates of a ten-fold dilution series of pBS-U7A and pBS-U7B (1-1x105 
copies per reaction) in a background of 10 ng of human genomic DNA. 
Figure 3-4A shows the amplification plots for each β-globin primer concentration and 1000 
copies of pBS-U7A. Lowering the β-globin primer concentration below 50 nM resulted in a 
right shift of the observed CT. The mean ΔCT (CTβ-globin – CTU7) for the three primer 
A B 
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concentrations was 10.1, 8.9 and 4.9, respectively. As well as the right shift in the 
amplification plot, reduced primer concentration caused reactions to plateau earlier. β-
globin assay efficiency was affected by the amount of pBS-U7A present (Fig 3-4B-D) and 
this became more pronounced the lower the β-globin primer concentration. However, 
lowering the β-globin primer concentration below 50 nM had little effect on the 
amplification of U7. Since lowering the β-globin primer concentration bellow 50 nM 
effected the β-globin assay efficiency without any further improvement in U7 
amplification, a β-globin primer concentration of 50 nM was chosen for subsequent 
experiments.  
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Figure 3-4: Duplex assay amplification plots using limited concentrations of β-globin 
primer. In all cases β-globin plots are blue whilst U7 plots are green. A) Duplex assay 
amplification plots using the three β-globin primer concentrations and U7 primers at 150 
nM and 1000 copies per reaction in a background of 10 ng human genomic DNA. B-D) 
Duplex amplification plots of pBS-U7A ten-fold dilution series (1-1x105 copies per 
reaction) in a background of 10 ng human genomic DNA. Reducing the β-globin primer 
concentration results in an increase β-globin CT range between the top and bottom ends 
of the pBS-U7A dilution series. 
 
A 
B C 
D 
50 nM 
25 nM 12.5 nM 
50 nM 25 nM 
12.5 nM 
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3.2.3 B-globin/U7 duplex assay on known iciHHV-6 cases 
β-globin and U7 in duplex and singleplex were then compared using DNA from an iciHHV-
6-positive individual. The aim was to ensure that the efficiency of each component of the 
duplex assay was similar to that of the singleplex equivalent. Each reaction was conducted 
in duplicate and was prepared as per section 2.6.1 with  either β-globin primers at 50 nM, 
U7 primers at 150 nM or both primer sets, probes at 200 nM and template DNA. Template 
DNA was a 1 in 10 dilution series of iciHHV-6B DNA (100, 10 and 1 ng). As shown in Fig. 3-
5A, at each DNA amount the β-globin amplification was comparable between the duplex 
and singleplex assays. Whilst the duplex β-globin amplification curves plateaued earlier 
than in the singleplex assays, the CT values showed little variation, with β-globin ΔCT (CT 
Duplex – CT Single) of 0.12, 0.07 and 0.55 for 100, 10 and 1 ng, respectively. These findings 
were mirrored in the U7 assay (Fig 3-5B). The lack of variation in the CT values indicates 
that the efficiency of each component of the duplex assay is similar to that of its 
singleplex equivalent. The fact that the amplification curves in the duplex assay plateau 
earlier than in the singleplex assay is expected since nucleotides will be depleted quicker 
when two targets are amplified simultaneously. 
 
 
Figure 3-5: Amplification plots comparing duplex components to their singleplex 
equivalents. A) Singleplex β-globin (yellow) and duplex β-globin (green) plots show there 
is little difference between the two for 100, 10 and 1 ng of iciHHV-6-positive DNA. B) 
Singleplex U7 (red) and duplex U7 (cyan) plots mirror the findings for β-globin. 
 
Given the above findings, it was decided that the duplex assay would use β-globin and U7 
primer concentrations of 50 nM and 150 nM, respectively. As this assay was to be used to 
screen for iciHHV-6, the optimised assay was tested on additional samples from iciHHV-
6-positive individuals. For this, DNA from a LCL generated from an individual with an 
integrated virus at 9q34.31 (donated by Dr Nicola Royle, University of Leicester) (Nacheva 
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et al., 2008), and DNA from an individual suspected of being iciHHV-6-positive, was used 
(Jarrett et al., 1988). Both of these viruses were HHV-6B. If both samples had only one 
integrated virus each, and both assays has similar efficiencies, a β-globin:U7 copy number 
ratio of 2:1 would be expected. If both the components of the duplex assay had the same 
efficiency this would equate to a ΔCT of 1, as during exponential amplification target copy 
number is expected to double each cycle. 
The duplex assay was conducted on the above two samples with β-globin primers at 50 
nM each, U7 primers at 150 nM each, both probes at 200 nM and 100 ng of template DNA 
in a final reaction volume of 30 µl. Amplification and data analysis were performed as 
above. The observed ΔCT values for the iciHHV-6-positive samples were 3.72 and 3.86 for 
the known and suspected iciHHV-6 samples, respectively, with a mean value of 3.79. 
The final assay had primer concentrations of 50 nM each for β-globin primers and 150 nM 
each for U7 primers. Testing on cases with known iciHHV-6 and suspected iciHHV-6 
confirmed that a ΔCT of approximately 3.8 is indicative of iciHHV-6. 
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3.3 B-globin/DR1 TaqMan duplex assay 
As this project progressed evidence emerged suggesting that regions of the viral genome 
could be lost possibly through the process of T-loop formation (Huang et al., 2013) 
(Discussed in Chapter 6). This raised the possibility of individuals whose genome contains 
only DR sequence which would not be detected by screening with the β-globin/U7 assay. 
To be able to detect inheritance of only DR sequence, a duplex assay that incorporated 
the human β-globin assay and an assay to the viral HHV-6 DR1 gene was developed. 
To design an assay that would detect the DR region of both HHV-6A and HHV-6B, the DRs 
of HHV-6A strains U1102 (NCBI accession number: NC001664) and GS (KC465951), and 
HHV-6B strains HST (AB021506) and Z29 (NC000898) were aligned using CLC genomics 
workbench V7.0, to identify regions of minimal variability. The primer and probe 
sequences were subsequently selected from a region within DR1 with homology between 
all four strains (Appendix 2). The primer and probe sequences were then aligned to the 
DR1 gene of two further HHV-6A and 14 HHV-6B sequences kindly provided by Dr Nicola 
Royle (University of Leicester, unpublished sequences), and no polymorphisms in primer 
and probe regions were detected. 
 
3.3.1 B-globin/DR1 TaqMan duplex assay optimisation 
To determine the optimal primer concentration, primer concentrations of 600 nM, 300 nM 
or 150 nM were compared. Reactions also contained probe at 200 nM and 100 ng of 
template DNA (a known iciHHV-6B positive sample, 3986), and reactions were performed 
in triplicate. The mean CT for 600, 300 and 150 nM primer reactions were 21.95, 22.17 
and 23.11, respectively. As there is little difference between the CT for 600 and 300 nM, 
a concentration of 300 nM for each DR1 assay primer was selected for subsequent 
reactions (Fig. 3-6). 
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Figure 3-6: Primer concentration titration for DR1 singleplex TaqMan® assay. There 
was little difference in the CT or ΔRn of the amplification curves for 600 nM and 300 nM 
primers. Using 150 nM primers the CT values increased and there was a reduced ΔRn. 
 
The efficiency of the DR1 singleplex assay and in duplex with the β-globin was assessed 
on iciHHV-6A-positive and iciHHV-6B-positive samples. The reactions contained DR1 
primers at 300 nM, β-globin primers at 50 nM and both probes at 200 nM. Template DNA 
was a 10-fold dilution series (10 pg- 1000 ng) of either a iciHHV-6A (subject 4298) or a 
iciHHV-6B (subject 3986) positive samples, and all reactions were performed in duplicate. 
For iciHHV-6A (Fig. 3-7A and B) the efficiency of the DR1 assay in singleplex was 98.31%, 
with an m value of -3.36 and a y intercept of 38.52. In duplex (Fig. 3-7C and D) the 
efficiency of the DR1 component was 97.47% with an m value of -3.38 and a y intercept 
of 38.86. The efficiency of the β-globin component was 97.66% with an m value of -3.38 
and a y intercept of 38.20 with R2 = 0.998. 
600/300 nM 150 nM 
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Figure 3-7: Singleplex (A) and duplex (C) amplification using the DR1 assay across a 
10-fold dilution series of an iciHHV-6A positive sample. Standard curves were generated 
for copy number (copies per reaction) of DR1 singlplex (B), and DR1 and β-globin in duplex 
(D). DR1 amplification plots shown are in orange and β-globin in blue. Though this subject 
has a DR copy number of 5 per cell (Chapter 6) amplification curves were right shifted 
compared to β-globin ones. 
 
For iciHHV-6B (Fig. 3-8) the efficiency of the DR1 assay in singleplex was 93.54%, with an 
m value of -3.49, a y intercept of 29.24 and R2 = 1. In duplex the efficiency of the DR1 
component was 94.47%, with an m value of -3.46, y intercept of 29.47 and R2 = 0.998. 
The efficiency of the β-globin component was 96.61%, with an m value of -3.4, y intercept 
of 37.99 and R2 = 0.998. 
For both iciHHV-6A and iciHHV-6B the DR1 assay was slightly less efficient when 
performed in duplex and the assay efficiency is slightly better when using iciHHV-6A DNA 
as a template. However, the efficiency of both duplex assays was good and they were 
therefore considered suitable for iciHHV-6 screening. 
A B 
C D 
DR
1 
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Figure 3-8: Singleplex (A) and duplex (C) amplification using the DR1 assay across a 
10-fold dilution series of an iciHHV-6B positive sample. Standard curves generated for 
DNA amount (ng) for DR1 singlplex (B) and DR1 and β-globin in duplex (D). Although curves 
overlay, two distinct curves can be identified at high DNA amounts. DR1 amplification 
plots shown are in orange and β-globin in blue. 
 
 
3.3.2 B-globin/DR1 duplex TaqMan® assay on known iciHHV-6-
positive samples 
As with the β-globin/U7 duplex TaqMan® assay, the β-globin/DR1 assay was used to screen 
for iciHHV-6 with a ΔCT value as the readout (CTβ-globin – CTDR1). To determine the range 
of expected ΔCT values, the β-globin/DR1 duplex assay was performed using DNA from six 
known iciHHV-6-positive subjects as template (two -6A and four -6B). Reactions contained 
300 nM DR1 primers, 50 nM β-globin primers, 200 nM probes and 100 ng of template DNA. 
Excluding the value for subject 3944, which appears as an outlier, the ΔCT range was 2.17-
2.51, with a mean of 2.28. Subject 3944 had a higher than expected DR1 CT value (Table 
3-1). Loss of a DR region (discussed in Chapter 6) or reduced assay efficiency due to 
A B 
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unexpected base changes in the DR1 primer and probe binding sights could account for 
the increased ΔCT for 3944. 
 
Table 3-1: β-globin/DR1 Duplex TaqMan® assay performed on multiple iviHHV-6-positive 
samples 
Sample 
HHV-6 
type 
CT value 
ΔCT 
Β-globin DR1 
3944 A 24.07 30.37 6.3 
3-10q23.3 A 21.47 23.98 2.51 
3627 B 26.05 28.22 2.17 
3799 B 25.67 27.93 2.26 
3982 B 26.16 28.38 2.22 
3986 B 26.04 28.29 2.25 
 
  
3.4 Droplet Digital PCR 
Droplet digital PCR uses TaqMan® like chemistry but enables more precise and accurate 
quantification of target molecules. After preparation of reactions, they are partitioned 
into ‘water-in-oil’ droplets, each of which supports amplification of the targets contained 
therein. Unlike TaqMan® qPCR, where the change in fluorescence is measured each cycle, 
digital PCR relies on end-point measurements of the fluorescence. In ddPCR the 
fluorescence intensity of each droplet is read, and droplets are scored as positive or 
negative, with each droplet acting as a reaction replicate. Coupled with the known 
volume of each droplet, this allows an estimate of DNA concentration. Segregating target 
molecules into droplets effectively increases the efficiency of a PCR by reducing 
competition between targets and confining the reaction into a smaller volume (Hindson 
et al., 2011). 
The improved accuracy of ddPCR over TaqMan® is particularly attractive for investigating 
iciHHV-6, where accurate copy numbers are crucial for determining human:viral gene 
copy numbers, and confirming iciHHV-6. Two recent publications have highlighted the 
accuracy and effectiveness of ddPCR for screening and confirming iciHHV-6. In these 
publications the HHV-6 copy numbers in samples with iciHHV-6 observed with ddPCR were 
1.03, 0.98 and 1.02 copies per cell (Leibovitch et al., 2014; Sedlak et al., 2014). 
The QX200 Droplet Digital PCR System (Bio-Rad Laboratories, Hertfordshire, UK) partitions 
20 µl PCRs into approximately 20,000 nanolitre-sized droplets. The β-globin/U7 assay with 
components described above was initially developed for use on this system. The QX200 
Droplet Reader is able to detect fluorescence in two channels enabling the use of duplex 
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assays with reported dyes 6-FAM and HEX or VIC. As there are only two channels TAMRA 
and other fluorescent quencher molecules cannot be used and instead probes must 
contain a dark quencher. 
 
3.4.1 ddPCR assays for quantifying HHV-6 
Five virus-specific assays for quantifying HHV-6A and HHV-6B with ddPCR were developed 
(Appendix 2). All viral assays were designed to be used in duplex initially with the human 
β-globin assay, and then later with a commercially available endogenous control assay, 
which amplifies a region of the human RPP30 gene (Bio-Rad Laboratories). 
Droplet digital PCR results were analysed with several outputs (Fig. 3-9). ‘One 
dimensional’ plots display the fluorescence amplitude on each droplet in each channel 
(Fig.9-3A and C), droplets are scored as either positive (coloured) or negative (grey). The 
total number of droplets analysed for each reaction should exceed 10,000 droplets, for 
accurate quantification. The quantity of each target per µl (data not shown) is calculated 
through Poisson statistics (Hindson et al., 2011). The QX200 platform allows one channel 
to be set as a reference and the other as an unknown, permitting quantification of the 
unknown target relative to the reference target. In the context of iciHHV-6 this provided 
HHV-6 copies per cell when β-globin or RPP30 were set as the reference (Fig. 3-9E). 
 
3.4.2 MGB β-globin/U7 duplex assay 
Minor-groove binder (MGB) probes (Life Technologies) which have 3’ dark quenchers were 
initially used. The sequences for both the β-globin and U7 probes were shortened as per 
Life Technologies guidelines for designing MGB probes (Appendix 2), and the assay 
optimised, first on the TaqMan® platform (data not shown) and then with ddPCR. 
Figure 3-9 shows the output from the ddPCR CNV analysis for the β-globin/U7 duplex assay 
on DNA from four iciHHV-6-positive LCLs. All reactions had in excess of 10,000 droplets. 
Droplets in the β-globin channel were seen to form five groups (in all cases), three 
negative and two positive (Fig. 3-9A & B), whilst the U7 channel had only two, one positive 
and one negative (Fig. 3-9C & D). With the exception of one (LCL 3-10q23.31) HHV-6 copy 
numbers clustered extremely close to 1 genome copy per cell (Fig. 3-9E). The reason for 
five groups of droplets appearing in the β-globin channel is unclear, though it does not 
seem to affect the HHV-6 copy number results. The two positive groups are not likely to 
be non-specific amplification or amplification of pseudo-gene as this would affect the 
observed HHV-6 copy number. Although ‘splitting’ of the lines of droplets on the one 
Chapter 3: Assay Optimisation 
89 
 
dimensional plots is a frequent feature of ddPCR (section 3.4.12), the presence of five 
lines of droplets was not adequately explained even after discussion with Bio-Rad experts 
and therefore it was decided to replace the β-globin assay with one for RPP30. 
 
 
 
Figure 3-9: Droplet digital PCR CNV analysis output for the β-globin/U7 assay 
performed on DNA from 4 LCLs. A) One-dimensional plot of droplets in the β-globin 
channel (channel 1) showing positive (blue) and negative droplets (grey). B) Histogram of 
the droplet frequency vs. droplet fluorescence amplitude for the β-globin channel. C) 
One-dimensional plot of droplets in the U7 channel showing positive (green) and negative 
droplets (grey). D) Histogram of the droplet frequency vs. droplet fluorescence amplitude 
for the U7 channel. E) Plot of the observed HHV-6 copy numbers, error bars indicate the 
Poisson 95% confidence intervals (CIs). 
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3.4.3 ddPCR RPP30 assay 
The human RPP30 gene encodes for the p30 subunit of the ribonuclease P protein (Eder 
et al., 1997). A commercially available primer and probe assay targeting RPP30 was used 
to replace β-globin (Bio-Rad Laboratories).  
The RPP30 assay was compared to β-globin by performing the assays in duplex (with RPP30 
with a HEX reporter dye) (Fig. 3-10). Unlike β-globin, the RPP30 assay had two discrete 
bands (Fig. 3-10A and 3-10B), which correspond to droplets positive for amplification 
(green) and negative droplets (grey). RPP30 concentrations of two replicates showed 
minimal variability (Fig. 3-10C), at 199 copies µl-1 and 200 copies µl-1, respectively. For 
these reasons it was decided that all duplex assays run on the ddPCR platform would now 
use the RPP30 assay as the endogenous control, using FAM as the reporter dye (detected 
in channel 1), and viral assays would use HEX (detected in channel 2) unless specified 
otherwise. 
 
 
Figure 3-10: Comparison of β-globin and RPP30 using duplex reactions. A) Droplet plot 
of the β-globin assay, the two blue bands indicate positive droplets, and the grey, 
negative droplets. B) Droplet plot of the RPP30 assay. Two discreet bands of droplets are 
seen, positive droplets (green) and negative droplets (grey). C) RPP30 copies ul-1 in two 
replicates.  
A 
B 
C 
Chapter 3: Assay Optimisation 
91 
 
3.4.4 ddPCR RPP30/U7 duplex assay 
The U7 MGB assay was subsequently combined with the RPP30 assay. Reactions were 
performed with 1x RPP30 primer and probe mix, 300 nM U7 primers and 200 nM probe. 
Other reaction components were as above with the exception of 100 ng of template DNA 
(the increase in DNA amount compared to reactions described earlier is discussed in 
section 3.4.10). Reactions were performed in triplicate, on DNA from the iciHHV-6B 
positive LCL 4-11p15.5 (Nacheva et al., 2008). 
The output from this assay is shown in figure 3-11. The assay generated highly 
reproducible concentrations for each component, with little variability in RPP30 copies 
(1530 copies µl-1) or U7 copy number (756 – 768 copies ul-1) (Fig. 3-11C). The estimated 
HHV-6 copies per cell range was 0.994–1.00 copies per cell with an average copy number 
of 0.996 copies per cell (95% Poisson CI, 0.975, 1.02) (Fig. 3-14D). 
 
 
Figure 3-11:  ddPCR output for the RPP30/U7 duplex assay conducted on DNA from 
the LCL 4-11p15.5. A) ‘One dimensional plot for analysis of the three replicates (A02-
C02) using the RPP30 assay (channel 1). Positive droplets are seen in blue and negative 
droplets in grey. B) ‘One dimensional plot for analysis of the three replicates (A02-C02) 
using the U7 assay (channel 2). Positive droplets are seen in green and negative droplets 
in grey. C) Concentrations of RPP30 (blue) and U7 (green) for each replicate and an 
average (merged). D) HHV-6 copies per cell for each of the replicates and an average 
(merged). Error bars representing the Poisson 95% CI are difficult to discern as CIs are 
very small. 
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3.4.5 ddPCR RPP30/HHV-6A Pol duplex assay 
The HHV-6A-specific TaqMan® assay designed to amplify a region of the viral DNA 
polymerase gene (Pol), or U38, has been descried previously (Gallagher et al., 2002). 
Reporter and quencher dyes were changed to HEX and BHQ1, respectively, for the 
purposes of ddPCR. Reactions were conducted as described in section 2.6.2 with 100 ng 
of template DNA that was HindIII digested before reaction set up, 0.5x RPP30 assay mix, 
300 nM primers and 200 nM probe. The reduction in the RPP30 concentration from 1x to 
0.5x is discussed in section 3.4.12. Reactions were performed in triplicate using DNA from 
the iciHHV-6A positive LCL 7-17p13.3. 
RPP30 concentration range between replicates was 1010–1060 copies µl-1, with an average 
concentration of 1030 copies µl-1 (Poisson 95% CI: 1020, 1050). HHV-6A Pol concentration 
range was 517–522 copies µl-1, with an average concentration of 520 copies µl-1 (Poisson 
95% CI: 511, 529) (Fig. 3-12C). The estimated range of HHV-6A copy number was 0.978–
1.04 copies per cell, with an average of 1.01 copies per cell (Poisson 95% CI: 0.984, 1.03) 
(Fig. 3-12D).  
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Figure 3-12: ddPCR output for the RPP30/HHV-6A Pol duplex assay conducted on DNA 
from the LCL 7-17p13.3. A) ‘One dimensional plot for analysis of the three replicates 
(B09-D09) using the RPP30 assay (channel 1). Positive droplets are seen in blue and 
negative droplets in grey. B) ‘One dimensional plot for analysis of the three replicates 
(B09-D09) using the HHV-6A Pol assay (channel 2). Positive droplets are seen in green and 
negative droplets in grey. C) Concentrations of RPP30 (blue) and HHV-6A Pol (green) for 
each replicate and an average (merged). D) HHV-6 copies per cell for each of the 
replicates and an average (merged). Error bars representing the Poisson 95% CI are 
difficult to discern as CIs are very small. 
 
3.4.6 ddPCR RPP30/HHV-6B Pol duplex assay 
As with the HHV-6A Pol-specific assay, the HHV-6B Pol assay has been described previously 
(Gallagher et al., 2002), and reporter and quencher dyes were changed to HEX and BHQ1 
respectively. Reactions were conducted with 1x RPP30 primer and probe mix, 300 nM U7 
primers and 200 nM probe. Other reaction components were as above with the exception 
of 100 ng of template DNA. Reactions were performed in triplicate, using DNA from the 
iciHHV-6B positive LCL 4-11p15.5 (Nacheva et al., 2008). 
The RPP30 concentration range between replicates was 1480–1500 copies µl-1, with an 
average concentration of 1490 copies µl-1 (Poisson 95% CI, 1470, 1510). The HHV-6B Pol 
concentration range was 728–757 copies µl-1, with an average of 745 copies µl-1 (Poisson 
95% CI, 733, 757) (Fig. 3-13C). The estimated HHV-6 copy number ranged from 0.981–1.01 
copies per cell, with an average of 0.999 copies per cell (95% CI, 0.978, 1.02) (Fig. 3-
13D). 
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Figure 3-13: ddPCR output for the RPP30/HHV-6B Pol duplex assay conducted on DNA 
from the LCL 4-11p15.5. A) ‘One dimensional plot for analysis of the three replicates 
(A01-C01) using the RPP30 assay (channel 1). Positive droplets are seen in blue and 
negative droplets in grey. B) ‘One dimensional plot for analysis of the three replicates 
(A01-C01) using the HHV-6B Pol assay (channel 2). Positive droplets are seen in green and 
negative droplets in grey. C) Concentrations of RPP30 (blue) and HHV-6B Pol (green) for 
each replicate and an average (merged). D) HHV-6 copies per cell for each of the 
replicates and an average (merged). Error bars representing the Poisson 95% CI are 
difficult to discern as CIs are very small. 
 
3.4.7 ddPCR RPP30/DR6A duplex assay 
A HHV-6A DR6 (DR6A) specific assay designed using PrimerExpressTM software (Appendix 
2). To assess its use as a ddPCR assay in duplex with RPP30, reactions were conducted as 
described in section 2.6.2 with 100 ng of template DNA AluI digested before reaction set 
up, 0.5x RPP30 assay mix, 300 nM primers and 200 nM probe. Reactions were performed 
in triplicate using DNA from the iciHHV-6A positive LCL 7-17p13.3. 
The RPP30 concentration range between replicates was 1290–1390 copies µl-1, with an 
average of 1340 copies µl-1 (Poisson 95% CI: 1321, 1357). The HHV-6A DR6A concentration 
range between replicates was 1290–1420 copies µl-1, with an average of 1360 copies µl-1 
(Poisson 95% CI: 1373, 1337) (Fig. 3-14C). The estimated copy number range was 2–2.05 
copies per cell, with an average of 2.02 copies per cell (Poisson 95% CI: 1.99, 2.06) (Fig. 
3-14D). 
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Figure 3-14: ddPCR output for the RPP30/DR6A duplex assay conducted on DNA from 
the LCL 7-17p13.3. A) ‘One dimensional plot for analysis of the three replicates (A08-
C08) using the RPP30 assay (channel 1). Positive droplets are seen in blue and negative 
droplets in grey. B) ‘One dimensional plot for analysis of the three replicates (A08-C08) 
using the DR6A assay (channel 2). Positive droplets are seen in green and negative droplets 
in grey. C) Concentrations of RPP30 (blue) and DR6A (green) for each replicate and an 
average (merged). D) HHV-6 DR copies per cell for each of the replicates and an average 
(merged). Error bars representing the Poisson 95% CI are difficult to discern as CIs are 
very small. 
 
3.4.8 ddPCR RPP30/DR6B duplex assay 
A HHV-6B DR6 (DR6B) specific assay designed using PrimerExpressTM software (Appendix 
2). To assess its use as a ddPCR assay in duplex with RPP30, reactions were conducted as 
described in section 2.6.2 with 100 ng of template DNA, digested before reaction set up, 
0.5x RPP30 assay mix, 300 nM primers and 200 nM probe. Reactions were performed in 
triplicate using DNA from the iciHHV-6B-positive LCL 1-9q34.3. 
The RPP30 concentration range between replicates was 1390–1460 copies µl-1, with an 
average of 1410 copies µl-1 (Poisson 95% CI: 1400, 1430). The HHV-6A DR6A concentration 
range between replicates was 1290–1360 copies µl-1, with an average of 1340 copies µl-1 
(Poisson 95% CI: 1310, 1340) (Fig. 3-15C). The estimated copy number range was 1.85–
1.91 copies per cell, with an average of 1.88 copies per cell (Poisson 95% CI: 1.84, 1.91) 
(Fig 3-15D). The DR6B copies per cell were lower than expected for a single integrated 
virus. To ensure this was not a problem with this duplex assay a plasmid was synthesised 
containing the RPP30 and DR6B amplicons (DNA2.0 Menlo Park, CA, USA). Droplet digital 
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PCR performed on this plasmid demonstrated a consistent 1:1 ratio between RPP30 and 
DR6B (data not show). 
 
 
 
Figure 3-15: ddPCR output for the RPP30/DR6B duplex assay conducted on DNA from 
the LCL 1-9q34.4. A) ‘One dimensional plot for analysis of the three replicates (A11-C11) 
using the RPP30 assay (channel 1). Positive droplets are seen in blue and negative droplets 
in grey. B) ‘One dimensional plot for analysis of the three replicates (A11-C11) using the 
DR6B assay (channel 2). Positive droplets are seen in green and negative droplets in grey. 
C) Concentrations of RPP30 (blue) and DR6B (green) for each replicate and an average 
(merged). D) HHV-6 DR copies per cell for each of the replicates and an average (merged). 
Error bars representing the Poisson 95% CI are difficult to discern as CIs are very small. 
 
3.4.9 ddPCR duplex assay temperature gradients 
A major factor that can affect the efficiency of any PCR, and in the case of ddPCR the 
concentration and copy number estimates, is the reaction annealing temperature (TA). 
The standard TA used in ddPCR reactions was 60
oC. To ensure this is the optimal TA for 
each of the duplex assays ddPCR across a TA temperature gradient of 55–65
oC (Individual 
temperatures: 55, 55.8, 57.1, 59, 61.2, 63.1, 64.1 and 65oC) was conducted. HHV-6A 
specific reactions were conducted on DNA from the iciHHV-6A-positive LCL 3-10q23 or 
sample 4298 and HHV-6B positive reactions on DNA from an iciHHV-6B positive individual, 
3986 (subjects 4298 and 3986 are described in Chapter 4) All reactions contained 0.5x 
RPP30 primer and probe mix (this reduction is discussed in 3.4.12), viral primers and 
A 
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probes at 300 nM and 200 nM respectively, 100 ng of template DNA for HHV-6A reactions 
and 50 ng of template DNA for HHV-6B reactions, in a final volume of 25 µl. DNA was 
digested prior to amplification with HindIII (HHV-6A Pol and DR6, HHV-6B Pol and DR6) or 
AluI (HHV-6 U7). DNA at a concentration of 50-100 ng µl-1 was digested as described in 
section 2.6.2.1. 
The RPP30 component of the assays was consistently more temperature-sensitive than 
the viral component (Fig. 3-16). For all assays the fluorescence amplitude of both the 
RPP30 and viral positive droplets did not reduce until the TA>61
oC. Only when TA>63.1
oC 
did the observed HHV-6 copies per cell differ by more than 10% of the expected value (Fig 
3-16D, data shown only for RPP30/HHV-6B duplex assay). In all cases this was due to 
reduction in the observed RPP30 concentration (Fig. 3-16C). Due to these results the TA 
was maintained at 60oC for all experiments. 
 
 
Figure 3-16: ddPCR output for the RPP30/HHV-6B Pol duplex assay conducted on DNA 
from an iciHHV-6B positive individual, conducted over a TA gradient of 55–65
oC (H01-
A01). A) Droplet plot for the RPP30 component showing positive (blue) and negative (grey) 
droplets. B) Droplet plot for the HHV-6B Pol component showing positive (green) and 
negative (grey) droplets. In both A and B, the fluorescence amplitude of the positive 
droplets reduces as the temperature increases. C) Concentrations of both targets of the 
duplex assay, RPP30 (blue) and HHV-6B Pol (green). D) HHV-6 copies per cell, the 
expected copy number for subject 3986 is 1 copy per cell.  In all panels temperature 
increase progresses from left to right. 
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3.4.10 DNA amounts and precision in ddPCR 
The appropriate amount of DNA needed to obtain both precise and accurate concentration 
and HHV-6 copy number estimates was determined. The RPP30/U7 ddPCR assay was 
performed using serial 10-fold dilutions of LCL 4-11p15.5 (100 pg–100 ng) and reactions 
were performed in duplicate. Reactions contained the appropriate amount of DNA and all 
other components as described in section 2.6.2. 
Reducing the amount of template DNA used increases the variability in concentration and 
copy number estimates (Fig. 3-17D), as well as widening of the Poisson 95% CIs. When the 
data for the replicates was merged, variability within 10% of the expected HHV-6 copies 
per cell was seen for 1-100 ng DNA. The merged HHV-6 copies per cell are 1.01 (95% 
Poisson CI, 0.978, 1.03), 1.09 (1.01, 1.17), 0.947 (0.726, 1.17) and 2.47 (0.874, 4.07) for 
100 ng, 10 ng, 1 ng and 100 pg of DNA, respectively (Fig. 3-17D). 
DNA amounts of 1-100 ng have HHV-6 copies per cell within acceptable levels of variability 
(10%); however, inter-replicate variability was reduced to less than 5% when 100 ng of 
DNA was used (1 and 1.01 copies per cell for each replicate). As a result of this 100 ng of 
DNA was used in all subsequent experiments where possible; if DNA was limited, 10 or 1 
ng of DNA was acceptable. These results were supported by a recent publication (Sedlak 
et al., 2014). However, Sedlak et al, (2014) suggest that 100 ng of DNA is the minimum 
amount of DNA that can be used. 
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Figure 3-17: ddPCR output for the RPP30/U7 duplex assay performed on duplicate 10-
fold serial dilutions of DNA from LCL 4-11p15.5 (100 pg – 100 ng). A) Droplet plot for 
the RPP30 component showing positive (blue) and negative (grey) droplets. B) Droplet 
plot for the U7 component showing positive (blue) and negative (grey) droplets. In both 
A and B, the number of positive droplets reduces as DNA amount does. C) Merged 
concentrations of both targets of the duplex assay, RPP30 (blue) and HHV-6B Pol (green). 
D) Merged HHV-6 copies per cell, the expected copy number for LCL 4-11p15.5 is 1 copy 
cell-1.  In all panels DNA amount reduces from left to right. 
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3.4.11 ddPCR DNA digestion 
It is advised that RE digestion of DNA is performed when conducting ddPCR on DNA 
amounts >66 ng. This is to ensure even partitioning of DNA into droplets, proper droplet 
formation and thus more efficient quantification of DNA (Hindson et al., 2011). 
In initial ddPCR experiments 10 ng of DNA were used per reaction; in later experiments 
100 ng was used. HHV-6 copy numbers did not vary greatly from the expected values; 
however, given the use of digestion in several studies, the RPP30/HHV-6B Pol duplex assay 
was performed using different DNA amounts with and without digestion (Hindson et al., 
2011; Leibovitch et al., 2014; Sedlak et al., 2014). 
DNA amounts compared were: 100, 75, 50, 25 and 10 ng of LCL 4-11p15.5. Rather than 
perform RE digestion first and then conduct ddPCR, an ‘in-reaction’ digest technique with 
HindIII was used as described in section 2.6.2.1. This was preferred as it can be performed 
using smaller sample amounts and involves fewer steps, thus reducing the possibility of 
contamination. 
With RE digestion, there were fewer droplets with fluorescence amplitudes between 
those of the positive and negative ‘bands’, in the RPP30 assay at all DNA amounts. In both 
components of the duplex assay, the fluorescence amplitude of the positive droplets was 
lower in 100 and 75 ng reactions without digestion (Fig 3-18A 6 and 7, 3-18B 6 and 7). RE 
digestion affected the observed concentrations for each target, for 100 and 75 ng of 
template DNA. The observed concentrations for 100 and 75 ng of undigested DNA were 
closer to those of 75 and 50 ng of RE-digested DNA, respectively, rather than their RE 
digested counterparts. For DNA amount ≤50 ng RE digestion had minimal effect on 
observed concentration of either target (Fig. 3-18C). 
Although RE digestion had a clear effect on droplet plots at all amounts of template DNA, 
and observed concentration of both targets on DNA amounts ≥75 ng, the effect on 
estimated HHV-6 copies per cell was minimal. 
Chapter 3: Assay Optimisation 
101 
 
 
Figure 3-18: ddPCR output for the RPP30/HHV-6B Pol duplex assay conducted on 
reducing DNA amounts (LCL 4-11p15.5), with and without RE digestion. A) Droplet plot 
for the RPP30 component showing positive (blue) and negative (grey) droplets. Samples 
1-5 are 100, 75, 50, 25 and 10 ng of RE digested DNA, and 6–10 undigested DNA). B) Droplet 
plot for the HHV-6B Pol component showing positive (green) and negative (grey) droplets. 
Samples 1-5 are 100, 75, 50, 25, 10 ng of RE digested DNA, and 6 – 10 un-digested DNA). 
C) Target concentrations (copies µl-1) for each template DNA amount with and without RE 
digestion. D) HHV-6B copies per cell for each DNA amount with and without RE digestion 
(in all cases the expected copy number is 1). 
 
3.4.12 ddPCR reaction ‘splitting’ 
A problem frequently encountered in these experiments as assayed DNA amounts 
increased was a ‘splitting’ of the droplet bands (Fig. 3-19). This generally presented in 
the HEX channel assays (with the exception of RPP30/U7 where it occurred in the FAM 
channel) where the positive and/or negative bands split into two bands each (Fig 3-19A). 
However, this unusual presentation of droplets did not affect the target concentration or 
HHV-6 copy number estimates. Each of these bands corresponded to a droplet cluster on 
the two-dimensional (2D) droplet plot (Fig. 3-19C). In this example the lowest band 
corresponded to the double negative droplets (grey); the upper negative band to FAM 
positive/HEX negative droplets, the lower positive band to FAM negative/HEX positive 
droplets, and the upper positive band to double positive droplets (Fig. 3-19B). 
 
Chapter 3: Assay Optimisation 
102 
 
 
Figure 3-19: Readout of ddPCR of the RPP30/HHV-6B Pol duplex assay demonstrating 
splitting. A) Droplet plot of the HHV-6A component of the assay showing 4 bands (labelled 
1 – 4). B) Histogram of droplet frequency plotted against fluorescence amplitude showing 
4 peaks corresponding to the 4 bands. C) ‘Two dimensional’ droplet plot showing four 
groups of droplets: double negative (grey); FAM positive/HEX negative (blue); FAM 
negative/HEX positive (green); and double positive (orange). Hashed lines and numbers 
corresponding to the band numbers in panel A. 
 
To investigate the cause of this banding pattern, the RPP30/HHV-6B Pol duplex assay with 
100 ng of template DNA from LCL 4-11p15.5 was compared using four reaction conditions. 
First, the standard reaction amounts and concentrations; secondly, HHV-6B Pol probe 
concentration increased to 750 nM; third, HHV-6B Pol primer concentrations increased to 
850 nM; and finally the RPP30 primer and probe mix reduced to 0.5x. All other reaction 
components remained unaltered. Digestions were performed in reaction as described in 
section 2.6.2.1, in a final volume of 25 µl. Droplet generation, and amplification and 
analysis were as described section 2.6.2. 
The results of each of these changes on the HHV-B Pol component can be seen in Figure 
3-20. Increasing the probe concentration reduced splitting in positive droplets, but not 
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negative droplets (Fig. 3-20B). Increasing primer concentration reduced splitting in the 
negative, but not the positive droplets (Fig. 3-20C). Reducing the concentration of the 
RPP30 assay components reduced splitting in both positive and negative droplet bands 
(Fig. 3-20D). Although increasing Pol probe concentration did not alter splitting in the 
negative droplet bands, it did result in the double-negative droplets now having a higher 
HEX fluorescence amplitude (channel 2) than the FAM positive/HEX negative droplets (Fig 
3-20E). 
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Figure 3-20: ddPCR output of the RPP30/HHV-6B Pol duplex assay conducted on LCL 
4-11p15.5 under four conditions. A) Droplet plot and histogram of Pol component under 
standard conditions. B) Droplet plot and histogram of Pol component with Pol assay probe 
concentration of 750 nM. C) Droplet plot and histogram of Pol component with Pol primer 
concentrations of 850 nM. D) Droplet plot and histogram of Pol component with RPP30 
primer and probe mixed at 0.5x. E) 2D droplet plot with Pol probe at 750 nM showing four 
groups of droplets: double negative (grey); FAM positive/HEX negative (blue); FAM 
negative/HEX positive (green); and double positive (orange). Note that the double-
negative droplets now have a higher fluorescence amplitude than the FAM positive/HEX 
negative ones (channel 2). 
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3.4.13 ddPCR duplex assay variability 
Droplet digital PCR is an ideal technique for determining small differences and changes 
in viral copy number. To best utilise ddPCR assays discussed here, intra-assay variability 
of the RPP30/U7, RPP30/HHV-6A Pol, RPP30/DR6A, RPP30/HHV-6B Pol and RPP30/DR6B 
duplex assays was evaluated. The HHV-6A-specific assays and RPP30/U7 assay were 
performed on DNA from LCL 7-17p13.3 whilst the HHV-6B specific assays were performed 
on DNA from LCL 1-9q13.3. Assays were performed with both an ‘in-reaction’ digest and 
on DNA pre-digested with the restriction enzyme AluI (New England Biolabs Ltd, Herts, 
UK). Assays were performed on two separate days with eight replicates on each day; a 
separate RE digestion was performed on each day for ‘pre-digested’ DNA samples. RE 
digestion, and ddPCRs were performed as described in sections 2.6.2.1 and 2.6.2, 
respectively. ddPCR reactions included 100 ng of template DNA, 300 nM primers, 200 nM 
probe and 0.5x RPP30 primer and probe mix in a final volume of 25 µl. Due to the analysed 
droplet number being bellow 10,000 only seven replicates were analysed for the 
RPP30/HHV-6A Pol and RPP30/HHV-6B Pol duplex assays. 
The complete results for all assays are presented in Appendix 3. Table 3-2 summarises 
the means, standard deviations (SD) and coefficients of variability (CV) for the ‘in-
reaction’ digests and in Table 3-3 for the pre-digested DNA reactions. Considering first 
the ‘in-reaction digest’, on day one the mean RPP30 concentration range between all 
HHV-6A and RPP30/U7 assays was 1506.25–1536.88 copies µl-1, and the CV range was 0.02–
0.03. Similar results were observed on day two demonstrating the robustness and 
reproducibility of the RPP30 assay in duplex with different viral assays. The viral 
components show equally low levels of variability on each day, all having CV values ≤0.04. 
As with the concentration data, the estimated viral copies per cell showed minimal 
variability between replicates, nor was there a significant difference in the CV values 
between assays. 
The HHV-6B specific assays RPP30/HHV-6B Pol and RPP30/DR6B had little variability in 
RPP30 concentrations (1761.25 and 1778.75, respectively) on day one, both having a CV 
of 0.04. The viral components also showed low variability with each having a CV of 0.04. 
On day two the results for both the viral and RPP30 components were much more variable, 
both had a CV of 0.35 – 0.39. This nearly 10-fold increase in variability between days 
could relate to the fresh RE digest used on day two or down to not fully re-suspended 
DNA. This hypothesis is supported by consistently low variability in the RPP30 assay in 
HHV-6A duplex assays on both days and HHV-6B assays on the first day. The increased 
variability in the concentration data led to only a small increase in the variability of the 
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estimated HHV-6B copies per cell, supporting further the hypothesis that different DNA 
amounts were present in the ‘replicate’ reactions. 
Table 3-3 contains summarised results for ddPCR on pre-digested DNA. There was no 
appreciable difference in variability in the HHV-6A specific assays and U7 on both days 
for reactions containing pre-digested DNA, compared to those with an ‘in-reaction’ 
digest. The CVs for the RPP30 and viral concentrations and copy number estimates were 
all ≤0.04. The CV values for the HHV-6B specific assays showed only minimal differences 
between days. 
Although there was little difference in the variability between the two reaction types, 
there were differences between the estimated viral copy numbers per cell. For RPP30/U7, 
estimated copy numbers are lower in the pre-digested reactions by approximately 0.06 
copies. The RPP30/HHV-6A Pol results suggest approximately 0.09 copies per cell lower 
in the pre-digested reactions. The estimated DR copy number per cell is higher in the pre-
digested reactions. The difference in copy number for DR6A ranges from 0.08-0.19 copies 
per cell. Similar to the HHV-6A specific assay, the estimated HHV-6B copies per cell are 
lower in the pre-digested DNA with a difference of approximately 0.07 copies per cell. 
The estimated DR copy number is again higher in the pre-digested reactions with the 
difference ranging from 0.21-0.27 copies per cell. 
Although variability is minimal between replicates it must be considered when using 
ddPCR to investigate iciHHV-6. When confirming the presence of iciHHV-6 the initial 
assumption is that iciHHV-6-positive cases will have a U region (U7, HHV-6A/B Pol) copy 
number of 1 copy per cell. To assess the effect of experimental variability on the observed 
copy number the percentage difference between the mean HHV-6 copy number for each 
of the U region assays (for all replicates) and the expected value of 1 copy per cell was 
determined (Table 3-4). The highest observed variability was for HHV-6A Pol (9%). Using 
this, criteria for interpreting ddPCR results of suspected iciHHV-6 cases was developed. 
Accepted variability was determined to be x(±9%), where x is an integer value. For 
example for one integrated virus the estimated copy number range is 0.9 – 1.09 copies 
per cell. This criteria is specific to ddPCR with an ‘in-reaction’ digest. Next the maximum 
percentage difference observed from the mean of all replicates on the two days (i.e. the 
furthest replicate from the mean) was determined. The ranges for each digest type were 
2.42%–6.71% for ‘in reaction’ digest and 2.44%–5.54% for pre-digested DNA. This supports 
reduced variability when using pre-digested DNA and can be used to aid interpreting 
replicate data. 
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Table 3-2: Mean, standard deviation and coefficients of variability for ddPCR assays with an ‘in reaction’ DNA digest 
Assay Day 
RPP30 concentration Viral target concentration Virus copies per cell 
Mean (SDa) 
(copies µl-1) 
CVb 
Mean (SDa) 
(copies µl-1) 
CVb 
Mean (SDa) 
(copies per 
cell) 
CVb 
RPP30/U7 
1 1511.25 (37.2) 0.02 800.75 (31.24) 0.04 1.06 (0.02) 0.02 
2 1567.50 (44.96) 0.03 841.00 (19.9) 0.02 1.07 (0.02) 0.02 
RPP30/DR6A 
1 1536.88 (51.09) 0.03 1438.88 (36.46) 0.03 1.87 (0.03) 0.02 
2 1530.00 (52.37) 0.03 1501.25 (48.53) 0.03 1.96 (0.02) 0.01 
RPP30/HHV-6A Pol 
1 1506.25 (24.43) 0.02 819.75 (24.43) 0.03 1.09 (0.03) 0.02 
2 1540.00 (46.55) 0.03 839.71 (26.17) 0.03 1.09 (0.01) 0.01 
RPP30/DR6B 
1 1761.25 (63.57) 0.04 1458.75 (59.87) 0.04 1.66 (0.03) 0.02 
2 1877.13 (648.71) 0.35 1532.13 (600.3) 0.39 1.61 (0.07) 0.04 
RPP30/HHV-6B Pol 
1 1778.75 (77.74) 0.04 884.63 (37.77) 0.04 0.99 (0.01) 0.01 
2 2004.14 (790.29) 0.39 986.00 (389.18) 0.39 0.98 (0.01) 0.02 
a Standard deviation (SD), b coefficient of variability (CV) 
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Table 3-3: Mean, standard deviation and coefficients of variability for ddPCR assays with pre-digested DNA 
Assay Day 
RPP30 concentration 
Viral target 
concentration 
Virus copies per cell 
Mean (SDa) 
(copies µl-1) 
CVb 
Mean (SDa) 
(copies µl-1) 
CVb 
Mean (SDa) 
(copies µl-1) 
CVb 
RPP30/U7 
1 1320.00 (28.28) 0.02 667.88 (13.72) 0.02 1.01 (0.01) 0.01 
2 1073.75 (28.25) 0.03 535.50 (9.38) 0.02 1.00 (0.02) 0.02 
RPP30/DR6A 
1 1313.75 (42.74) 0.03 1340.00 (40.36) 0.03 2.04 (0.03) 0.01 
2 1048.75 (25.74) 0.02 1077.50 (12.82) 0.01 2.06 (0.03) 0.02 
RPP30/HHV-6A Pol 
1 1312.50 (43.67) 0.03 639.75 (18.55) 0.03 0.97 (0.02) 0.02 
2 1035.71 (32.59) 0.03 515.57 (20.09) 0.04 1.00 (0.02) 0.02 
RPP30/DR6B 
1 1400.00 (27.77) 0.02 1315.00 (31.17) 0.02 1.88 (0.03) 0.02 
2 1398.75 (31.82) 0.02 1311.25 (31.82) 0.02 1.88 (0.05) 0.02 
RPP30/HHV-6B Pol 
1 1417.50 (56.25) 0.04 640.63 (24.15) 0.04 0.90 (0.01) 0.01 
2 1384.29 (24.40) 0.02 627.86 (18.90) 0.03 0.91 (0.02) 0.02 
a Standard deviation (SD), b coefficient of variability (CV) 
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Table 3-4: Maximum percentage differences between the mean HHV-6 copy number and 
replicates 
Assay 
‘In reaction’ digest Pre-digested DNA 
Mean copy 
number 
Max % 
difference 
Max % 
difference 
from 1 
Mean copy 
number 
Max % 
difference 
RPP30/U7 1.07 3.74 6.50 1.01 5.54 
RPP30/DR6A 1.92 4.69 - 2.05 2.44 
RPP30/HHV-6A Pol 1.09 4.59 9.00 0.98 3.06 
RPP30/DR6B 1.64 6.71 - 1.88 4.26 
RPP30/HHV-6B Pol 0.99 2.42 1.19 0.91 3.19 
 
 
3.5 Discussion 
TaqMan® qPCR is an accurate, high throughput technique that has been previously used 
to screen for iciHHV-6 (Faten et al., 2012; Gravel et al., 2013b; Hubacek et al., 2013; 
Hubacek et al., 2009a; Hudnall et al., 2008; Leong et al., 2007; Ward et al., 2006). 
Described here is the development of a duplex TaqMan® assay which targets the human 
β-globin gene and a region of the viral U7 gene homologous between both HHV-6A and 
HHV-6B. To do this, the efficiency and sensitivity of the previously described U7 assay 
were evaluated before combining it with the β-globin assay (Gallagher et al., 2003; 
Tavakoli et al., 2007). The U7 assay was found to have efficiencies of 90.15% and 85.21%, 
for HHV-6A and HHV-6B respectively, and sensitivities of 10 copies of plasmids pBS-U7A 
and pBS-U7B per reaction. When this duplex assay was performed using known and 
suspected iciHHV-6-positive samples an average ΔCT was 3.8. The ΔCT values are larger 
than expected; however, the two assays have different efficiencies, which can account 
for the increased ΔCT. One possible explanation for the difference in efficiency is 
amplicon size. The β-globin amplicon is 67 base pairs in length, which is shorter than the 
97 base pair U7 amplicon. As the ΔCT was consistent between DNA samples from iciHHV-
6-positive samples, it was decided that this duplex assay would be used to screen for 
iciHHV-6 with a ΔCT of 3.8 or less suggestive of iciHHV-6. 
Although TaqMan® qPCR has advantages, it lacks the precision needed to confirm the 
presence of iciHHV-6. Precision and accuracy are crucial when investigating iciHHV-6 and 
possible disease associations, as well as in a clinical setting, where confirming iciHHV-6 
can be the difference between initiating unnecessary antiviral treatment with attendant 
cost and health implications, or not. FISH provides confirmation of iciHHV-6 but is a 
difficult and time consuming technique that requires metaphase cells, which are not 
always available. Droplet digital PCR offers the possibility of complimenting and, where 
appropriate, replacing FISH as a means of confirming iciHHV-6. 
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During the course of this project, a ddPCR QX200 platform (Bio-Rad Laboratories) was 
purchased by our centre. When performing duplex assays on ddPCR, probes must be 
labelled with a dark rather than fluorescent quencher due to the QX200 system only being 
able to measure fluorescence in the FAM and HEX/VIC channels. The U7 and β-globin 
probes were redesigned to be suitable for use with MGB, before checking that the assay 
efficiencies were maintained. The efficiencies were similar to those of the TAMRA-
labelled probes (data not shown). These were then used to validate ddPCR as an 
appropriate technique for confirming iciHHV-6. With the exception of one of the tested 
LCLs (3-10q23.3) the observed HHV-6 copies per cell were extremely close to one (Fig.3-
12E). However due to the unusual droplet banding pattern consistently observed for the 
β-globin component, this was replaced with an assay that targets the human RPP30 gene. 
The RPP30 component was combined with five virus specific assays. In all but one example 
the HHV-6 copies per cell were close to the expected value (Fig. 3-11–3-15). RPP30/DR6B 
performed on LCL 1-9q34.4 had a lower than expected copy number, that was likely due 
to DR loss (other similar examples are discussed in Chapter 6). 
The amount of DNA required for accurate HHV-6 copy number analysis was also optimised 
(Fig. 3-17), and inter-replicate variability was inversely proportional to DNA amount in 
the examined range. The addition of an ‘in-reaction’ RE digest had a marked effect on 
the estimation of target concentrations with DNA amounts >50 ng. Without RE digestion, 
for DNA amounts ≥75 ng the florescence amplitude of positive and negative droplets was 
lower than those of reactions containing ≤50 ng target DNA. For 50 ng or less DNA, the 
inclusion of RE digestion reduced the number of scattered droplets with intermediate 
fluorescence amplitude between positive and negative droplet bands. Though affecting 
concentration the addition of a RE digestion had minimal effect on the HHV-6 copy 
number analysis (Fig. 3-18). This suggested that the reduced efficiency seen without 
digestion is proportionate for both components of a duplex assay. For further work ‘in-
reaction’ digestion with 100 ng of template DNA was preferred for routine use and pre-
digestion were precision and accuracy was required. 
Throughout optimisation the problem termed ‘splitting’ was encountered (Fig. 3-19). The 
pattern of the splitting could be altered by changing primer and probe concentrations of 
each component of the duplex assay (Fig. 3-20). Increasing HHV-6B probe concentration 
increased HEX channel positive and negative fluorescence amplitudes; whilst reducing 
RPP30 primer and probe mix concentrations reduced the positive and negative 
fluorescence amplitudes in the FAM channel. As these both reduced splitting it is likely it 
is caused by the relative difference in fluorescence amplitudes of each channel. 
Increasing the Pol primer concentration reduced splitting in the negatives, this appeared 
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to be the result of a slight reduction in the FAM (RPP30) positive droplet amplitudes (both 
double and single positive); the reasons for this remain unclear. 
Finally in an attempt to determine the degree of experimental variability replicate 
ddPCRs with two different RE digestion techniques over two days were performed. 
Without considering this set of replicates, CVs of all assays on both days were ≤0.04. 
Whilst CV values did not vary largely between digest types the mean copy numbers per 
cell did show variation. As digestion facilitates the even partitioning of DNA into droplets 
allowing accurate quantification, pre-digestion should allow for the best fragmentation 
of the DNA and thus produce the most accurate results. For convenience ‘in-reaction’ 
digests are used in later chapters for the confirmation of iciHHV-6, with the criteria of 
copy number = x(±9%) where x is an integer value, any samples outside of this are either 
not iciHHV-6 or warrant further investigation. For the comparison of two ddPCR results 
(e.g. the investigation of DR loss through a time course) the level of experimental 
variability is crucial. For this it was proposed to use only pre-digested DNA, with the 
criteria of x(±6%) and y(±6%) where x and y are the observed copy number values being 
compared. If these ranges overlap then experimental variability cannot be ruled out as a 
cause of observed differences. For the investigation of small differences, the trend of 
multiple replicates and the Poisson CIs should also be considered. If replicate data on the 
same ddPCR run fall outside of the proposed 6% margin then these should be repeated. It 
is impossible to know the precise copy numbers in iciHHV-6-positive samples but ddPCR 
is the best technique to accurately determine copy numbers. 
In conclusion TaqMan® qPCR coupled with ddPCR offers a reliable means to both screen 
for and confirm iciHHV-6. The conditions described here were used in subsequent 
experiments discussed in later chapters. 
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Disclaimer: Some of the data and text presented in this chapter were published in the 
Journal PLoS ONE on the 10th November 2014 and are reproduced in accordance with the 
journal’s reproduction policy (Bell et al., 2014). DOI: 10.1371/journal.pone0112642 
 
4.1 Introduction 
Recent publications suggest an association between HHV-6B and cHL (Lacroix et al., 2010; 
Siddon et al., 2012; Strenger et al., 2013). cHL has a peak incidence in young adults (15-
35 years) and epidemiological evidence suggests that an infectious agent may be involved 
in the aetiology of these cases (Chang et al., 2004). A third of all cHL cases in 
industrialised countries are causally associated with EBV; however, these cases are 
relatively more common in older adults and young children. It is therefore plausible that 
another virus is involved in the pathogenesis of EBV-negative cHL (Chang et al., 2004). 
HHV-6A and HHV-6B are two distinct but related human herpesviruses (Ablashi et al., 
2013). A feature unique to HHV-6A and B among human herpesviruses is their ability to 
integrate into the telomeres of human chromosomes (Arbuckle et al., 2010; Nacheva et 
al., 2008). In a proportion of individuals the integrated virus is present in every nucleated 
cell in the body and passed to subsequent generations in a Mendelian fashion (Daibata et 
al., 2000; Daibata et al., 1999). The reported prevalence of  iciHHV-6 among healthy 
individuals ranges from 0.8-4% (Leong et al., 2007). 
Luppi et al. (1993) first described integrated HHV-6 genomes in three patients with high 
viral loads in peripheral blood; one of these patients had cHL and a second had a B-cell 
non-Hodgkin’s lymphoma. Strenger et al. (2013) also documented iciHHV-6 in a cHL case, 
raising the possibility of a specific association between iciHHV-6 and cHL. However, a 
recent study from Hubacek et al. (2013) did not find a difference in iciHHV-6 prevalence 
in patients with malignant disease and healthy controls. Whilst this study did include 267 
patients with cHL, it did not explicitly look at the prevalence of iciHHV-6 among these 
individuals. To conclusively determine whether iciHHV-6 is associated with cHL, 936 cases 
of cHL and 563 healthy controls were screened for iciHHV-6 using a quantitative PCR 
assay. The presence of iciHHV-6 was confirmed with ddPCR. Any association of 
exogenously acquired HHV-6 and cHL was also examined by screening tumour DNA samples 
from 77 cHL cases for the presence of exogenously acquired HHV-6A and HHV-6B and 
investigated associations with tumour EBV-status. 
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4.2 Materials and Methods 
4.2.1 Subjects and samples 
iciHHV-6 and cHL 
DNA from 1508 cHL cases and controls were analysed. These subjects were from four 
case-control studies: 375 cases and 349 controls from the Scottish and Newcastle 
Epidemiological Study of Hodgkin’s disease (SNEHD) (Alexander et al., 2003); 70 cases and 
40 controls from the Young Adult Haematological malignancy and Hodgkin’s disease Case 
Control Study (YHHCCS) (Alexander et al., 2000); 170 cases and 174 controls from the 
Epidemiological and Genetics Lymphoma Case Control Study (ELCCS) (Willett et al., 
2007); and 321 cases from a prospective collection of newly diagnosed cHL cases in 
Scotland and the north of England. 
Subject’s characteristics including sex, age, tumour EBV status, and histological subtype 
are summarised in Table 4-1. DNA had been extracted from peripheral blood samples 
using standard procedures and subsequently whole genome amplified (WGA) 
(KBioscience, Herts, UK). 
Exogenously acquired HHV-6 and cHL 
Classical Hodgkin lymphoma tumour DNA samples from 77 individuals were screened for 
HHV-6A and HHV-6B. These cases were part of a prospective collection of newly diagnosed 
cHL cases in Scotland and the north of England. Twenty-three control DNA samples from 
reactive nodes were also tested. 
 
4.2.2 TaqMan® quantitative PCR assays 
iciHHV-6 and cHL 
Germ-line DNA samples were analysed using the duplex TaqMan® assay that detects both 
the single copy human gene β-globin and the U7 ORF of HHV-6A and HHV-6B (described in 
Chapter 3). Reactions were prepared, conducted and analysed as described in section 
2.6.1 with β-globin primers and probe at 50 nM and 200 nM, respectively, U7 primers and 
probes at 150 nM and 200 nM respectively, and 50-100 ng of WGA template DNA. A NTC 
was included after every two samples. Where possible, cases suspected of having iciHHV-
6 were retested using the original DNA sample, i.e. non-WGA DNA. 
Samples containing iciHHV-6 were further analysed to determine whether the virus was 
HHV-6A or HHV-6B using assays specific to the Pol genes of each virus type (Appendix 2). 
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HHV-6 and cHL tumours 
Tumour DNA samples were analysed with HHV-6A and HHV-6B-specific Pol TaqMan® assays 
as described in section 2.6.1. Primer concentrations were 300 nM, probe 200 nM and 
either 500 or 1000 ng of template DNA. All samples were assessed separately for 
amplifiability using the β-globin TaqMan® assay (Appendix 2). 
 
4.2.3 Droplet digital PCR 
Droplet digital PCR CNV analysis with either the RPP30/HHV-6A Pol or RPP30/HHV-6B Pol 
assay, was used to confirm the presence of iciHHV-6 in positive samples identified in the 
qPCR screen. Reactions were performed in duplicate as described in section 2.6.2 with 
an ‘in-reaction’ HindIII digest, 1 x RPP30, 300 nM viral primers, 200 nM viral probes and 
10-100 ng of template DNA. DNA from LCLs 7-17p13.3 (HHV-6A) and 4-11p14.5 (HHV-6B) 
were used as positive controls. One NTC reaction was used for every two sample 
reactions. 
 
4.2.3 Statistical analysis 
The proportion of individuals with iciHHV-6/HHV-6 in cases and controls, and subgroups 
stratified by age group and sex (all subjects), and histological subtype and EBV status 
(cases), were compared and Pearson’s chi-squared test was used to test whether 
differences were statistically significant. All statistical analyses were implemented using 
SPSS v19.0 (IBM, Middlesex, UK). 
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Table 4-1: Characteristics of case and control groups screened for iciHHV-6 
 
SNEHD 
N (%) 
YHHCCS 
N (%) 
ELCCS 
N (%) 
Case Series 
N (%) 
Total 
N (%) 
Case Control Case Control Case Control Case Control 
Total 375 (100) 349 (100) 70 (100) 40 (100) 170 (100) 174 (100) 321 (100) 936 (100) 563 (100) 
Age Group (years)          
 <15 1 (0.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 11 (3.4) 12 (1.3) 0 (0) 
 15-34 185 (49.3) 112(32.1) 70 (100) 40 (100) 70 (41.2) 71 (40.8) 159 (49.5) 484 (51.8) 223 (39.6) 
 35-49 82 (21.1) 92(26.4) 0 (0) 0 (0) 53 (31.2) 57 (32.8) 69 (21.5) 204 (21.8) 149 (26.4) 
 ≥50 107 (28.5) 145(41.5) 0 (0) 0 (0) 47 (27.6) 46 (26.4) 82 (25.6) 236 (25.1) 191 (34.0) 
Sex          
 Female 162 (43.2) 148(42.4) 33 (47.1) 20 (50) 66 (38.8) 71 (40.8) 144 (44.9) 405 (43.3) 239 (42.4) 
 Male 213 (56.8) 201(57.6) 37 (52.9) 20 (50) 104 (61.2) 103 (59.2) 177 (55.1) 531 (56.7) 324 (57.6) 
Histological Subtype          
 MC 80 (21.3) - 9 (12.9) - 29 (17.1) - 62 (19.3) 180 (19.2) - 
 NS 257 (68.6) - 57 (81.4) - 133 (78.2) - 223 (69.5) 670 (71.6) - 
 Other 38 (10.1) - 4 (5.7) - 8 (4.7) - 36 (11.2) 86(9.2) - 
EBV Status*         - 
 Positive 98 (30.0) - 14 (21.2) - 33 (31.1) - 98 (35.8) 243 (31.4) - 
 Negative 229 (70.0) - 52 (78.8) - 73 (68.9) - 176 (64.2) 530 (68.6) - 
 Missing 48 - 4 - 64 - 47 163 - 
*Percentage EBV-positive and negative includes only samples with known EBV status. 
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4.3 Results 
4.3.1 iciHHV-6 screen of cHL cases and controls 
As discussed in section 3.2.3, when the β-globin/U7 duplex TaqMan® assay was tested on 
known iciHHV-6-positive samples a mean ΔCT of 3.8 was observed. However, using WGA 
DNA the U7 component of the duplex TaqMan® assay was less efficient than the β-globin 
component resulting in larger and more variable ΔCT values. All samples with a ΔCT ≤6 
were therefore considered likely to contain iciHHV-6. All samples had a β-globin CT ≤32. 
Testing of replicates of WGA DNA from confirmed iciHHV-6-positive samples highlighted 
that iciHHV-6 was consistently detected when a CT of 32 was observed in the β-globin 
assay. 
Following the initial screen, 26 of the subjects were identified as potentially iciHHV-6-
positive. The ΔCT values of the respective samples ranged from 0.94-5.67. Non-WGA DNA 
was available from 21 of these subjects and analysis of these samples gave ΔCT values in 
the range 2.61 – 3.69, with the exception of one sample (from subject 4298), which had 
a ΔCT of 0.97 consistent with the presence of more than one integrated viral genome. 
Occasional other samples gave rise to low-level HHV-6-positive results but, of these, the 
lowest ΔCT in the duplex assay was 10.4; thus samples with iciHHV-6 and exogenously 
acquired HHV-6 appeared clearly separable. 
HHV-6 typing was performed on all 26 samples with iciHHV-6; two subjects were HHV-6A-
positive and the remainder HHV-6B-positive. 
 
4.3.2 Confirmation of iciHHV-6 
To confirm the presence of iciHHV-6 in suspected positive samples, ddPCR was performed 
on 21 samples with available material. Both RPP30/HHV-6A Pol and RPP30/HHV-6B Pol 
ddPCR duplex assays showed good separation of positive and negative droplets when run 
on iciHHV-6-positive LCL DNA (Fig. 4-1). The average number of HHV-6 genome copies per 
cell was 1.07 and 1.01 for LCLs 7-17p13.3 (HHV-6A) and 4-11p14.5 (HHV-6B) respectively 
(Fig. 4-2). The appropriate duplex assay was conducted in duplicate on samples identified 
in the initial screen, with the exception of samples from subjects 3572 and 3757 where 
DNA was limited. Approximately 14,000 droplets per reaction were analysed. In all but 
one case the average HHV-6 copy number clustered around 1 copy per cell (range 0.884-
1.2 copies per cell) (Fig. 4-2). The sample from subject 4298 had a HHV-6 copy number 
of 4.05 copies per cell (Poisson 95% CI: 3.96, 4.14). Droplet digital PCR was repeated on 
this sample using a duplex assay which amplified RPP30 and the HHV-6 U7 gene; the 
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observed HHV-6 copy number was 3.95 copies per cell (Poisson 95% CI: 3.69, 4.22). There 
was no evidence of off target amplification, consistent with all these genomes being HHV-
6A. These data suggest that subject 4298 has four integrated copies of HHV-6A per cell. 
 
  
Figure 4-1: Analysis of iciHHV-6 by droplet digital PCR. One dimensional ddPCR plots 
for positive controls 7-17p13.3 (HHV-6A, panels A & B) and 4-11p14.5 (HHV-6B, panels C 
& D). Each control has two plots one representing the RPP30 FAM (blue) channel (panels 
A & C) and the other the HHV-6 HEX (green) channel (panels B & D). Each point represents 
a single droplet, which is scored as positive (coloured) or negative (grey) depending on 
the fluorescent amplitude. 
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Figure 4-2: HHV-6 copies per cell in individuals identified as iciHHV-6-positive and 
positive controls (7-17p13.3 and 4-11p14.5). HHV-6A subjects are plotted in red and 
HHV-6B subjects in green. Error bars indicate the Poisson 95% CI for each point. 
 
4.3.3 iciHHV-6 prevalence in cHL cases and controls 
Of the 26 iciHHV-6-positive subjects identified, 16 (1.7%) were cases and 10 (1.8%) 
controls; there was therefore no statistically significant difference between cases and 
controls (p=0.92). When cases and controls were broken down by study (Table 4-2) there 
was no evidence of significant heterogeneity. Of the subjects with HHV-6A, one was a 
case the other a control. 
The prevalence of iciHHV-6 was analysed by sex and in four age groups: 0-14, 15-35, 35-
49 and ≥50 years. No statistically significant difference was observed (data not shown). 
Cases were further analysed with respect to EBV status of the tumour, histological subtype 
(nodular sclerosis versus mixed cellularity), and age in two groups (15-34 years and ≥50 
years, to reflect the bimodal age distribution of cHL), or sex. Older adult cases (7/236, 
2.97%) were more likely to have iciHHV-6 then younger adult cases (5/484, 1.03%) and 
this difference was close statistical significance (p=0.057). The difference between these 
two age groups among controls (4/233, 1.79% and 4/191, 2.09%, respectively) was not 
statistically significant (p=0.83). 
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Table 4-2: Prevalence of iciHHV-6 in cases and controls by study 
 
Cases 
(N) 
Controls 
(N) 
ciHHV-6 positive N(%) 
p value Cases Controls 
SNEHD 375 349 8 (2.1) 8 (2.3) 0.88 
YHHCCS 70 40 1 (1.4) 0 (0) - 
ELCCS 170 174 2 (1.2) 2 (1.1) 0.98 
Case Series 321 - 5 (1.6) - - 
Total 936 563 16 (1.7) 10 (1.8) 0.92 
 
 
4.3.4 HHV-6 and cHL tumours 
Prior to commencing work for this thesis next generation sequencing and digital 
transcriptome subtraction was performed on sorted H/RS cells from three cHL subjects. 
In one of these cases (EBV-negative) HHV-6B U18, U26, U28, U57, U83 and U90 transcripts 
were identified (data not shown). To further analysis this DNA from cHL tumour samples 
were screened for HHV-6. 
DNA samples from 77 cHL tumours were screened for HHV-6A and HHV-6B with assays that 
targeted either the HHV-6A or HHV-6B Pol genes. These assays were consistently able to 
detect 5 copies reaction-1 when controls of cloned HHV-6A and -6B amplicons were used 
(data not shown). All cHL and reactive node DNA samples were negative for HHV-6A. For 
HHV-6B, 1/23 (4.3%) reactive node samples were positive compared to 50/77 (64.9%) cHL 
tumour samples (p <0.001). 
The EBV status of the cHL tumours was known for 63/77 samples, of which 23 were EBV-
positive and 40 EBV-negative. More EBV-negative cases were HHV-6B-positive (29/40, 
72.5%) compared to EBV-positive cases (12/40, 52.2%); however, this finding was not 
statistically significant (p =0.103).  The analysis of EBV status was adjusted for sex, age 
of diagnosis, and cHL subtype (nodular sclerosis and mixed cellularity only), whilst the p 
value reduced slightly (p =0.098) it was not significant (0.337, 95% CI: 0.093, 1.224). Sex, 
age at diagnosis, and histological subtype did not influence tumour HHV-6 positivity (data 
not shown). 
HHV-6B genomes were detected in the majority of tumour samples and HHV-6B copy 
numbers were low. Only five HHV-6B-positive cHL tumour samples had CT values ≤32 
(approximately 500 copies reaction-1 or more). Two of these samples gave CT values 
comparable to iciHHV-6-positive cases run at the same time, but due to lack of sample 
DNA it was not possible to confirm the iciHHV-6 status by ddPCR. Fluorescence 
immunophenotyping and interphase cytogenetics (FICTION) were performed on sections 
of paraffin embedded tumours from these samples (Performed by Dr Maciej Giefing in the 
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Laboratory of Prof. Reiner Siebert, University of Kiel, Kiel, Germany). HHV-6B DNA was 
not identified in any cells (data not shown). 
 
4.4 Discussion 
This is the largest study, to date, to investigate the prevalence of iciHHV-6 among cHL 
patients and also one of the largest screens for iciHHV-6 in control subjects in the UK. 
Twenty-six subjects were identified including 16 (1.7%) cHL cases and 10 (1.8%) controls 
with iciHHV-6. There was no difference in the prevalence of iciHHV-6 in cHL cases and 
controls, suggesting that inheritance of an integrated HHV-6 genome does not increase 
risk of the disease. The prevalence of iciHHV-6 among control subjects reported here is 
within the range previously reported for Western populations and the proportion of 
positive subjects is not significantly different from other studies of controls with sample 
size ≥100 (Geraudie et al., 2012; Huang et al., 2013; Hubacek et al., 2013; Leong et al., 
2007; Torelli et al., 1995; Ward et al., 2005). 
Further analysis of cases did not reveal any association between prevalence of iciHHV-6 
and EBV status and histological subtype of cHL. When cases were stratified by age group, 
older adult cases were found to be more frequently iciHHV-6-positive than younger adult 
cases and these differences approached statistical significance (p=0.057). Given the small 
number of iciHHV-6-positive samples and lack of case control differences, this is likely to 
be due to chance; however, since HHV-6 integrates into telomeres and telomeres are 
involved in cell senescence (Artandi and DePinho, 2010), it remains possible that this is 
biologically relevant, and therefore this should be addressed in future studies. 
The results confirm that ddPCR is more precise than conventional TaqMan® PCR for 
detecting the presence of iciHHV-6 in DNA samples. The HHV-6 genome copy number 
estimates clustered around values which suggest inherited genomes. A copy number range 
of 0.844-1.2 copies per cell was observed in all individuals except subject 4298, and in 
most cases the average value was extremely close to 1 with 95% CI approaching or crossing 
1. Failure to detect a copy number of exactly 1 may relate to the age of the samples as 
recent reports in the literature suggest that sample age can affect CNV analysis results 
(Roberts et al., 2014). The iciHHV-6-positive samples analysed in this study were collected 
between 1992 and 2009 and therefore sample DNA was between 5 and 22 years old. 
However, it cannot be ruled out that subjects with HHV-6 copy number >1 copies per cell 
have some degree of active infection, and that subjects with HHV-6 copy number <1 copy 
per cell have some cells that have deleted all or part of the viral genomes, as has been 
described recently (Huang et al., 2013). 
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For the first time an individual who is likely to have four integrated copies of HHV-6A has 
been identified. There has been a reported case of iciHHV-6 with two integrated viruses; 
in this case it was confirmed that a single copy HHV-6 genome had been inherited from 
each parent (Daibata et al., 1998c). It is possible that this individual has inherited two 
integrated viruses from each parent; however, other possibilities such as new primary 
integration events, reactivation and further integration of already present virus, or 
integration of a viral genome concatemer cannot be excluded. Further analysis of this 
subject is presented in chapter 6. 
Exogenously acquired HHV-6A appears to have a low prevalence in industrialised 
countries. In the USA, 97-100% of all symptomatic and asymptomatic primary infections 
in infants are HHV-6B (Dewhurst et al., 1993; Hall et al., 2006; Zerr et al., 2005). This is 
mirrored in European populations where up to 95% of primary infections are HHV-6B 
(Aberle et al., 1996; Boutolleau et al., 2006). In contrast, sub-Saharan Africa HHV-6A is 
the dominant species accounting for 86% of asymptomatic infections in Zambian infants 
(Bates et al., 2009). It has been suggested previously that between one-fifth and one-
third of iciHHV-6 genomes are HHV-6A (Clark and Ward, 2008). Given that most of the 
contributing studies analysed individuals from industrialised countries, this in turn leads 
to the suggestion that HHV-6A may integrate more frequently than HHV-6B. In studies 
with ten or more iciHHV-6-positive subjects HHV-6A has accounted for 6.8-40% of iciHHV-
6 genomes (Hall et al., 2004; Huang et al., 2013; Ward et al., 2005). In the present study 
only 2 subjects (8%) with iciHHV-6A were identified. These data are more consistent with 
the idea that the proportion of HHV-6A among iciHHV-6-positive subjects reflects the 
proportions of HHV-6A and HHV-6B in the underlying population. Both iciHHV-6A subjects 
identified in this study are white British. 
Prior to performing work presented in this thesis HHV-6B transcripts had been identified 
in H/RS cells from and EBV-negative cHL case (data not shown). The array of transcripts, 
particularly U57 which encodes the major capsid protein, suggests the possibility of an 
active infection. H/RS cells were sorted by flow cytometry; however, as T-lymphocytes 
rosette H/RS cells in a cHL tumour, T-lymphocyte contamination is likely. It is possible 
that active infection presents in H/RS cells or contaminating T-lymphocytes. Following 
this and recent reports of an association with exogenously acquired HHV-6 cHL, cHL 
tumour samples were screened for HHV-6A and HHV-6B. All samples were HHV-6A-
negative whilst 64.9% were HHV-6B-positive. There is little consistency between the 
prevalence of HHV-6B in other studies; the prevalence ranges from 35.1% to 79% (section 
1.6.1). The observed prevalence of HHV-6B in cHL samples was significantly higher than 
in reactive nodes (p <0.001), the importance of which remains unclear. The cellular make 
up of these two pathologies may play a role in this distribution; the predominant T-cell 
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infiltrate in reactive nodes is generally CD8-positive whilst in cHL it is CD4-positive 
(unpublished data). HHV-6B has a greater tropism for CD4-positive T-cells, possibly 
contributing to the higher frequency in cHL (Lusso et al., 1988; Lusso et al., 1987). 
Any association HHV-6B had with tumour EBV status was examined; no significant 
association was found. In EBV-positive cHL EBV genomes are clonal and present in all H/RS 
cells (Gledhill et al., 1991). If HHV-6B is directly involved in pathogenesis of cHL, similar 
results would be expected. All but five samples had a CT value consistent with ≤500 viral 
copies µg of DNA which is not consistent with the virus being present in all H/RS cells. 
This could be improved on by examining sorted or enriched populations of H/RS cells. 
Without the virus present in all H/RS cells it is unlikely that exogenously acquired HHV-
6B has a direct role in the pathogenesis of cHL. 
In conclusion, the data presented here suggest that the prevalence of iciHHV-6 in the UK 
is ~1.8% but do not support an association between iciHHV-6 and cHL risk. Whilst 
inconclusive, data presented here do not support a direct role in the pathogenesis of cHL; 
however an indirect role or a role in a subset of cHL cases cannot be ruled out. 
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Chapter 5.  Inherited chromosomally integrated HVH-6 in the 
Generation Scotland: Scottish Family Heath Study – A hypothesis 
generating study 
 
  
Chapter 5: iciHHV-6 in the GS:SFHS cohort 
125 
 
5.1 Introduction 
HHV-6A and HHV-6B are unique amongst HHVs in their ability to integrate into the 
telomeres of human chromosomes. Further to this, integration can occur in the germ-line 
and be inherited in a Mendelian fashion through subsequent generations. 
The reported iciHHV-6 prevalence in healthy individuals is between 0.8-4%. In France and 
the Czech Republic the prevalence amongst the general population is 0.5% and 1.2% 
respectively. The prevalence of iciHHV-6 is reported in other populations around the 
world; however, these data have been generated from disease groups or disease 
association studies, which whilst no associations with iciHHV-6 were reported may result 
in some degree of bias. In these studies the iciHHV-6 prevalence ranges from 0.21% in 
Japan, 2.9% in Tunisia, and 14% in a study of congenital HHV-6 infections in the USA. To 
date there has been no consideration as to if iciHHV-6 prevalence differs by geographical 
region, whilst it could be inferred, for example, that Japan has a lower prevalence than 
European populations, the sample size used in most studies means any comparisons would 
be underpowered statistically. Although case-control studies have investigated possible 
associations between iciHHV-6 and specific diseases, there is little understanding of the 
phenotypic effects of viral integration. 
Telomeres are regions that protect the ends of chromosomes and are crucial for processes 
such as cellular senescence. Several serious diseases are associated with telomere 
dysfunction including degenerate diseases and cancers (Artandi and DePinho, 2010; Kong 
et al., 2013; Oeseburg et al., 2010). Huang et al (2013), recently presented evidence 
suggesting telomeres associated with HHV-6 integration were significantly shorter than 
their non-associated counterparts, raising the real possibility that iciHHV-6 could 
influence disease through ways other than just reactivation. During the writing up of this 
thesis, work was published investigating iciHHV-6 in the population of Québec, Canada. 
Gravel et al, (2015) identified a statistically significant association between iciHHV-6 and 
angina pectoris, with an odds ratio of three (Gravel et al., 2015). 
Selecting and investigating individual diseases as a way of investigating associations with 
iciHHV-6 is an expensive and laborious method. Instead, presented here is a hypothesis 
generating study investigating physical, social, and disease phenotypes in a large 
population-based study of families in Scotland. This study aimed to determine the iciHHV-
6 prevalence in the Scottish population and determine the relative proportions of iciHHV-
6A and iciHHV-6B; to perform an exploratory study of disease and other phenotypic 
associations; and to test the previously described association with angina pectoris. 
The Generation Scotland: Scottish Family Health Study (GS:SFHS) comprises over 23,000 
individuals from over 5,000 families from across Scotland. For each participant, detailed 
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physical and clinical measurements, social information, disease history, relatedness and 
family structure were collected (Smith et al., 2006). In a pilot study samples from 2,304 
participants from the GS:SFHS cohort were screened with the β-globin/U7 TaqMan® assay 
(assay described in section 3.2). Subsequently all 23,986 participants were screened with 
the β-globin/DR1 TaqMan® assay (assay described in section 3.3). Inherited 
chromosomally integrated HHV-6 was confirmed with ddPCR, and possible associations 
with iciHHV-6 investigated.  
 
5.2 Materials and Methods 
5.2.1 Participants 
Sample collection methods for the GS:SFHS has been presented in the literature (Smith 
et al., 2006). Briefly, individuals, from across Scotland deemed eligible to participate in 
the study by their general practitioner, were invited to participate. These individuals 
were aged between 35 and 55 years and had at least one first degree relative over the 
age of 18. When approached, individuals gave informed consent to participate and 
provided contact information, and verbal consent from all willing first degree relatives. 
These relatives were contacted by the study team and the process repeated. Complete 
families were also approached through the Walker Birth Cohort database. Each 
participant completed a pre-clinical questionnaire which included demographic and 
health information; physical, personality, cognitive function and psychological distress, 
and mental health measurements. Several samples of blood were taken for DNA extraction 
and cryopreservation of cells. 
Initially DNA samples from 2,304 were screened in a pilot study followed by the complete 
23,986 participants for the presence of iciHHV-6. Summarised in Appendix 4 are all the 
investigated categorical and continuous variables, the latter stratified by sex, for the 
complete study participants included in down-stream statistical analysis. 
 
5.2.2 TaqMan® quantitative PCR assays 
Β-globin/U7 TaqMan® assay reactions included β-globin primers and probes at 50 nM and 
200 nM respectively, U7 primers and probe at 150 nM and 200 nM, respectively; reactions 
were in a final volume of 12.5 µl with 1x TaqMan® Universal MasterMix (Life Technologies, 
UK). Reactions contained either 100 ng of template DNA, pBS-U7A as a positive control or 
water as a NTC. Thermal cycling and analysis were performed as described earlier. 
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At a later date, the complete GS:SFHS cohort was screened with the β-globin/DR1 
TaqMan® assay. Reactions contained β-globin primers and probe at 50 nM and 200 nM 
respectively and DR1 primers and probe at 300 nM and 200 nM, respectively; reactions 
were in a final volume of 12.5 µl with 1x TaqMan® Universal MasterMix (Life Technologies, 
UK). Reactions contained either 100 ng of template DNA, iciHHV-6-positive DNA as a 
positive control or water as an NTC. Thermal cycling and analysis were performed as 
described earlier. 
These TaqMan® assays were performed by Angie Fawkes and Lee Murphy at the Wellcome 
Trust Clinical Research Facility, University of Edinburgh, Western General Hospital, 
Edinburgh, Scotland, UK. Amplification plots and multicomponent plots for each reaction 
were examined for any anomalies by both Angie Fawkes and Adam Bell. 
Samples suspected to be iciHHV-6-positive in the pilot screen were typed as either HHV-
6A or HHV-6B using TaqMan® assays designed to the HHV-6A or HHV-6B Pol gene. Reactions 
were performed, conducted and analysed as described in section 2.6.1 with primer and 
probe concentrations of 300 nM and 200 nM respectively, and 10 ng of template DNA. 
Each sample was screened with both the HHV-6A and HHV-6B specific assay. 
 
5.2.3 Droplet digital PCR 
Droplet digital PCR CNV analysis was used to confirm the presence of iciHHV-6 and 
samples suspected from the TaqMan® screen. Duplex ddPCR assays performed included: 
RPP30/HHV-6A Pol, RPP30/HHV-6B Pol, RPP30/U7, RPP30/DR6A and RPP30/DR6B. 
Reactions were performed as described in section 2.6.2 with either ‘in reaction’ digestion 
or pre-digested DNA. For Assays targeting HHV-6 U7, HHV-6A Pol or HHV-6B Pol an ‘in 
reaction’ digest was performed.  
 
5.2.3 Statistical analysis 
The proportion of iciHHV-6-positive individuals was compared to categorical and 
continuous variables described in Appendix 4, through several statistical methods. X2 
analysis was used to compare the distribution of iciHHV-6 positivity by age group, sex and 
other categorical variables. Continuous variables were analysed using T-tests. Self-
reported disease associations were analysed using binary logistic regression, with iciHHV-
6 status as the dependent variable, and were adjusted for age group and sex. Analyses 
were performed on the whole data set and, where p<0.1, also performed on a subset of 
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unrelated individuals. Power analyses were performed with PASS14 (NCSS, Kaysville, UT, 
USA); all other statistical analyses were implemented with SPSS V20.0 (IBM, UK). 
P values for sex, and age, height, weight and BMI, for both sexes; age group, years in 
education, qualification, Scottish Index of Material Deprivation (SIMD), ethnicity, 
nationality (all British Isles) and angina were adjusted for multiple testing using the 
Benjamini-Hochberg method (n=16). Correction was performed as described in the 
literature (Lesack and Naugler, 2011). The script was kindly provided by Dr Christopher 
Naugler (University of Calgary, Calgary, AB, Canada) and was run in Python 3.4.3 (Python 
Software Foundation, Delaware, USA). 
Graphs were generated with GraphPad Prism V6.0 (GraphPad Software Inc, California, 
USA), and Maps were produced using the website SimpleMappr (www.simplemappr.net). 
 
5.3 Results 
5.3.1 Prevalence of iciHHV-6 in a pilot study 
To assess the validity of using the GS:SFHS cohort to investigate phenotypic associations 
with iciHHV-6, 2,304 samples were initially screened. On the basis of previous results, 
samples with a ΔCT ≤ 3.8 were considered likely to be iciHHV-6. Samples that displayed 
abnormal amplification plots or had a β-globin CT>32 were excluded from further analysis, 
resulting in the loss of 19 samples; 2,285 samples were included in subsequent analyses. 
In the initial screen, 60 subjects were identified as potentially iciHHV-6-positive. The 
range of ΔCT values was 0.28-3.21. There was a clear separation of ΔCT values; the next 
closest ΔCT value was 8.57, with 87 samples positive for HHV-6 at a lower level. 
All samples suspected to be iciHHV-6-positive were typed with TaqMan® assays to the Pol 
genes of HHV-6A and HHV-6B. Two samples were HHV-6A-positive and the remaining were 
HHV-6B-positive. There was clear distinction between HHV-6A and HHV-6B samples with 
the exception of one; DNA from subject 20119 amplified well with both HHV-6A and HHV-
6B assays. 
To confirm the presence of iciHHV-6, these 60 samples were subjected to ddPCR with the 
RPP30/HHV-6A Pol or RPP30/HHV-6B Pol assays (described in Chapter 3). As subjects were 
already typed only the appropriate assay was used, with the exception of sample 20119 
which was analysed with both Pol assays and also the RPP30/U7 assay. 
Clear separation of positive and negative droplets was observed in all reactions. Results 
were scored only if more than 10,000 droplets had been analysed and the average was 
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approximately 14,000 droplets per reaction. In all but two samples the copy number 
clustered around 1 copy per cell (range 0.95 – 1.1 copies per cell). Two samples exhibited 
higher copy numbers of 2.07 (Poisson 95% CI: 2.00 – 2.14) and 2.14 (Poisson 95% CI: 2.08 
– 2.2) (Fig. 5-1). 
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Figure 5-1: HHV-6 copies per cell in individuals suspected of being iciHH-6-positive. 
HHV-6A-positive subjects are plotted in red and HHV-6B-positive subjects in green. Error 
bars, although not visible due to their small range, indicate the Poisson 95% CI for each 
point. 
 
All cases suspected of being iciHHV-6-positive were confirmed as being positive, giving a 
prevalence of 2.62% (60/2285). Of these 3.3% (2/60) were HHV-6A and 96.7% (58/60) were 
HHV-6B. As the GS:SFHS cohort is made up of families we addressed the possibility of bias 
for iciHHV-6 in the sample set. A maximum unrelated data set was generated by selecting 
the oldest member of a family and excluded all blood-related individuals; the resulting 
sample set included 2077 individuals. Among unrelated individuals 2.65% (55/2077) were 
iciHHV-6-positive.  
 
5.3.2 Prevalence of iciHHV-6 in GS:SFHS 
Before initiating a screen of iciHHV-6 of the full GS:SFHS cohort, evidence was presented 
in the literature that raised the possibility of only finding DR regions in the human 
chromosome (Huang et al., 2013). To ensure that no such cases were missed a duplex 
TaqMan® assay was designed to detect a region of DR1 homologous between both HHV-6A 
and HHV-6B, and the human β-globin gene (discussed in section 3.3). The entire GS:SFHS 
cohort of 23,986 DNA samples was screened; samples with abnormal amplification plots 
or β-globin CT>32 were excluded from further analysis resulting in the loss of 298 samples 
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(23,632 remaining). In this analysis two groups of samples could not be clearly 
distinguished (Fig. 5-2). 
 
 
Figure 5-2: Histogram of ΔCT values of samples positive for DR1 amplification. 
Frequency is plotted on a Log10 scale. 
 
Samples positive for DR1 amplification were broken down into four groups: Group A 
(ΔCT≤3), Group B (3<ΔCT≤6), Group C (6<ΔCT≤9) and Group D (ΔCT>9). Individuals in group 
A were deemed highly likely to be iciHHV-6-positive so ddPCR targeting U7/RPP30 was 
initially performed on samples in group B. Group B contained 35 samples, one of which 
was identified as iciHHV-6A positive in the pilot screen (DR1/β-globin ΔCT = 4.53). Twenty-
eight samples in this group had HHV-6 copy number of 0.72–1.27 copies per cell (Fig 5-3). 
In cases where a copy number of less than 0.9 was observed, the family was checked and 
other suspected iciHHV-6-positive members were identified who were in group A. The 
sample with the largest ΔCT (ΔCT = 5.95) had a HHV-6 U7 copy number of 1.27 copies per 
cell and was therefore considered iciHHV-6-positive. 
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Figure 5-3: HHV-6 copies per cell in Group B samples. Error bars, although not visible 
due to their small range, indicate the Poisson 95% CI for each point. 
 
Subsequent to the completion of my PhD ddPCR was performed on all samples in Group 
C. Amongst these 70 samples, 47 were positive for HHV-6 and the range of HHV-6 U7 
copies per cell was 7x10-4-3.3x10-2. The remaining 28 samples had a HHV-6 copy number 
too low to determine with the amount of DNA used (data not shown). All samples in group 
C, and by extension group D were deemed negative for iciHHV-6. Confirmation of iciHHV-
6 in Group A samples is ongoing, to date all have been designated iciHHV-6-positive. Given 
the results from Group B, ΔCT does not correlate with HHV-6 copy number in iciHHV-6-
positive samples. The increased ΔCT is likely due to different efficiencies of the two 
components, or sequence differences in the primers and probe and their homologous 
regions. 
In this study, three samples had DR sequence in the absence of U regions; given the 
presence of DR were considered iciHHV-6-positive in subsequent analysis (discussed 
further in Chapter 6). Two samples with ΔCT values of 5.09 and 5.56 had HHV-6 copy 
numbers of 0.05 and 0.03 respectively, but due to lack of DNA it was not possible to test 
these with DR specific assays. Although it is possible these samples could contain single 
integrated DRs as it was not possible to confirm this, these samples were considered 
negative. One sample had exceptionally low DNA amounts and it was not possible to 
determine the iciHHV-6 status, thus was deemed negative. A final sample was found to 
have 0 copies per cell of U7, DR6A and DR6B (data not shown) suggesting the absence of 
virus; however a ΔCT of 4.57 was observed. This sample likely requires further 
examination using ddPCR of the DR1 region but is considered iciHHV-6-negative at this 
time. 
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Based on ddPCR confirmations, iciHHV-6 prevalence in the full GS:SFHS cohort is 2.7% 
(646/23,632). In a maximum un-related data set of the full study the prevalence was also 
2.7% (245/9109). 
 
5.3.3 Phenotype association analysis: biological variables 
The prevalence of iciHHV-6 was compared in males and females in the full data set. The 
prevalence of iciHHV-6 in females was 2.7% (375/13,632) and in males was 2.8% 
(275/13890) (adjusted p = 0.764). 
Mean age, height, weight and BMI were examined in the full cohort, stratified by sex 
(Table 5-1). No statistically significant differences were observed by iciHHV-6 for male 
age, height, weight or BMI; or female age, weight and BMI. Amongst females, iciHHV-6-
positive individuals were on average 1 cm shorter than iciHHV-6-negative individuals (p = 
0.016); however, after correction for multiple testing significance was lost (p = 0.068). 
This difference was not observed in the unrelated data set (p = 0.143).Age was broken 
down into groups (0-14, 15-24, 25-34, 35-44, 45-54, and 55+ years) and iciHHV-6 
prevalence examined. No statistically significant association was observed (adjusted p = 
0.764). 
 
Table 5-1: Analysis of height, weight and BMI in the complete cohort, stratified by sex. 
Characteristic 
Female 
Mean(±SD) Adjusted 
p value 
Male 
Mean(±SD) Adjusted 
p value iciHHV-6 
negative 
iciHHV-6 
positive 
iciHHV-6 
negative 
iciHHV-6 
positive 
Age (years) 47.8(±15.7) 47.1(±15.2) 0.710 47.4(±15.5) 47.8(±15.9) 0.764 
Height (cm) 162.5(±6.6) 161.6(±6.5) 0.068 176.2(±7.0) 176.0(±6.7) 0.764 
Weight (kg) 70.0(±15.2) 68.8(±14.7) 0.417 83.6(±15.0) 82.7(±13.9) 0.710 
BMI 26.5(±5.7) 26.3(±5.5) 0.764 26.9(±4.5) 26.7(±4.5) 0.764 
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5.3.4 Phenotypic association analysis: years in education 
The education level of participants was examined with two variables: years in education 
and qualification level. Inherited chromosomally integrated HHV-6-positivity by years in 
education is summarised in Table 5-2. 
 
Table 5-2: iciHHV-6 prevalence and years in education. 
Years in 
Education 
Full Cohort Unrelated 
iciHHV-6 prevalence 
%(N) 
Adjusted 
p value 
iciHHV-6 prevalence 
%(N) 
p value 
0 12.5 (1/8) 
0.071 
0 (0/4) 
0.079 
1-4 0 (0/41) 0 (0/19) 
5-9 2.9 (12/415) 3.2 (7/218) 
10-11 3.4 (107/3,102) 3.7 (64/1,737) 
12-13 3.3 (84/2,547) 3.3 (32/983) 
14-15 2.7 (50/1,846) 2.3 (16/693) 
16-17 1.9 (48/2,544) 1.3 (11/823) 
18-19 2.3 (31/1,338) 1.5 (6/393) 
20-21 2.6 (10/379) 3.3 (4/121) 
22-23 4.1 (5/121) 2.3 (1/43) 
24+ 1.7 (1/59) 0 (0/20) 
 
Inherited chromosomally integrated HHV-6-positive individuals reported fewer years in 
education (p = 0.021) in the full cohort; however, after correction significance was not 
maintained (adjusted p = 0.071). In the unrelated data set, a similar finding was observed 
but the difference were not statistically significant (p = 0.079). To rule out bias due to 
the small numbers of participants in some groupings the prevalence was examined in 
groups with more than 100 participants, in the full cohort. The association with iciHHV-6 
and years in education between 5 and 23 years was statistical significance (p = 0.019), 
with iciHHV-6-positive individuals in general reporting fewer years in education. There 
was no association with iciHHV-6 and qualification level in the full cohort (adjusted p = 
0.730). 
Finally the SIMD score, broken down into quintiles, was examined. No association was 
found between SIMD quintile and iciHHV-6 in the full cohort (p = 0.724). 
 
5.3.5 Phenotypic association analysis: ethnicity and nationality 
The different ethnic groups in the GS:SFHS cohort are summarised in Appendix 4 (Table 
A4-2), though 96.4% of the participants are white, association between iciHHV-6 and 
ethnicity was examined excluding ‘other’ and ‘not specified’. No Black or Asian 
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participants were iciHHV-6-positive, leaving a 2.8% (620/22,401) and 2.8% (3/108) in 
white individuals and individuals with mixed ethnicity, respectively (adjusted p = 0.710). 
The prevalence of iciHHV-6 was examined across the countries of the British Isles. 
Inherited chromosomally integrated HHV-6 was found to be associated with self-identified 
nationality in the full cohort (p = 0.003, adjusted p = 0.025) and in the unrelated sample 
group (p = 0.059) (Table 5-3). 
 
Table 5-3: iciHHV-6 prevalence broken down by self-identified nationality. 
Nationality 
Full Cohort Unrelated 
iciHHV-6 prevalence 
%(N) 
Adjusted 
p value 
iciHHV-6 prevalence 
%(N) 
p value 
English 1.2 (19/1,528) 
0.025 
1.1 (8/719) 
0.059 
Irish 2.6 (6/230) 2.3 (3/131) 
Northern Irish 3.7 (2/54) 3.6 (1/28) 
Scottish 2.9 (576/19,802) 3.0 (219/7,448) 
Welsh 0 (0/46) 0 (0/27) 
Italics indicate significance 
 
There was a notable difference in prevalence between Scotland, England and the Republic 
of Ireland. When only Scottish and English individuals were examined alone the difference 
in prevalence was highly significant in the full cohort (p < 0.001) and the unrelated sample 
set (p = 0.004). To investigate this further and to eliminate any bias from self-
identification iciHHV-6 prevalence was compared to place of birth. Due to the small 
number of participants identified from Northern Ireland, subsequent analyses are 
between those born in England and Scotland only. There was a statistically significant 
difference between the prevalence of iciHHV-6 in people born in England (1.8%) and 
Scotland (2.8%) in the complete cohort (p =  0.006) (Fig. 5-4). 
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Figure 5-4: Prevalence of iciHHV-6 in individuals born England (red) and Scotland 
(blue) in GS:SFHS. 
 
As a final means of analysing national differences, the parental birth place was examined 
(Fig. 5-5). The prevalence amongst individuals with two parents born in Scotland was 2.9% 
(465/16,011); one born in Scotland and one not from England or Scotland was 2.8% 
(61/2,176), one born in England and one not from England or Scotland was 1.7% (6/345), 
and two parents born in England was 1.4% (16/1172) (p = 0.025). 
 
 
Figure 5-5: iciHHV-6 prevalence stratified by the birthplace of participants parents. 
X2 p value is indicated. 
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To check the difference between Scottish regions, iciHHV-6 prevalence was examined 
across the four regions where most participants resided at the time of sampling 
(Aberdeen, Dundee, Glasgow and Perth postal code areas). Given the possibility of 
sampling error caused by family members residing in close areas, this was only examined 
in the unrelated cohort. There was no statistically significant difference in the prevalence 
of iciHHV-6 across the four regions (p = 0.625) (Fig 5-6). 
 
 
Figure 5-6: iciHHV-6 prevalence across Aberdeen (blue), Dundee (red), Glasgow 
(green) and Perth (yellow) postal code regions in the unrelated data set. 
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5.3.6 Phenotypic association analysis: disease variables 
Self-reported history of 16 conditions was available for GS:SFHS participants, including 
four cancers (Appendix 4). Owing to the fact that cancer is to some degree associated 
with telomere dysfunction and a possible candidate for iciHHV-6 association, a power 
analysis was performed for breast cancer, bowel cancer, lung cancer, prostate cancer 
and ‘any cancer’, a variable that represents the reporting of one or more cancers. Power 
calculations were based on the frequency of each cancer and the prevalence of iciHHV-
6, in the full cohort. 
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Figure 5-7: Power analysis of cancers in the full GS:SFHS cohort. Plot indicates the 
statistical power (y) of achieving statistical significance (p = 0.05) at odds ratios of 1.2, 
1.4, 1.5, 2, 3, 4 and 5. 
 
Figure 5-7 presents a power analysis of the specified cancers, showing the power (or 
chance of observing) statistically significant differences (p <0.05) at odds ratios (ORs) 
between 1.2 and 5 if there were statistically significant differences in the data set. 
Considering a cut-off of 80% power, we are likely to only observe statistical significance 
for OR≤2 in combined cancers (any cancer) or breast cancer. For other cancers we are 
likely only to identify OR>2.5. 
Logistic regression analysis of iciHHV-6 in relation to the diseases in the full cohort is 
presented in Table 5-4. With the exception of breast cancer and prostate cancer (where 
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only a single sex was analysed) the analysis was adjusted by sex; all were adjusted for 
age group. 
 
Table 5-4: Odds of self-reported disease in iciHHV-6-positive individuals. 
Disease 
iciHHV-6 prevalence 
%(N) p value 
Odds 
Ratio 
OR 95% CI 
No disease Disease 
Asthma 
2.7 
(563,20,544) 
2.6 
(68/2,607) 
0.693 0.95 
0.74-1.23 
COPD1 
2.7 
(622/22,878) 
2.6 
(7/265) 
0.952 0.98 
0.46-2.08 
HBP2 
2.7 
(535/19,979) 
3.0 
(95/3,172) 
0.262 1.14 
0.91-1.44 
Heart disease 
2.7 
(605/22,243) 
2.8 
(25/908) 
0.942 1.02 
0.67-1.53 
Stroke 
2.7 
(621/22,812) 
2.7 
(9/339) 
0.951 0.98 
0.50-1.91 
Alzheimer’s disease 
2.7 
(626/23,111) 
10 
(4/40) 
0.009 4.00 
1.42-11.24 
Parkinson’s disease 
2.7 
(629/23,097) 
1.9 
(1/54) 
0.700 0.68 
0.09-4.91 
Breast cancer (female 
only) 
2.7 
(354/13,323) 
4.1 
(13/319) 
0.098 1.62 
0.92-2.87 
Bowel cancer 
2.7 
(628/23,013) 
1.4 
(2/138) 
0.368 0.53 
0.13-2.13 
Lung cancer 
2.7 
(628/23,089) 
3.2 
(2/62) 
0.803 1.20 
0.29-4.91 
Prostate cancer (male 
only) 
2.7 
(259/9,423) 
4.7 
(4/86) 
0.314 1.67 
0.61-4.66 
Any cancer 
2.7 
(610/22,600) 
3.6 
(20/551) 
0.168 1.38 
0.87-2.19 
Osteoarthritis 
2.8 
(588/21,420) 
2.4 
(42,1731) 
0.462 0.89 
0.64-1.23 
Rheumatoid arthritis 
2.7 
(619/22,732) 
2.6 
(11/419) 
0.924 0.971 
0.53-1.78 
Hip fracture 
2.7 
(603/23,025) 
2.9 
(27/917) 
0.442 0.58 
0.14-2.34 
Depression 
2.7 
(565/21,016) 
3.0 
(65/2,135) 
0.318 1.14 
0.88-1.48 
Diabetes 
2.7 
(609/22,375) 
2.7 
(21/776) 
0.989 1.00 
0.64-1.56 
1chronic obstructive pulmonary disease, 2High blood pressure. Italics indicate statistical 
significance. 
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In the complete cohort a statistically significant association was noted between 
Alzheimer’s disease (AD) and iciHHV-6, with an iciHHV-6 prevalence of 10% in the disease 
group and OR of 4.00 (p = 0.009). In the unrelated data set the effect size is maintained 
but the significance reduced (p =0.052). 
In the full cohort the prevalence of iciHHV-6 in females who reported breast cancer was 
4.1% (OR =1.62), the difference between this and the non-disease group was near 
statistical significance (p = 0.098). In the unrelated sample set, the iciHHV-6 prevalence 
in the breast cancer group was 4.8% (OR = 1.98, CI: 1.03-3.83), the difference between 
this and the prevalence in the non-disease group was statistically significant (p = 0.042). 
Although not significant, with the exception of bowel cancer the iciHHV-6 prevalence was 
higher in all cancer groups than the non-disease groups. 
Due to the significant association with breast cancer in women this was next addressed 
in men. The prevalence of iciHHV-6 in male breast cancer was 20% (2/10) compared to 
2.8% (264/9,499) (p = 0.03) in the full cohort, and 20% (1/5) in the unrelated data set (p 
= 0.133). Further examination of these two individuals highlighted they had also reported 
having had all the diseases addressed in the GS:SFHS questionnaire, suggesting 
misreporting, this has implications on the association with AD. 
Given the possible association with AD, cognitive variables were also examined (Appendix 
4, Table A4-4). A small but statistically significant difference in the Mill Hill vocabulary 
test score was detected in females in the full cohort. The mean score in iciHHV-6-negative 
(n = 11,998) was 29.76 compared to 29.22 in iciHHV-6-positive (n = 337) (p = 0.037). A 
difference is also observed in unrelated individuals, 30.64 in iciHHV-6-negative and 29.84 
in iciHHV-6-positive, but this was not statistically significant (p = 0.076). None of the 
other variables showed statistically significant differences in either sex; however, iciHHV-
6-positive individuals had lower scores in the general health questionnaire (GHQ), Likert 
and delayed logical memory scores with p <0.1. 
 
5.3.4.1 iciHHV-6 and angina pectoris 
Association of iciHHV-6 and angina pectoris was confirmed in the GS:SFHS cohort. The 
prevalence of iciHHV-6 in people suspected of having angina pectoris based on the 
responses in the Rose angina questionnaire, was 4.3% (39/917) compared to 2.7% 
(611/22,715) in those without angina (p = 0.005, adjusted p = 0.028). 
To validate the accuracy of the Rose angina questionnaire data, the association between 
angina and known risk factors were examined. The risk of angina was increased in older 
individuals (p <0.001), smokers (ever smoked) (p <0.001), BMI (p <0.001), higher weight 
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(p = 0.041) and lower SIMD quintile (p <0.001). Statistically significant associations were 
not observed with sex (p = 0.277) and systolic blood pressure (p = 0.126). After correction 
for these, iciHHV-6 association was still significant (p = 0.001, OR: 1.79, CI: 1.26-2.54). 
 
5.4 Discussion 
To date this is the largest study of iciHHV-6. The prevalence of iciHHV-6 in the GS:SFHS 
and by extension the Scottish population is 2.7%, notably higher than any UK, European, 
and Japanese study with more than 100 participants. An investigation of nationality within 
the GS:SFHS found that the iciHHV-6 prevalence of individuals born in Scotland was 
approximately 1.5x higher than people born in England, and this finding was statistically 
significant (p = 0.006). These findings were in concordance with the findings for parent’s 
birth place. There was also no statistically significant difference in the iciHHV-6 
prevalence across four Scottish postcode regions. The difference in iciHHV-6 prevalence 
between Scotland and England can also be seen in Chapter 4, section 4.3.3. The iciHHV-
6 prevalence in the SNEHD sample group, which includes individuals born in Scotland was 
2.2% (16/724) compared to 1.2% (4/344) in the ELCCS sample set which is likely mostly 
made up of individuals born in England. 
During the writing-up of this thesis, a population based study of iciHHV-6 in Québec, 
Canada was published (Gravel et al., 2015). Gravel et al, (2015) determined that the 
iciHHV-6 prevalence in Quebec was 0.58%, lower than both the prevalence in individuals 
born in Scotland and England in the GS:SFHS. Given that Gravel et al, screened 19,597 
individuals this difference observed between Scotland and Québec is likely significant.  
Several possibilities exist as to how iciHHV-6 prevalence is associated with nationality. 
Frist, either the viruses circulating in the Scottish population integrates with a greater 
frequency than the one circulating in England and elsewhere. Second, Individuals born in 
Scotland are more susceptible to integration than those born elsewhere. These two 
possibilities seem unlikely; a more reasonable explanation is that of a founder effect. To 
date no new integration events have been identified and it remains possible that iciHHV-
6 integration events are historic and rare. Inherited chromosomally integrated HHV-6 
could act as a marker of a founder effect, one that is less pronounced in the English 
population. Alternatively the prevalence observed in Scotland could be reflective of that 
of an older population whilst that in England could have had a greater influence from 
historic immigration events from Europe (Leslie et al., 2015). This theory is added to by 
European studies having a similar iciHHV-6 prevalence to those performed in England. 
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A key feature of the GS:SFHS not utilised in this study is the availability of genome wide 
association study (GWAS) data for many of the participants; with the addition of 
identifying the site of integration and sequencing of the viral genome, the hypothesis of 
founder effect could be further investigated. As has already been mentioned iciHHV-6 
prevalence in Europe and the US is often quoted as being 0.5-2%. The difference in 
prevalence between Scotland and England, may highlight how two geographically close 
populations can become isolated from one another. This suggests it is an over 
simplification to present combined prevalence data from multiple countries, which is 
becoming a more frequent practice. 
Although typing of the virus was not performed on all iciHHV-6-positive samples, in the 
pilot study HHV-6A accounted for 3.3% (2/60) of positive cases. Clark & Ward (2008) 
suggested in their review of iciHHV-6 that HHV-6A was over represented, accounting for 
up to one-third of identified iciHHV-6 genomes. Findings presented in this chapter and 
Chapter 4 suggest that this may not be the case in the UK population; however, at the 
time of writing iciHHV-6 typing was still ongoing. As has already been discussed with 
regards to nationality, disparity in exogenous HHV-6A and iciHHV-6 prevalence may 
highlight the problem with not considering birth place and population dynamics. 
The GS:SHFS is a large and well characterised cohort which making it an ideal data set to 
identify possible phenotypic associations with iciHHV-6. The available disease and 
phenotypic information are presented in Appendix 4. AD was significantly associated with 
iciHHV-6 in the full cohort (p = 0.009) and was close to significance in the unrelated data 
set (p = 0.053). Further investigation suggested that two iciHHV-6-positive individuals may 
have misreported disease information. After removal of these individuals from the 
analysis the prevalence of iciHHV-6 is still higher than controls (2/38) but, it must be 
noted that the AD group is particularly small. Whilst there is some evidence to suggest 
that exogenously acquired HHV-6 is associated with cognitive deterioration and 
progression of AD, there is no reported association with iciHHV-6 in the literature 
(Carbone et al., 2014). 
Association of iciHHV-6 with breast cancer was close to statistical significance in females 
in the full cohort (p = 0.098) and was significant in the unrelated sample set (p = 0.042) 
with an OR of approximately 2 in the latter. Given the study does not have a high degree 
of statistical power due to the relatively small number of individuals in the disease groups, 
identification of a relatively small OR could be significant, and warrants further 
investigation. It is also noted that there is a general trend of increased iciHHV-6 
prevalence in other cancer groups. To date there is no evidence of an association with 
iciHHV-6 and cancer in the literature, but given that telomere dysfunction is associated 
with both it remains a possibility. 
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Analysis of iciHHV-6 and angina pectoris confirmed recently published association of 
iciHHV-6 (Gravel et al., 2015). The integrity of the Rose angina questionnaire data was 
assessed through adjustment for multiple covariates and the association with iciHHV-6 
remained statistically significant (p = 0.001). Gravel et al, (2015) showed that angina 
pectoris was 3.3x elevated in iciHHV-6-positive individuals. The effect size reported here 
is smaller, OR: 1.79 (CI: 1.26-2.54), which could be as a result of sampling or population 
differences. The cause of this association is not clear; however, viral reactivation from 
iciHHV-6 has been suggested as a cause of symptoms of unexplained heart failure (Kuhl 
et al., 2015). 
Significant associations were also noted with the mean Mill Hill vocabulary test score and 
mean height in females, however after correction for multiple testing the latter lost 
significance. The Mill Hill vocabulary test is a measure of intelligence where participants 
are asked to identify the meaning of words from provided examples (French and 
Beaumont, 1990). Females positive for iciHHV-6 were on average able to define one less 
word than those iciHHV-6-negative. Taken alone this is perhaps a small difference; 
however in a study in the USA iciHHV-6 was associated with lower Bayley scores (a 
measure of development) in infants (Caserta et al., 2014). An association was also noted 
between years in education and iciHHV-6. This was a more complex association than 
others (Fig. 5-8), and is difficult to contextualise, but a higher iciHHV-6 prevalence was 
seen in people with lower years in education, followed by a drop below the unrelated 
average between 14 and 19 years. The complexity of this is added to by the fact the full 
cohort includes families which may bias peoples persistence in education, and the 
unrelated sample set having relatively small numbers in each year grouping. 
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Figure 5-8: Graphical representation of iciHHV-6 prevalence compared to years in 
education (5-23 years), in the unrelated data set. Indicated with a solid line is the 
prevalence of iciHHV-6 in the unrelated data set. 
Chapter 5: iciHHV-6 in the GS:SFHS cohort 
143 
 
  
The investigation into possible phenotypic associations with iciHHV-6 presented here is a 
hypothesis generating study and although a large sample set, due to the sizes of individual 
disease groups it lacks statistical power to be able to identify small statistically significant 
differences in iciHHV-6 prevalence in these groups. Due to these, no correction for 
multiple testing was performed for disease and cognitive variables, with the exception of 
angina pectoris. Most results presented here are meant as a basis for further study. 
Also identified in the pilot screen were two individuals with two U regions per cell. If 
these are separate viruses, the prevalence of double integrations was 0.09% (2/2,285). 
The prevalence of single integrated viruses was 2.5% (58/2,285), meaning the expected 
double integration prevalence was 0.06%. Although only a small sample set there does 
not appear to be any over representation of multiple integration events in individuals. 
Further characterisation of these samples is presented in Chapter 6. 
In summary, this study identifies multiple associations with iciHHV-6 which warrant 
further examination in appropriately tailored studies. Particularly interesting is a trend 
for higher iciHHV-6 prevalence in multiple cancers, and the confirmation of a significant 
association with angina pectoris. A key novel observation is a significant difference in the 
prevalence of iciHHV-6 across Scotland and England. This phenomenon may not be 
confined to the UK and investigating prevalence on a country by country basis with 
particular care to consider population dynamics is crucial for a greater understanding of 
iciHHV-6. 
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Chapter 6.  Inherited chromosomally integrated HHV-6, 
genome configuration and dynamics 
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6.1 Introduction 
HHV-6 is hypothesised to integrate into the human telomere by homologous 
recombination of either the T2 region of DRR alone, or through recombination between 
the T2 region of DRR and the T1 region of DRL. This leads to insertion of the complete viral 
genome with the exception of the outermost pac1 and pac2 sequences. In all cases DRR is 
the most sub-telomeric due to the orientation of the human telomeres and viral TLRs.  
(Arbuckle et al., 2010; Arbuckle and Medveczky, 2011; Huang et al., 2013). 
Huang et al, (2013) recently described extra-chromosomal telomere circles that 
contained either single DR regions, or U plus DR regions in iciHHV-6-positive individuals. 
The authors suggested that these were the products of T-loop formation followed by 
excision, thus raising the possibility that the integrated HHV-6 genome is dynamic, and 
that genomic regions can be lost from the host chromosomes, possibly prior to viral 
reactivation. As discussed previously there are now several reports of HHV-6 reactivation 
from iciHHV-6 but all are in unusual circumstances such as immunosuppression or drug-
induced reactivation. It is not clear, however, how frequently these events occur in vitro 
and in vivo. In addition the configuration of the excised and remaining viral sub-genomic 
regions is not well investigated. 
The aim of this investigation was to analyse iciHHV-6 genome configuration both in an in 
vitro cell model and in vivo in individuals in the GS:SFHS. An investigation of iciHHV-6 
genome dynamics in vitro was performed in collaboration with Dr Nicola Royle (University 
of Leicester). For this ddPCR was used to track the copies per cell of HHV-6 U and DR 
regions over time and demonstrate the loss of DR regions from a single integrated copy 
of HHV-6A. Further to this, the prospect of loss of viral sub-genomic regions in vivo was 
examined in iciHHV-6-poisitive individuals identified in a screen of the GS:SFHS cohort 
(Chapter 5). 
It is not currently known what drives the process of HHV-6 integration or when after 
infection of a cell integration occurs. To date all examined iciHHV-6 genomes are single 
and intact, with rare exception. Earlier in this thesis (Chapter 4) an iciHHV-6A-positive 
individual was identified with four U regions per cell (subject 4298). This could be four 
separately integrated viruses; however, from the same sample set the iciHHV-6A 
prevalence was 0.13% and thus the chance of an individual being positive for four separate 
integrated HHV-6A genomes is 2.9x10-4%. Another possibility is through the integration of 
viral genome concatemers, such as the head-to-tail ones generated in HHV-6 replication 
(Deng and Dewhurst, 1998; Thomson et al., 1994). To determine the configuration of viral 
genomes in this case a novel ddPCR and a mathematical, model based around the 
Poissonian statistics of ddPCR, was designed and utilised (termed here linkage analysis). 
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The linkage model works by calculating the proportion of DR adjacent (linked) to each 
end of the U region (Fig.6-1). This is presented alongside a pedigree analysis of an 
individual identified in the GS:SFHS cohort and their family as further evidence to the 
integration of, and inheritance of HHV-6 genome concatemers. 
To ensure clarity the results and methods used to investigate each aim of this chapter are 
discussed together. 
 
Figure 6-1: Schematic representation of linkage analysis of HHV-6 genomes. A) DNA is 
digested with restriction enzyme X, which leads to DR6 and U2 PCR targets on the same 
strand of DNA (linked). Droplet digital PCR is then performed with a duplex assay targeting 
DR6 and U2, and the droplet numbers used to determine if DR6 and U2 are present on the 
same segment of DNA. B) A similar approach for DR6 and U100 when digested with 
restriction enzyme Y. C) DNA is digested with restriction enzyme Z, in this scenario neither 
U2 nor U100 are on the same piece of DNA as DR6. The numbers of droplets positive for 
each single target, both targets and neither target are used in the described 
mathematical model (Appendix 5) to determine the proportion of present DR6 linked to 
U2 and the proportion of DR6 linked to U100. In this example 50% of DR should be observed 
linked to U2 and 50% linked to U100. 
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6.2 The number of viral genomes per cell fluctuates in vitro 
 
6.2.1 Materials and Methods 
6.2.1.1 Samples 
An analysis of iciHHV-6 genome configuration was performed on the LCL 3-10q26.3 (cell 
line first described in (Nacheva et al., 2008)). Cell culture was performed at the University 
of Leicester. At the indicated time points cells were removed from the culture and 
subjected to DNA extraction; T1 (day 14), T1-2 (day 35), T2 (day 58), T2-C (day 65), T2-
3 (day 119), T3 (day 170), T4 (day 225) and T5 (day 299). 
 
6.2.1.2 Droplet digital PCR 
Droplet digital PCR CNV analysis was used to determine the copies per cell of U and DR 
regions of DNA at each time point. U regions were quantified using the RPP30/HHV-6A Pol 
assay, and DR regions with the RPP30/DR6A assay (Chapter 3). Reactions were performed 
as described in section 2.6.2 with ‘in reaction’ digestion for the RPP30/HHV-6A Pol assay. 
Reactions included 0.5x RPP30 primer and probe mix, 300 nM viral primers, 200 nM viral 
probes, 100 ng template DNA and an RE ‘digest mix’ in a final volume of 25 µl. For 
RPP30/DR6A, 150 ng of DNA was digested in 5 µl with 5 units of AluI in 1x CutSmart® Buffer 
(Both NEB, UK) at 37oC for approximately 16 hours, before heat inactivation at 80oC for 
20 minutes. Prior to use the RE digests were diluted five-fold with 20 µl double distilled 
nuclease free water. Subsequent ddPCR contained 0.5 x RPP30 primer and probe mix, 300 
nM viral primers, 200 nM viral probes and approximately 60 ng of pre-digested DNA in a 
final volume of 25 µl. 
 
6.2.1.3 Analysis of HHV-6 genome configurations in the LCL 3-
10q26.3 time course 
Loss of iciHHV-6 sequence from a cell-line containing a single complete integrated copy 
can result in cells with no integrated viral sequence, cells that contain U+DR and cells 
that contain only a single DR region. The proportion of these possible genome 
configurations was calculated based on the maximum and minimum proportions of cells 
that could contain a complete genome for any given U or DR copy number per cell with 
U>0 and ≤1 and DR>1 and ≤2. 
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The maximum number of complete genomes (xmax) was assumed to be equal to the number 
of U region copies per cell based on analysis of Pol, or, half the copy number of DR6A 
depending which was lower. The proportion of cells containing DR.U was, maximum 
complete genomes minus the copy number of U region per cell (in reality this is 0 for xmax 
as all U regions are incorporated in complete genomes). The proportion of cells with a 
single DR at xmax was the DR copies per cell minus the proportion of DR regions in complete 
genomes. 
The minimum number of complete genomes (xmin) was the copy number of DR6A per cell 
minus one, as, at DR>1, DR regions must be present in a complete genome. At xmin the 
proportion of DR.U was the copy number of U region per cell minus one; the proportion 
of cells with only a single DR was one minus the sum of complete and DR.U proportions. 
The proportion of negative cells at xmax and xmin was one minus the sum of the other 
genome configuration proportions. 
 
6.2.2 Results  
The LCL 3-10q26.3 which contains a single integrated copy of HHV-6 on the q-arm of 
chromosome 10 (Nacheva et al., 2008), was examined through multiple passages over a 
period of approximately 300 days. Droplet digital PCR was used to examine the copies per 
cell of HHV-6A U (Pol) and DR (DR6A) regions. The results at each time point are 
summarised in Table 6-1 and figure 6-2. 
 
Table 6-1: Droplet digital PCR analysis of the iciHHV-6A genome at multiple time points 
in LCL 3-10q26.3. 
Time point 
Pol Copies per 
cell 
(95% Poisson CI*) 
DR6A copies per 
cell 
(95% Poisson CI*) 
DR6:Pol Ratio 
T1 0.94 (0.90-0.96) 1.94 (1.89-1.98) 2.07 
T1-2 0.94 (0.92-0.97) 1.89 (1.84-1.93) 2.00 
T2 0.95 (0.92-0.98) 1.93 (1.87-1.98) 2.03 
T2-C 0.92 (0.89-0.95) 1.83 ((1.77-188) 1.99 
T2-3 0.93 (0.90-0.96) 1.87 (1.82-1.91) 2.02 
T3 0.76 (0.74-0.79) 1.76 (1.72-1.81) 2.30 
T4 0.84 (0.82-0.87) 1.88 (1.84-1.93) 2.23 
T5 1.06 (1.03-1.09) 2.06 (2.01-2.11) 1.94 
       *Confidence interval (CI) 
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Figure 6-2: Graphical representation of ddPCR analysis of Pol and DR6A copy numbers 
at multiple time points in LCL 3-10q26.3. 
 
At the start of the time course, there is approximately 1 copy per cell, with a DR6A:Pol 
ratio slightly greater than 2. Between time points T1-2 and T2-3 the virus copy number is 
consistently slightly less than 1 copy per cell, with DR6A:Pol ratios suggesting 2 DR per U 
region. Although within the acceptable range of variability for 1 copy per cell, the fact 
that the copy number is consistently less than 1 across these time points implies this may 
not be due to experimental error. At time point T3 there is a drop in both the Pol and 
DR6A copy numbers; however, there remains an excess of DR. There is a concomitant 
increase in the DR6A:Pol ratio to 2.3. At T4 the copy number of both Pol and DR6A 
increases, and the DR6A:Pol ratio is slightly lower at 2.23. By the final time point there 
is approximately 1.06 and 2.06 copies per cell of Pol and DR6A respectively, and both are 
close to the expected ratio for complete viral genomes (DR6A:Pol = 1.94). Between T2 
and T3 the LCL growth rate slowed from 0.45 population doublings (PD) day-1 to 0.34 PD 
day-1. After T3 the growth rate increased to 0.53 PD day-1. 
The HHV-6 U and DR region copy numbers can be influenced by the loss of a single DR, a 
DR and U region or an entire genome. The proportion of each remaining structure at the 
maximum (Xmax) and minimum (Xmin) possible proportions of complete genomes were 
calculated for T2-3 and T3, before and after the drop in HHV-6 copies per cell (Table 6-
2). At T2-3 the majority of cells are likely to contain a complete viral genome (proportion, 
0.87-0.93). At T3 the majority of cells still contain a complete genome; however 
approximately 24% are predicted to contain a single DR region. Whilst viral sequence is 
lost between T2-3 and T3, the resulting increase in copy number and return to 
approximately 1 copy per cell of complete virus suggests the viability was reduced in cells 
were excision had occurred. 
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Table 6-2: Maximum and minimum proportions of different genome configuration before 
and after the loss of sub-genomic regions. 
Integrated 
configuration 
Time point 
T2-3 T3 
Xmax Xmin Xmax Xmin 
Complete genome 0.93 0.87 0.76 0.76 
DR + U 0 0.06 0 0 
Single DR 0.01 0.07 0.24 0.24 
No genome 0.06 0 0 0 
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6.3 Analysis of in vivo direct repeat loss 
 
6.3.1 Materials and Methods 
6.3.1.1 Samples 
The ex vivo analysis was performed using DNA from 59 of the 60 iciHHV-6-positive 
individuals identified in the pilot screen of GS:SFHS, and a further 9 samples identified 
through screening the entire GS:SFHS cohort that were suspected to be positive for only 
DR sequence. 
 
6.3.1.2 Droplet digital PCR 
Droplet digital PCR targeting the U region was performed as described above with the 
additional use of the RPP30/HHV-6B Pol and RPP30/U7 assays. These reactions included 
1x or 0.5x RPP30 primer and probe mix, 300 nM viral primers, 200 nM viral probes, 100 ng 
template DNA and an RE ‘digest mix’ in a final volume of 25 µl. Droplet digital PCR 
targeting the DR region was also performed as above with the additional use of the 
RPP30/DR6B assay and digestion prior to ddPCR. 
For DR6 (n=24) specific assays, ddPCR was performed in duplicate and results merged 
using QuantaSoft software on. For the remaining samples and Pol and U7 assays, a single 
PCR was performed. 
 
6.3.2 Results 
6.3.2.1 Loss of direct repeats in vivo is infrequent 
The frequency at which viral sequences are lost in vivo was examined in the GS:SFHS 
cohort. Fifty-nine iciHHV-6-positive cases identified in the pilot screen were tested with 
either HHV-6A or HHV-6B RPP30/DR6 assay as appropriate (Fig. 6-3). 
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Figure 6-3: DR6 and Pol copy number per cell (ordered by DR6 copy number) in 59 
iciHHV-6-poitive individuals identified in a pilot screen of the GS:SFHS cohort. 
Subjects are ordered by DR copy number and Error bars, although not always visible due 
to their small range, indicate the Poisson 95% CI for each point. 
 
Droplet digital PCR analysis of DNA extracted from blood samples demonstrates no 
noticeable loss of U regions (Pol). For single integrated viruses the Pol copy number 
ranged from 0.95-1.10 copies per cell and the DR6 copy number per cell ranged was 1.41-
2.30 copies per cell. The DR6:Pol ratio was calculated for each sample; for those with a 
single U region the range was 1.41-2.21. For complete viral genomes the DR6:Pol ratio is 
expected to be 2 (2 DR and 1 U region). Forty-one samples had a DR6:Pol ratio between 
1.90-2.10, 8 samples had a ratio between 2.11-2.21, and 6 between 1.41-1.87. Those with 
a ratio above 2.10 may have an excess of direct repeats; the ratio is particularly high in 
subjects 79678, 117873, 164027 and 117307. These four samples have a Pol copy number 
of approximately 1 copy per cell; however DR6 copy numbers are 2.21, 2.30, 2.19 and 
2.17 copies per cell respectively. Those with a ratio less than 1.90 may be suggestive of 
DR loss (Table 6-3). Of the 57 subjects with single integrations examined a degree of 
potential DR region loss was observed in 14% (8/57). 
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Table 6-3: Summary of ddPCR results for subjects displaying DR region loss. 
Subject 
Pol copies per 
cell 
(Poisson 95% CI*) 
DR6 copies per 
cell 
(Poisson 95% CI*) 
DR6:Pol 
ratio 
127808 1.03 (0.99-1.07) 1.93 (1.88-1.98) 1.87 
18823 1.02 (0.99-1.05) 1.91 (1.86-1.97) 1.87 
31588 1.07 (1.01-1.14) 1.93 (1.85-2.01) 1.80 
10050 1.07 (1.03-1.11) 1.74 (1.69-1.80) 1.63 
28514 1.04 (1.00-1.07) 1.63 (1.58-1.68) 1.57 
54825 1.00 (0.97-1.03) 1.41 (1.35-1.47) 1.41 
*Confidence interval (CI) 
 
Two samples in the pilot study had 2 U regions per cell: 125833 (2.14 copies per cell, 
Poisson 95% CI: 2.08-2.20) and 161838 (2.07 copies per cell, Poisson 95% CI: 2.00-2.14). 
These samples had DR6 copy numbers of 3.21 (Poisson 95% CI: 3.12-3.29) and 3.15 (Poisson 
95% CI: 3.06-3.25), respectively. For two separate integration events, 4 DR region copies 
per cell are expected; the lower DR copy number could be as a result of DR loss or through 
the integration of a viral concatemer as discussed later. 
 
6.3.2.2 Inheritance of single HHV-6 direct repeats 
The results from the pilot study, initially screened with a U7 specific assay and the screen 
of the full cohort, which utilised a DR1 specific assay, were compared to identify any 
samples positive for only DR sequence. Six samples were negative for HHV-6 U7 but 
positive for HHV-6 DR1. Droplet digital PCR targeting RPP30 and four viral regions, Pol 
U7, DR6A or DR6B were performed on these six samples. All samples were negative for 
U7, five had DR6B copies of 0.93 (Poisson 95% CI: 0.90-0.97), 0.99 (Poisson 95% CI: 0.95-
1.02), 1.00 (Poisson 95% CI: 0.97-1.03), 1.00 (Poisson 95% CI: 0.96-1.05) and 1.22 (Poisson 
95% CI: 1.19-1.25) copies per cell, and one had DR6A copy number of 0.98 copies per cell 
(Fig. 6-4). All were negative for HHV-6A or HHV-6B Pol. 
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Figure 6-4: Copy numbers of HHV-6 U7 and HHV-6 DR6 in samples positive for only DR 
sequence. 
 
These six individuals fell into five families in the GS:SFHS cohort. In three families there 
were no other positive family members. The remaining individuals were from Family 2184 
and 5475 (Fig. 6-5).  
Six members of family 2184 were negative for DR1 amplification in the TaqMan® screen. 
Subjects 10360, 2086 and 37354 were positive for DR1 amplification in the TaqMan® screen 
of the full cohort, further ddPCR analysis showed negativity for U7 and a DR6B copy 
numbers 1.00 (Poisson 95% CI: 0.96-1.05), 0.99 (Poisson 95% CI: 0.95-1.02) and 0.96 
(Poisson 95% CI: 0.91,1.02) copies per cell, respectively (Fig. 6-5). 
 
Figure 6-5: Pedigrees of Family 2184 and Family 5474 showing inheritance of a single 
DR. Females (circle) and males (square) with participant numbers were screened with 
TaqMan PCR. Empty shapes indicate no iciHHV-6 and black are positive for DR sequence, 
copies per cell (c cell-1) of DR are indicated under shapes. 81064 and 152028 of Family 
5474 were not tested with ddPCR; however, ΔCT values were 2.23 and 2.01 respectively. 
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Four samples were identified that were negative for U7 sequence in the screen of the 
GS:SFHS samples that had a ΔCT between 3-6. These samples from subjects 66041, 94728, 
99159 and 131993 had ΔCT values of 4.57, 4.52, 5.56 and 4.29 respectively. Since it was 
possible that these subjects are positive for only DR sequence, assays for RPP30/DR6A 
and RPP30/DR6B were performed. All four were negative for HHV-6B DR6; however, three 
samples were positive for HHV-6A DR6 with 2.12, 1.01 and 2.2 copies per cell, for 94728, 
99159 and 131993 respectively. 
At the time of writing, the prevalence of single DR in the full cohort is not currently 
known as all samples have not yet been tested for both U7 and DR1. The prevalence of 
individuals with a single DR in the pilot study was 0.26% (6/2285) if these are classified 
as iciHHV-6-positive, iciHHV-6 prevalence in the pilot study was 2.9% (65/2285). 
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6.4 Integration and inheritance of HHV-6 genome concatemers 
 
6.4.1 Materials and Methods 
6.4.1.1 Samples 
Linkage analysis and investigation of inheritance of HHV-6 genome concatemers was 
performed on DNA samples from subject 4298 (Chapter 4) and subjects 125833, 16177, 
175727 and 2029 (Chapter 5). Subject 4298 was a healthy adult male recruited as a control 
in the SNEHD cohort. Subject 125833 was identified as being iciHHV-6-positive in the pilot 
screen of the GS:SFHS cohort and subjects 16177, 175727 and 2029 are iciHHV-6-positive 
family members identified in the screen of the entire cohort. 
 
6.4.1.2 Droplet digital PCR 
Prior to linkage analysis ddPCR was performed with the RPP30/U7 and RPP30/DR6A to 
quantify the U and DR regions. Each reaction contained 0.5x RPP30, 300 nM viral primers, 
200 nM viral probes and approximately 100 ng of pre-digested DNA in a final volume of 25 
µl. For these assays 500 µg of DNA was digested in 10 µl with 5 units of AluI in 1x CutSmart® 
Buffer (Both NEB, UK) at 37oC for approximately 16 hours, before heat inactivation at 
80oC for 20 minutes. Prior to use the digest mix was diluted five-fold with 40 µl double 
distilled nuclease free water. 
For DNA samples form subjects 125833, 16177, 175727 and 2029 ddPCR for RPP30/U7 and 
RPP30/DR6B was performed as described in section 6.3.1.2. 
 
6.4.1.3 HHV-6 genome concatemer linkage analysis 
Droplet digital PCR was used to perform linkage analysis to predict iciHHV-6 genome 
configurations as outlined in Fig. 6-1. To determine the proportion of DR regions linked 
to the 5’ end of the U region, 500 ng of DNA was digested with restriction enzymes AlwN1, 
StuI or BSu36I in the appropriate buffer in a final volume of 10 µl for approximately 16 
hours. The digestion reaction was then diluted five-fold with double distilled nuclease 
free water. Droplet digital PCR was performed as described in section 2.6.2 with a duplex 
assay that targets HHV-6A DR6 and U2. Each reaction contained 300 nM primes, 200 nM 
probes and 10-50 ng of pre-digested DNA in a final volume of 25 µl. To determine the 
proportion of DR regions linked to the 3’ end of the U region 500 ng of DNA was digested 
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with restriction enzyme HindIII in the appropriate buffer in a final volume of 10 µl, for 
approximately 16 hours. The digestion reaction was then diluted five-fold with 40 µl of 
water. Droplet digital PCR was performed as described in section 2.6.2 with a duplex 
assay that targets HHV-6A DR6 and U100. Each reaction contained 300 nM primers, 200 
nM viral probes and 10-50 ng of pre-digested DNA in a final volume of 25 µl. Finally as a 
control were no linkage should be observed, 500 ng of DNA was digested with AluI in the 
appropriate buffer in a final volume of 10 µl, for approximately 16 hours. Droplet digital 
PCR was performed as described in section 2.6.2 with a duplex assay that targeted HHV-
6A DR6 and U2 or DR6 and U100 and each reaction contained 300 nM primers, 200 nM 
probes and 50 ng of pre-digested DNA in a final volume of 25 µl. The numbers of droplets 
that were double-positive, single positive for each target and double-negative were used 
in a mathematical model to predict HHV-6 genome configuration. 
The mathematical model for linkage analysis was kindly produced by Dr Paul Johnson and 
is presented in Appendix 5. 
 
6.4.2 Results 
In the analyses presented in Chapter 4 and 5, three subjects were identified with more 
than one U region per cell. The first, subject 4298, was in the control group of the iciHHV-
6 and cHL while the others subjects 125833 and 161833 were identified in the pilot screen 
of the GS:SFHS. Subject 4298 had 4.05 HHV-6A Pol copies per cell (Poisson 95% CI: 3.96-
4.14) (section 4.3.2). Further ddPCR analysis revealed a U7 copy number of 4.11 copies 
per cell (Poisson 95% CI: 3.97-4.25), a DR6A copy number of 5.03 copies per cell (Poisson 
95% CI: 4.85-5.20) and a DR1 copy number of 5.13 copies per cell (Poisson 95% CI: 4.94-
5.31). It would therefore appear that subject 4298 has inherited 4 U and 5 DR regions. It 
is possible that a DR:U ratio of 5:4 could arise from four separate integrated viruses, 
through loss of multiple DR regions; however, the analyses presented here suggests that 
this would be an extremely unlikely event. A 5:4 ratio could be reached through multiple 
possible configurations of concatemers of HHV-6A genomes as detailed in Fig. 6-6. 
Droplet digital PCR linkage analysis was utilised to determine whether HHV-6A genome 
concatemers were integrated in subject 4298. The analysis employed duplex assays 
targeting DR6A and either the U2 or U100 ORF at either end of the U region. The possible 
genome configurations (Fig. 6-6) have different proportions of DR6A adjacent to U2 and 
U100. DNA restriction enzymes were selected to ensure that DR6A and U2 or DR6A and 
U100 were on the same strand of DNA if directly linked. As a control DNA was also digested 
with a restriction enzyme that cleaves between these targets. When the digested DNA is 
partitioned into droplets targets that are on the same fragment of DNA will be present 
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within the same droplet leading to double-positive droplets. When the DNA is digested 
with a restriction enzyme that cleaves between the targets, any droplets positive for both 
targets are the result of random assortment of the DNA fragments. The numbers of 
double-positive, single positive for each target and double-negative droplets were used 
in the presented mathematical model (Appendix 5) to determine the proportion of DR6A 
molecules linked to U2 and the proportion linked to U100. The expected percentage 
linkage for each model is presented in Table 6-4. 
Table 6-4: Percentage of DR linkage to U2 and U100 in each of the possible configurations 
presented in Figure 6-7. 
Configuration 
(Fig. 6-7) 
Percentage of linked DRs  
U2 U100 
A 20 80 
B 0 80 
C 20 80 
D 40 80 
E 60 80 
F 60 80 
G 60 80 
H 80 80 
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Figure 6-6: Possible genome configurations with 5 DR and 4 U regions per cell.  
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Figure 6-6 (continued): A) Four separate integration events where three genomes have lost a DR. B) Five integration events, four have lost a DR region whilst one has lost a 
DR and U region. C) Integration of 2 single viruses, each with only one DR, and a head-to-tail genome concatemer. D) Integration of two single genomes, one of which has lost 
a DR region, in addition to integration of concatemer of (DR.U)2. E) Integration of two concatemers with the configuration of (DR.U)2.DR, one of which has lost a DR region. 
F) Integration of a whole genome and a concatemer of (DR.U)3.DR. In this example either could have lost a DR region. G) Integration of a single genome which has lost a DR 
and U region, in addition to a concatemer of (DR.U)4. H) Integration of a single concatemer of (DR.U)4DR. 
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As the proportion of DR6A linked to U100 was expected to be the same in all configuration 
models (Table 6-4) this was used as a control. DNA was digested with either HindIII 
(maintaining any linkage) or AluI (rendering targets on separate DNA fragments) and 
ddPCR targeting DR6A and U100 performed. Figure 6-7 shows 2D ‘heat plots’ for the linked 
(HindIII) and unlinked (AluI) reactions. In the linked reaction there is an increase in the 
proportion of double-positive and double-negative droplets, along with a reduction in 
single positive droplets, indicative of linkage. 
 
Figure 6-7: Droplet digital PCR 2D ‘heat plots’ for the DR6A/U100 assay. Groupings are 
based on the fluorescence amplitude; those low on both axes are double-negative, high 
on a single axis are positive for a single target, and those high on both axes are double-
positive. Increased droplet frequency in a given area of the plot is observed as the colour 
moves from dark blue, through light blue, to green and red. Droplet numbers are A) total: 
13,851, double-negative: 3,442 (25%), double-positive: 8,246 (60%), U100 positive: 545 
(4%), and DR6 positive: 1,618 (11%); B) total: 13,576, double-negative: 1,236 (9%), double-
positive: 6,644 (49%), U100 positive: 2,338 (17%), and DR6 positive: 3358 (25%). 
 
The estimated proportion of DR6A linked to U100 in two linked reactions were 0.78 (CI: 
0.77-0.8) and 0.81 (CI: 0.8-0.82). The linkage estimates in two unlinked reactions were 
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both 0 (CI: 0-0.02). In all cases the DR6:U100 ratio was maintained at approximately 1.25 
(5 DR6A, 4 U100) (Data not shown). 
DNA was next digested with three restriction enzymes that do not cut between DR6A and 
U2. The estimated linkage proportion of DR6A molecules linked to U2 were 0.83 (CI: 0.82-
0.85) for AlwNI, 0.86 (CI: 0.85-0.87) for StuI and 0.86 (CI: 0.85-0.88) for Bsu36I. For DNA 
digested with AluI (unlinked) the estimated proportion of DR6A molecules linked to U2 
was 0 (CI: 0-0.01). Taking these and the DR6/U100 linkage estimates together, it is highly 
likely that subject 4298 inherited a single integrated concatemer with the configuration 
(DR.U)4.DR. Further to this, next generation sequencing performed on the complete 
genome from 4298 (described in chapter 7) identified only two SNPs in the entire U region; 
these were present in 74.2% and 75.2% of the reads consistent with polymorphisms in one 
of the four genomes. The frequency of polymorphisms here is lower than that presented 
between iciHHV-6A genomes in Chapter 7. 
Two samples identified in the GS:SFHS pilot screen had U region copy numbers of 
approximately 2. Droplet digital PCR revealed that subjects 161838 and 125833 had 3.15 
(Poisson 95% CI: 3.06-3.25) and 3.21 (Poisson 95% CI: 3.12-3.29) DR6 copies per cell, 
respectively (Fig. 6-8). 
 
 
Figure 6-8: Copy numbers per cell of Pol and DR6B targets in subjects 161838 and 
125833. Error bars indicate the Poisson 95% CIs. 
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Due to DNA availability it was not possible to perform the linkage analysis on these 
samples; however ddPCR was used to investigate U and DR region copies per cell in family 
members of subject 125833 (Fig. 6-9). 
 
 
Figure 6-9: Pedigree of family 4188 showing inheritance of iciHHV-6B. Where no 
subject identifier is provided the individuals was not present in the GS:SFHS. Positive 
males (square) and females (circles) are in solid black, and negatives white with a grey 
outline. HHV-6B Pol, U7 and DR6 copies per cell are provided for positive subjects. All 
individuals with identifiers were included in the TaqMan® screen presented in Chapter 5, 
and negative subjects are based on the results from this. 
 
Inherited chromosomally integrated HHV-6 positivity was identified in three other family 
members of subject 125833 (two sisters and a nephew). The DR6B copy number range was 
2.97-3.17. U region copy numbers were below 2 in subjects 2029 and 175727 but these 
displayed less than 10% variability from the expected copy number. Inheritance of U and 
DR regions with this copy number ratio could have occurred from inheritance of two 
separate viruses (one of which has lost a single DR region) or through inheritance of a 
concatemer with the configuration (DR.U)2.DR. Given that subject 125833 and their 
siblings are all iciHHV-6-positive, it is more likely that these are the result of inheritance 
of a concatemer. Assuming Mendelian inheritance the probability of inheriting two 
separate viruses from one parent or one genome from each parent is 0.25, when on 
separate chromosomes. The probability of such an event occurring through three 
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generations is 0.0156. The probability of inheriting a single viral concatemer through 
three generations is 0.125. Although it was not possible to confirm whether a single viral 
concatemer or two separate viruses were present the former is more probable. 
 
6.5 Discussion 
HHV-6 is able to stably integrate into the telomeres of human chromosomes resulting in 
germ-line transmission of the complete viral genome through subsequent generations. 
Recently it was demonstrated that regions of the viral genome can be excised from the 
host chromosome in the form of circular DNA (Huang et al., 2013; Prusty et al., 2013). In 
collaboration with Dr Nicola Royle the stability of an iciHHV-6A genome was investigated 
in a culture of an LCL generated from PBMCs of an iciHHV-6-positive individual. The LCL 
was cultured over a period of 299 days without any deliberate attempts to induce excision 
of the viral genome. At time point T3 a drop in the number of HHV-6 copies per cell was 
observed, as demonstrated by a reduction in U and DR region copy numbers (Fig. 6-2). 
After T3 the number of U and DR copies per cell increase until they were similar to the 
levels at the start of the time course, i.e. approximately one copy per cell. At T3 and T4 
there was also an excess of DR regions; this supports the suggestion that genome loss has 
occurred in a small proportion of cells and that where loss has occurred a single DR has 
been retained. It is possible that genome excision has occurred through T-loop formation 
between the end of the telomere and T1 of DRR (Fig. 6-10). 
 
 
Figure 6-10: Excision of the viral U and single DR region by T-loop formation 
between the end of the telomere and T1 of DRR.The result is an episome containing 
the excised viral sequence and a single integrated DR region. 
 
As the U and DR region copy numbers subsequently increase, coincident with a decrease 
in PD, it is possible that the reduction in viral copy number was associated with reduction 
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in cell viability. Between T2 and T3 the PDs per day reduced before increasing between 
T3 and T4. If it is assumed that loss of sub-genomic regions occurs through T-loop 
formation and excision of viral sequence as circular DNA, it is possible that the resulting 
telomeres are short and may induce cellular senescence leading to a reduction in PDs per 
day. Any excision could have occurred at time point T2; however, if the 
extrachromosomal circles containing viral sequence were still present then U and DR 
copies per cell would remain the same. The gradual increase in U and DR copies per cell 
could reflect an outgrowth of cells that retain the complete viral genome, whilst those 
with a single DR region and possibly short telomeres senesce and eventually enter 
apoptosis. In this time course experiment, there was no deliberate attempt to induce 
excision and loss of viral sequence and it remains possible that the integration is unstable 
in this cell-line. There have been reports in the literature that telomere shortening by T-
loop formation can be induced by oxidative stress (Kamranvar et al., 2011); it is possible 
that oxidative stress could have been induced by delays whilst manipulating the cell 
culture. 
As has been described by Huang et al (2013) excision of viral sub-genomic regions has 
been observed in vivo. The analysis of 59 iciHHV-6-positive individuals identified in the 
GS:SFHS pilot screen  showed no reduction in the U region copy number per cell. Six 
subjects were identified where DR region loss had occurred. Four of these subjects were 
over 50 years of age when sampled and it is possible that DR loss could be a marker of 
telomere shortening. For these reasons further work is needed to characterise DR loss in 
different age groups, and cell and tissue types. 
For the first time inherited single HHV-6A and HHV-6B DR sequences in the absence of U 
regions have been identified (Fig. 6-4). Inheritance of single direct repeats was tracked 
through two families, and the single DR regions were identified in all generations of each 
family (Fig. 6-5). There are several possibilities as to how inherited single DR regions 
could arise. First, as the DR region is flanked by TLRs it is possible that homologous 
recombination has occurred between these sequences and the cellular telomeres 
resulting in integration of a single DR and the loss of the remaining viral genome. An 
alternative explanation is that a full viral genome has integrated into the telomere but 
the majority has been excised through T-loop formation. This excision would have 
occurred in a germ-cell or its precursor. It is not clear what, if any, effect a single 
integrated DR would have on the cell. Any effect would depend on multiple factors such 
as how the single DR arose. Other possible effects are similar to those postulated for full 
iciHHV-6: can protein products be generated; is sub-telomeric gene expression affected; 
and does the integration event or presence of the viral sequence have a destabilising 
effect on the telomere. Regardless of the consequences of a single integrated DR region, 
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the presence of DR in the absence of U highlights the need to screen with assays specific 
to the DR and confirm using ddPCR assays that target both the U and DR regions. 
Finally, through use of a novel ddPCR linkage analysis and mathematical model, an 
individual with inherited HHV-6A genome concatemers was identified. This concatemer is 
made up of four U and five DR regions with the configuration (DR.U)4.DR (Fig. 6-6H). There 
are no previous reports in the literature of HHV-6 genome concatemers with this 
configuration. Replication of Exogenously acquired HHV-6 results in the generation of 
head-to-tail genome concatemers (i.e. (DR.U.DR)n), and it is not clear how the 
concatemer described here was generated. Excision of a single DR and U region in a T-
loop could generate such a concatemer if rolling circle amplification followed; however 
in such a case a single DR would remain integrated in the cell. Although the precise 
derivative is not clear, the idea that this is a form of replication intermediate is favoured. 
If this is the case, then replication must have been aborted at the time of integration, 
otherwise cell death would have occurred. 
In conclusion, loss of sub-genomic regions of iciHHV-6 can occur in cell culture, and likely 
has consequence on cell viability. This raises the possibility that similar events can occur 
in vivo and leads to cellular senescence and apoptosis; however, blood samples from 
iciHHV-6-positive individuals suggests that such events are relatively infrequent. 
Nevertheless the identification of individuals with low DR:U ratios is consistent with the 
idea that iciHHV-6 genomes are dynamic structures rather than fossilised remains. 
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7.1 Introduction 
HHV-6A and HHV-6B are two closely related members of the Betaherpesviriae subfamily 
of herpesiviruses. Now considered two distinct viruses, they share approximately 90% 
nucleotide sequence homology. Many regions such as the viral DNA polymerase gene have 
greater sequence identity (96.2%) between HHV-6A and HHV-6B whilst others, such as the 
first exon of the ORF U91 have only 76.3%. 
Both HHV-6A and HHV-6B are able to integrate into the telomeres of human chromosomes 
and there is increasing evidence that this is the natural form of latency. In 2.7% of the 
Scottish population this integration has occurred in the germ-line and is inherited through 
multiple generations. Evidence presented here (Chapter 6) and in the literature (section 
1.7.6 and section 1.8) suggest that iciHHV-6 is not a dead end for the virus, and it is able 
to be excised from the telomere and reactivate. 
HHV-6A and HHV-6B, although geographically distinct in their distribution are collectively 
ubiquitous, yet only a small proportion of the population are iciHHV-6-positive. The 
reasons behind this disparity are not clear and is likely influenced by the host and the 
virus. To date there is only one study of iciHHV-6 genome characteristics. Tweedy et al, 
(2015) compared ORF U83 of iciHHV-6A genomes and iciHHV-6B genomes to those from 
exogenously acquired HHV-6A and HHV-6B. Phylogenetic analysis showed iciHHV-6A U83 
grouping in a clade away from exogenous HHV-6A; however, this was not observed for 
HHV-6B. Although suggestive of relatedness between iciHHV-6A U83, little can be said 
about the distinctiveness of iciHHV-6 genomes from a single region. 
To date no new integration events have been identified. Inherited chromosomally 
integrated HHV-6 found in the population could represent rare or historic events. Once 
integrated the viral genome may accumulate mutations at a similar rate as the human 
genome, leading to a loss of protein coding sequence integrity over time. 
To determine the integrity of, and if there any specific characteristics of, iciHHV-6 
genomes, phylogenetic analysis was performed. The present analysis was restricted to 
five regions of the genome that display a range of nucleotide sequence homologies 
between HHV-6A and HHV-6B: U46, U47, U48, U83 and U90. These regions were chosen 
as they have the most available nucleotide sequences in the NCBI database. A more 
detailed description of these ORFs is provided in Chapter 1, briefly, U46 encodes gN and 
shares 96.9% nucleotide sequence homology between HHV-6A an HV-6B; U47 encodes gO 
which shares 93.4 and 69.8% nucleotide and amino acid sequence homology between HHV-
6A and HHV-6B, respectively; U48 encodes gH which shares 95.5% nucleotide sequence 
homology, U83 encodes viral chemokine which shares 92.4% and 87.5% nucleotide and 
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amino acid sequence homology respectively; in HHV-6A this protein lacks a signalling 
peptide and exists in both a long and short form in HHV-6B. Finally, U90 consists of three 
exons whose nucleotide homology ranges from 80.5% to 85.8%. 
As part of an ongoing collaborative study of iciHHV-6 genomes, nucleotide sequence from 
26 complete or almost complete iciHHV-6 genomes were available and these were 
compared to complete and partial CDS nucleotide sequences either from the NCBI 
database or provided by Prof. Henri Agut (Université Pierre et Marie Curie, Paris, France). 
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7.2 Materials and Methods 
7.2.1 iciHHV-6-positive samples 
Inherited chromosomally integrated HHV-6A and HHV-6B sequences were obtained from 
subjects 4298 (HHV-6A) and 3986 (HHV-6B) identified in Chapter 4; subjects 98485 (HHV-
6A), 20119 (HHV-6A), 125833 (HHV-6B), 161838 (HHV-6B) and 173242 (HHV-6B) identified 
in Chapter 5, and from LCLs 7-17p13.3 (HHV-6A) and 3-10q23.3 (HHV-6A) described 
previously (Nacheva et al., 2008). 
Sequence was also provided by Dr Nicola Royle (University of Leicester) for iciHHV-6A and 
iciHHV-6B positive subjects. These were:  subjects 1501 and 18999 (both HHV-6A), and 
subjects 92, 813, 1065, 1375-02, 7022, Ban519, Cor264, Cum082, Der512, NewP, LCL 2-
9q34.3, LCL 4-11p23.5, Orcadian1, Orcadian2 and Orcadian3 (all HHV-6B). 
 
7.2.3 PCR amplification of HHV-6 genome fragments 
Next generation sequencing was performed on a pooled mix of 32 (HHV-6A) or 33 (HHV-
6B) overlapping amplicons spanning the length of the HHV-6 genome. PCR was performed 
using AccuPrimeTM Taq High Fidelity DNA Polymerase (Life Technologies, UK) as described 
in section 2.6.3 with approximately 8 ng of template DNA per reaction. The primers pairs 
and cycling conditions are described in Appendix 6. 
Post-amplification 5 µl of product was examined with agarose gel electrophoresis in 0.8% 
agarose TAE gels at 8.6 V cm-2 (section 2.6.3). If non-specific products were not detected, 
removal of PCR components was performed with Agencourt AMPure XP beads (GE 
Healthcare) as described in section 2.7.1. When non-specific products were present, 10-
20 µl of the PCR product was separated with agarose gel electrophoresis (section 2.7.2). 
The band of appropriate size was cut from the gel with a scalpel and extracted with the 
PureLink® Quick Gel Extraction Kit (Life Technologies, UK). The concentration of purified 
DNA product was determined with either the Qubit® BR or Qubit® HS dsDNA quantification 
kits depending on the amount of purified DNA. 
PCR products generated from each subject were pooled in a mix of equal molarity for 
each product. The concentration of the most dilute product determined the 
concentration of the overall mix. 
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7.2.4 Illumina Sequencing 
DNA sequencing and read assembly were performed at the MRC – University of Glasgow 
Centre for Virus Research. Library generation and sequencing were performed by Dr Gavin 
Wilkie, Nicolás Suárez and Maggie Baird. Briefly, DNA from pooled iciHHV-6A amplicons 
were sheared to an average size of 650 bp in a Covaris S220 focused ultrasonicator (Covaris 
Inc., Woburn, MA, USA). Fragment size was measured on an Agilent 2200 TapeStation 
(Agilent, Santa Clara, CA, USA). A KAPA library preparation kit (KAPA Biosystems, 
Wilmington, MA, USA) was used to prepared the sheared DNA fragments for Illumina 
Sequencing and end-repaired DNA was purified by using 0.7x volume of AMPure XP beads 
(GE Healthcare, UK) in order to remove fragments smaller than the anticipated read 
length (300 bp). Adapters and index-tagged PCR primers were obtained from New England 
BioLabs. 
An Illumina MiSeq platform running v3 chemistry (Illumina, San Diego, CA, US) was used 
to generate 300 bp paired-end reads from pooled libraries. Sequences were assembled by 
Drs Andrew Davison and Gavin Wilkie and contigs were assembled de novo from sequence 
reads using SPAdes (Bankevich et al., 2012). ABACAS (Assefa et al., 2009) was used to 
produce draft genomes by ordering contigs against HHV6-A and HHV-6B reference 
genomes. Gaps in the assembly were closed by using GapFiller (Boetzer and Pirovano, 
2012). The integrity of the final genomes was verified by aligning against the original 
sequence reads using BWA and visualised using Tablet (Milne et al., 2010).  
 
7.2.5 Phylogenetic and sequence analysis 
The U46, U47, U48, U83 and U90 sequences obtained from iciHHV-6-positive subjects 
were compared to sequences from exogenous HHV-6 with the following NCBI accession 
numbers: NC001664 (U1102), KC465951 (GS), KP257584 (AJ), NC000898 (Z29) and 
AB021506 (HST). Inherited chromosomally integrated HHV-6 sequences were also 
compared to 18 U46 partial CDS (FJ610376-FJ610393), 42 U47 partial CDS (FJ610398-
FJ610438), 80 complete U83 CDS (AB443457-AB443531, AB465584, KF130945-KF130947) 
and 12 U90 complete CDS (AY245902-AY245913). Thirty-four complete U48 CDS were 
kindly provided by Prof Henri Agut. 
Comparisons of nucleotide and amino acid sequences were performed using CLC Genomic 
Workbench V7.5.2 (CLC Bio, Aarhus, Denmark). Alignments were performed with ClustalW 
and phylogenetic trees for nucleotide sequence were generated using the maximum-
likelihood method and the Tamura-Nei model using MEGA6 (Tamura et al., 2013); each 
tree used 1000 bootstrap replicates.  
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7.3 Results 
7.3.1 Amplification of iciHHV-6 genomes 
For ongoing work, beyond the scope of this thesis, the complete sequence of 26 iciHHV-6 
genomes was ascertained. To do this, PCR primer pairs were designed and utilised to 
amplify overlapping fragments of iciHHV-6A and iciHHV-6B genomes (Fig. 7-1). These 
fragments were pooled and sequenced as described above. A review of HHV-6 sequences 
deposited in the NCBI databases revealed the majority of these were from U46, U47, U83 
and U90 ORFs. These were compared to the respective ORFs from the 26 iciHHV-6 
genomes, and U48 sequences. In all cases the iciHHV-6 genomes had been typed as either 
HHV-6A or HHV-6B (data not shown). 
 
 
Figure 7-1: Image of agarose gel electrophoresis displaying products of the 32 PCR 
reactions spanning the iciHHV-6A genome of LCL 3-10q23.3. Numbers above lanes 
indicate the primer pair (Appendix 6, Table A6-1). Reactions for pair 2A and 27A were not 
successfully amplified in this experiment but were amplified later. Shown on these gel 
images. Marker (M) was λHindIII (New England BioLabs, UK). 
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7.3.2 U46 
Complete nucleotide and amino acid sequences for the U46 CDS, of the iciHHV-6A 
genomes (7-17p13.3, 3-10q23.3, 98485, 20119, 4298, 1501 and 18999) were compared to 
those of U1102, GS and AJ. Percentage nucleotide and amino acid sequence identity is 
summarised in Table 7-1. The iciHHV-6A U46 had higher percentage nucleotide and amino 
acid sequence identity with each other than with the reference sequences (U1102, GS, 
and AJ), when pair-wise comparisons were performed. Analysis of amino acid sequence 
revealed that the ORF was conserved with no frameshift mutations in iciHHV-6A U46. 
Pairwise comparisons of iciHHV-6B and reference U46 (Z29 and HST) revealed 100% 
nucleotide and amino acid sequence identity (data not shown). 
 
Table 7-1: U46 nucleotide and amino acid sequence identity of iciHHV-6 genomes with 
U1102 and 7-17p13.3. 
Genome 
% Nucleotide identity % Amino acid identity 
With 
U1102 
With 
7-17p13.3 
With 
U1102 
With 
7-17p13.3 
U1102 - 93.73 - 92.94 
GS 98.43 92.16 96.47 89.41 
AJ 98.04 91.76 95.29 88.24 
7-17p13.3 93.73 - 92.94 - 
3-10q23.3 94.12 99.58 94.12 98.75 
98485 93.73 100.00 92.94 100.00 
20119 93.73 100.00 92.94 100.00 
4298 94.12 99.58 94.12 98.75 
1501 93.73 100.00 92.94 100.00 
18999 92.94 98.33 92.94 97.50 
 
Phylogenetic analysis of the iciHHV-6 genomes, reference sequences and 18 partial U46 
CDS (240 bp) was then performed (Fig. 7-2). There was clear distinction between iciHHV-
6A and iciHHV-6B. HHV-6A formed two clades with bootstrap values higher than 70%, one 
containing the AJ and GS reference sequences, the other made up iciHHV-6A and HHV-6A 
sequences. The final HHV-6A clade contains four iciHHV-6A sequences; however, the 
bootstrap percentage is 57%. Inherited chromosomally integrated HHV-6B genomes 
grouped in a single clade with Z29 and HST U46. 
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Figure 7-2: Phylogenetic analysis of partial CDS of U46 of iciHHV-6A and iciHHV-6B, 
and exogenously acquired HHV-6A and HHV-6B. Asterisks indicate iciHHV-6 sequence 
and branch labels indicate bootstrap percentages. 
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7.3.3 U47 
The U47 ORF was conserved in all iciHHV-6 genomes with no frameshift mutations. 
Alignment of iciHHV-6A U47 and U1102, GS and AJ sequences revealed high degree 
homology with U1102 (Table 7-2), however all lacked a 99 bp (33 amino acid) insertion 
that was present in the GS and AJ ORFs. Pairwise comparisons of iciHHV-6B and reference 
genomes (Z29 and HST) showed 100% sequence identity between iciHHV-6B U46 and HST 
with the exception of subjects Orcadian2, 92 and 813 (% identity 99.95, 99.82 and 99.95 
respectively). 
 
Table 7-2: U47 Percentage nucleotide and amino acid sequence identity of iciHHV-6 
genomes with U1102 and 7-17p13.3. 
Genome 
Nucleotide % identity Amino acid % identity 
With 
U1102 
With 
7-17p13.3 
With 
U1102 
With 
7-17p13.3 
U1102 - 97.47 - 95.32 
GS 93.40 91.93 92.33 89.59 
AJ 93.10 92.04 91.56 90.05 
7-17p13.3 97.47 - 95.32 - 
3-10q23.3 97.58 99.26 95.32 98.71 
98485 97.58 99.68 95.48 99.52 
20119 97.58 99.89 95.32 100.00 
4298 97.31 99.52 94.68 99.03 
1501 97.58 99.68 95.48 99.52 
18999 97.74 99.09 95.48 99.55 
 
Phylogenetic analysis was next performed on iciHHV-6, reference U47 and 42 partial (207 
bp) U47 CDS. There was clear distinction between HHV-6A and HHV-6B with a bootstrap 
value percentage of 99%. As with U46, AJ and GS formed a separate clade from other 
HHV-6A sequences. All other HHV-6A groupings had bootstrap percentages less than 70%, 
but 1501, 20119, 98485 and 7-17p13.3 grouped in a different clade to other sequences. 
HHV-6B showed minimal divergence, but there were only three exogenous HHV-6B 
sequences included in the analysis (Z29, HST and 467M6Gi). 
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Figure 7-3: Phylogenetic analysis of partial CDS of U47 for iciHHV-6A and iciHHV-6B, 
and exogenously acquired HHV-6A and HHV-6B. Asterisks indicate iciHHV-6 sequence 
and branch labels indicate bootstrap percentages. 
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7.3.4 U48 
The complete U48 CDS is conserved in all iciHHV-6B sequences. Alignment and pairwise 
comparison shows little divergence between reference HHV-6A and iciHHV-6A sequences 
(Table 7-3). Although overall there is only a small difference in percentage identity, 
divergence amongst iciHHV-6A sequences is less than between iciHHV-6A and reference 
U48. Pairwise comparison of iciHHV-6B and reference strains shows 100% nucleotide 
sequence identity with HST with the exception of subjects 813, 7022, NewP and LCL 7-
17p13.3. 
 
Table 7-2: U47 Percentage nucleotide and amino acid sequence identity of iciHHV-6 
genomes with U1102 and 7-17p13.3. 
Genome 
Nucleotide % identity Amino acid % identity 
With 
U1102 
With 
7-17p13.3 
With 
U1102 
With 
7-17p13.3 
U1102 - 98.75 - 98.99 
GS 99.95 98.80 100.00 98.99 
AJ 99.90 98.75 99.86 98.58 
7-17p13.3 98.75 - 98.99 - 
3-10q23.3 98.80 99.28 99.28 99.71 
98485 98.71 99.95 98.99 100.00 
20119 98.75 100.00 98.99 100.00 
4298 98.85 99.62 98.85 99.28 
1501 98.71 99.95 98.99 100.00 
18999 98.80 99.28 99.28 99.71 
 
Phylogenetic analysis of complete iciHHV-6 and exogenously acquired HHV-6 U48 
sequences revealed clear separation between iciHHV-6A and iciHHV-6B (Fig. 7-4). In a 
previous study U48 of HHV-6B grouped into two clades (Achour et al., 2008). This is also 
seen here; one iciHHV-6B sequence is present in clade gB-B1 and the remainder in gH-B2. 
HHV-6A also displays two distinct clades (gH-A1 and gH-A2). All iciHHV-6A sequences 
group in gH-A2, a divergent clade with multiple branches. 
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Figure 7-4: Phylogenetic analysis of the complete nucleotide sequence of the U48 CDS 
for iciHHV-6A and iciHHV-6B, and exogenously acquired HHV-6A and HHV-6B. Asterisks 
indicate iciHHV-6 sequence and branch labels indicate bootstrap percentages. Both HHV-
6A and HHV-6B sequences group in two clades each: gH-B1 and gH-B2, and gH-A1 and gH-
A2. 
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7.3.5 U83 
HHV-6 U83 encodes a viral chemokine that is divergent both between and within HHV-6A 
and HHV-6B. Multiple forms of U83 have been described in the literature: first coding for 
a full length product (U83L), this is predominately seen in HHV-6B. HHV-6A U83 product 
lacks a region that functions as signalling peptide and this form is known as short form 
U83 (U83S). U83L is the complete unaltered product of the CDS, whilst U83S is the result 
of deletion of two thymine bases in a thymine mononucleotide repeat (Fig. 7-5). These 
deletions result in a frameshift mutation and a premature stop codon at amino acid 
position 23. Downstream of the start codon for U83L is a further start codon, transcription 
initiation from here would give rise to U83S. U83S is predominately seen in exogenously 
acquired HHV-6A genomes (Tweedy et al., 2015) 
 
U1102 U83L: ATGTCCATTCGGCTTTTTATTGGTTTTTTTTATACGGCATATATTGGTATGGCTATCGGA 
U1102 U83S: ATGTCCATTCGGCTTTTTATTGGTTTTTT--ATACGGCATATATTGGTATGGCTATCGGA 
 
Z29 U83L:   ATGTTCATTTGGCTTTTTATTGTTTTTTTTTATGCGGCATATATTGGTATGGCTATCGGA 
Z29 U83S:   ATGTTCATTTGGCTTTTTATTGTTTTTTT--ATGCGGCATATATTGGTATGGCTATCGGA 
Figure 7-5: Nucleotide alignment of U83L and U83S of HHV-6A and HHV-6B. In bold are 
the hypothesised utilised start codons; bold and underlined indicate the initiating start 
codon. 
 
U83 CDS of iciHHV-6A-positive subjects were present in both the long and short form. 
U83L was present in 4/7, and U83S was present in 2/7. Subject 4298 had incurred a G>T 
substitution at base 181 of the U83L CDS. This results in an amino acid change from 
glutamic acid to a stop codon at position 61. Sequence identity between iciHHV-6A and 
reference sequences is high, and slightly higher among iciHHV-6A sequences (Table 7-4). 
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Table 7-4: U83 Percentage nucleotide and amino acid sequence identity of iciHHV-6 
genomes with U1102 and 7-17p13.3. 
Genome 
Nucleotide % identity Amino acid % identity 
With 
U1102 
With 
7-17p13.3 
With 
U1102 
With 
7-17p13.3 
U1102 - 98.64 - 95.92 
GS 96.94 96.94 95.92 95.92 
AJ 98.30 98.94 94.90 96.94 
7-17p13.3 98.64 - 95.92 - 
3-10q23.3 97.62 98.98 93.88 100.00 
98485 98.62 100.00 95.92 100.00 
20119 98.64 100.00 95.92 100.00 
4298 98.30 99.66 95.92 100.00 
1501 98.64 100.00 95.92 100.00 
18999 97.62 98.98 93.88 97.96 
 
Pairwise comparison of iciHHV-6B and reference sequences revealed approximately 97% 
nucleotide sequence identity between iciHHV-6B and HST. Among iciHHV-6B nucleotide 
sequences there was 98-100% sequence identity (data not shown). 
For iciHHV-6B, sequence from subject 92 encodes the complete CDS for U83L. Sequence 
from subjects 813 and Cor264 have deletions at position 22 and 23 of the CDS, consistent 
with the frameshift that leads to U83S; however, these were followed by a further 
deletion at position 31. The latter mutation brought the U83L CDS back into frame, and 
the resulting protein product would be U83L that lacked a valine residue at amino acid 
position 8. The remaining 16/19 (84%) encoded U83S. 
As with all other regions phylogenetic analysis revealed good separation between iciHHV-
6A and iciHHV-6B nucleotide sequences. HHV-6A sequences were more divergent with a 
greater degree of branching; however, there were two main groups, U83-A1 and U83-A2. 
All iciHHV-6A sequences fall in the latter group. Similarly, HHV-6B U83 has two main 
groups, U83-B1 and U83-B2, with all iciHHV-6B in the latter (Fig. 7-6). Analysis of amino 
acid recapitulated these findings (data not shown).  
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Figure 7-6: Phylogenetic analysis of the complete nucleotide sequence of the U83 CDS 
for iciHHV-6A and iciHHV-6B, and 80 exogenously acquired HHV-6A and HHV-6B. 
Asterisks indicate iciHHV-6 sequence and branch labels indicate bootstrap percentages. 
Both HHV-6A and HHV-6B sequences group in two clades each: U83-A1 and U83-A2, and 
U83-B1 and U83.B2. 
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7.3.6 U90 
Finally the U90 region was analysed. U90 contains three ORFs, which after splicing of the 
RNA product generates IE-1. Nucleotide alignment and pairwise comparison of the full 
U90 region and ORFs of iciHV-6A and the reference strains revealed sequence identity in 
excess of 90% (Table 7-5). Alignment and pairwise comparison of amino acid sequence 
showed a similar degree of homology. Whilst there are synonymous and non-synonymous 
changes, no frameshift mutations are present. Nucleotide alignment and pairwise 
comparison of iciHHV-6B and Z29 highlighted high levels of sequence identity both 
between iciHHV-6B and Z29 (approximately 97%) and within iciHHV-6B (>99.5%). All three 
iciHHV-6B U90 ORFs are conserved. 
 
Table 7-5: U90 Percentage nucleotide and amino acid sequence identity of iciHHV-6 
genomes with U1102 and 7-17p13.3. 
Genome 
Nucleotide % identity Amino acid % identity 
With 
U1102 
With 
7-17p13.3 
With 
U1102 
With 
7-17p13.3 
U1102 - 97.76 - 94.58 
GS 97.73 98.06 95.32 95.11 
AJ 90.78 91.00 95.54 95.54 
7-17p13.3 97.76 - 94.54 - 
3-10q23.3 96.35 96.62 91.51 91.72 
98485 96.25 96.35 91.40 91.40 
20119 97.76 100.00 94.58 100.00 
4298 69.22 96.38 91.30 91.61 
1501 96.25 96.35 91.40 91.40 
18999 96.25 96.62 91.40 91.83 
 
Phylogenetic analysis was performed with complete U90 CDS from all iciHHV-6 sequence, 
U1102, GS, AJ and Z29 and 13 sequences from exogenous HHV-6 (Fig. 7-6). Compared to 
other regions, the U90 CDS phylogenetic tree showed a greater degree of branching, 
including clear separation of HHV-6A and HHV-6B with a bootstrap percentage of 100% 
(data not shown). iciHHV-6B grouped in two clades, though each clade had multiple 
branches with bootstrap percentages above 70%. All iciHHV-6B sequences grouped in the 
same clade displaying little variability, with the exception of Orcadian2 and Cor264 which 
were in a subclade including exogenous isolates (Fig. 7-7). 
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Figure 7-7: Phylogenetic analysis of the complete nucleotide sequence of the U90 CDS 
for iciHHV-6A and iciHHV-6B, and 13 exogenously acquired HHV-6A and HHV-6B. HHV-
6A and HHV-6B trees were generated as one but due to high degree of branching were 
separated by the function in MEGA6 to aid viewing, bootstrap percentage of HHV-6A and 
HHV-6B falling in separate clades was 100%. 
 
7.4 Discussion 
A phylogenetic analysis of five regions of the HHV-6A and HHV-6B genomes utilising 
nucleotide and amino acid sequence data from 26 iciHHV-6-positive individuals generated 
as part of an ongoing collaborative study. Sequence from U46, U47, U48, U83 and U90 
genes and ORFs were compared to reference sequences (U1102, GS, AJ, Z29 and HST) and 
additional sequences obtained from the NCBI database. 
In all five regions there was distinct separation of iciHHV-6A and iciHHV-6B sequences. 
There was no evidence that large scale homologous recombination has occurred between 
HHV-6A and HHV-6B. There have been several reports in the literature of possible small 
scale intragenic homologous recombination events in both exogenous HHV-6 and iciHHV-
6 and a more in depth analysis will be needed to address this here (Achour et al., 2008; 
Tweedy et al., 2015b). 
At all loci iciHHV-6A was more divergent than iciHHV-6B, with all trees showing multiple 
branches with bootstrap values above 70%. It was also noted that, with the exception of 
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U90, there was higher nucleotide and amino acid sequence identity within iciHHV-6A than 
between iciHHV-6A genomes and the HHV-6A reference strains U1102, GS and AJ. Analysis 
of U46, U47, U48 and U83 showed four subjects consistently grouping together on the 
same branch: 1501, 20119, 98485 and LCL 7-17p13.3. For U90 these four subjects were in 
different clades but within these clades 1501 and 98485, and 20119 and LCL 7-17p13.3 
are on the same branches respectively. This suggests possible shared ancestry between 
these viruses, and more detailed sequence analysis along with the integration site analysis 
would provide more information on this. Inherited chromosomally integrated HHV-6B was 
much less divergent than iciHHV-6A; at most loci many subjects had 100% nucleotide and 
amino acid sequence identity with the reference strains Z29. Although this lack of 
diversity could suggest a common viral ancestor, it was observed in exogenous sequences. 
Even when HHV-6B sequences grouped into two major clades, there was little branching 
observed within these clades. 
As has been discussed earlier the HHV-6 U83 ORF exists in two forms, encoding a full U83L 
or a smaller form lacking a signalling peptide (U83S). Of the iciHHV-6A U83 CDSs 4/7 
encoded U83L and 2/7 encoded U83S. Subject 4298 had a substitution mutation that 
resulted in a stop codon at amino acid position 61, resulting in a truncation in the U83L 
CDS. Among iciHHV-6B sequences, 3/19 (16%) encoded either complete U83L or one 
lacking a single valine residue. The remaining 16/19 (84%) encoded the complete U83S 
CDS. The results here are similar to those reported by Tweedy et al, (2014), who found 
50% iciHHV-6A had U83S, and 100% of iciHHV-6B had U83L; however, iciHHV-6A sequence 
with premature stop codons were not described. 
Although only five loci were examined here, there is some evidence to suggest a common 
viral ancestor in a subset of iciHHV-6A-positive subjects. In iciHHV-6B there is less 
diversity than iciHHV-6A; whilst it is possible that all iciHHV-6B have arisen from a 
common ancestor this could simply highlight a lack of diversity in HHV-6B isolates.  
In conclusion, U46, U47, U48 and U90 ORFs are conserved in all 26 iciHHV-6 genomes. 
Inherited chromosomally integrated HHV-6A genomes tend to group together and 
separately from reference and deposited exogenous sequences. In contrast iciHHV-6B 
lacked divergence from each other, reference and deposited exogenous sequences. To 
fully characterise the relationship between exogenous and iciHHV-6 analysis of complete 
genomes, including non-coding regions such as the length of TLRs is required.  
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8.1 Introduction 
Since the initial discovery of HHV-6 and its subsequent classification as two distinct but 
related viruses, HHV-6A and HHV-6B, our understanding of their life cycle and disease 
mechanisms have increased greatly. However, the ability of HHV-6A and HHV-6B to 
integrate into the human telomeres, inheritance, and consequences thereof remain 
relatively poorly understood.  
Although likely not the main form of latency, recent developments have highlighted that 
reactivation can occur from iciHHV-6. Studies have shown that sub-genomic regions can 
be excised from the integrated virus by the formation of T-loops, and that these 
extrachromosomal circles can be replicated. Clinical case reports have demonstrated that 
disease can arise from reactivation from iciHHV-6. These provides support for the 
hypothesis that integration into the telomeres of somatic cells is the true form of latency. 
Since iciHHV-6 only occurs in 0.5-2% of the general population it seems likely that iciHHV-
6 is incidental to this. Given the virus is present in every nucleated somatic cell of an 
iciHHV-6-positive individual, and the presence of the virus may have a destabilising effect 
on the telomere it is integrated on, phenotypic consequences could be numerous. 
The work in this thesis set out to address the possible consequences of iciHHV-6 for the 
host and the virus, and summarised and discussed here are the findings and implications 
for future research. 
 
8.2 Inherited chromosomally integrated HHV-6 and exogenously 
acquired HHV-6, and classical Hodgkin lymphoma 
In the largest study to date investigating any association between iciHHV-6 and cHL, 16 
iciHHV-6-positive cHL cases were identified with a prevalence of 1.7%. This was not 
significantly different from controls (1.8%). No associations were noted when cases were 
stratified by sex, tumour EBV status and cHL histological subtype. Older adult cases of 
cHL had a higher iciHHV-6 prevalence than younger adults, and this approached statistical 
significance. This finding was likely due to sample error, and it was concluded there is no 
association between iciHHV-6 and cHL. 
An analysis of exogenously acquired HHV-6 and cHL revealed that although HHV-6B was 
more prevalent in cHL tumours compared to reactive nodes (p = 0.001) the virus was often 
present at low level. This fact, together with the virus not being identifiable by FICTION 
in H/RS cells, led to the conclusion that HHV-6B is not directly involved in the 
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pathogenesis of cHL, but HHV-6 active infection in the tumour and possible H/RS cells is 
possible. 
 
8.3 Inherited chromosomally integrated HHV-6 in the Generation 
Scotland: Scottish Family Health Study – A hypothesis generating 
study 
In the largest study to date, the prevalence of iciHHV-6 in the Scottish population was 
found to be 2.7%. This is notably higher than that of other UK, European, Japanese and 
Canadian studies with over 100 participants. Further analysis revealed that the iciHHV-6 
prevalence in individuals born in Scotland (2.8%) was significantly different to the 
prevalence in individuals born in England (1.8%). The reasons behind this difference are 
not clear but could reflect different founder effects in the Scottish and English 
populations. The availability of GWAS data for the GS:SFHS cohort should allow for a 
deeper analysis of the possibility of founder effect. 
An investigation of iciHHV-6 association with self-reported disease revealed iciHHV-6-
positive females were twice as likely to have reported breast cancer. Although not 
statistically significant in the full study, significance was present in the unrelated sample 
set (p = 0.042). An increase in iciHHV-6 prevalence was also present in individuals that 
reported all other cancers except bowel cancer. Given the relatively low statistical power 
for investigating cancer these warrant further investigation. Although likely down to 
participant misreporting an association was found between iciHHV-6 and AD. Analysis of 
iciHHV-6 and angina pectoris confirmed a previously described association between the 
two, however with a smaller effect size (OR: 1.79). 
Females positive for iciHHV-6 had a statistically significantly lower Mill Hill vocabulary 
test score compared to iciHHV-6-negative females. Also noted was that iciHHV-6-positive 
individuals had participated in education for fewer years (p = 0.019). 
The study presented here is meant as a means of generating hypotheses for future tailored 
hypothesis testing studies, and has identified numerous avenues for this. 
 
8.4 Inherited chromosomally integrated HHV-6 genome 
configurations and dynamics 
Investigation in an LCL generated from an iciHHV-6A-positive individual revealed that the 
integrated genome is a dynamic structure. Through no deliberate manipulation, the 
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copies per cell of the U and DR sub-genomic regions was seen to fluctuate through time. 
It was postulated that viral sub-genomic regions were lost through T-loop formation and 
excision. The growth rate of the culture reduced at the time point prior to the observed 
drop in HHV-6 copies per cell, suggesting a reduction in cell viability possibly at the point 
of excision. The HHV-6 copy number gradually returned to approximately 1 copy per cell 
and this was likely caused by an outgrowth of cells where no loss had occurred, along with 
senescence and apoptosis of cells where viral sequence was lost. Taken together this 
suggests that excision of HHV-6 sub-genomic regions can occur, but this has consequences 
to on cell viability. 
Whilst loss of sub-genomic regions was observed in vitro, this was found to occur 
infrequently in iciHHV-6-positive individuals. In an ex vivo analysis of DNA from blood 
samples of 59 iciHHV-6-positive individuals, six were identified that displayed some 
degree of DR loss. Fifty-seven samples had approximately one U region per cell and two 
had two U regions per cell. Inheritance of a single DR region was identified in six 
individuals and was observed through multiple generations of two families. 
Through a novel ddPCR model the genomic configuration was predicted for an iciHHV-6-
positive individual that had four U and five DR regions per cell. The model supported the 
prediction of integration of a single HHV-6A genome concatemer that had the 
configuration (DR.U)4.DR. Although it is not clear how this concatemer was generated it 
is hypothesised that this is a replication intermediate, and integration resulted in the 
abortion of viral replication. Though it was not possible to predict the genome 
configuration through ddPCR, a further two individuals positive for HHV-6B genomes with 
the probable configuration (DR.U)2.DR were identified. For one of these individuals three 
family members were also identified with 2 U and 3 DR regions per cell. 
Data presented here highlight the dynamic nature of iciHHV-6 genomes, providing further 
evidence that regions of the viral genome can be excised from the telomere. For the first 
time the inheritance of viral genome concatemers is evidenced which may have 
implications on the consequences of integration of viral replication.  
 
8.5 A phylogenetic analysis of inherited chromosomally integrated 
HHV-6 
A phylogenetic analysis of five regions of 26 iciHHV-6 genomes revealed no evidence for 
large scale homologous recombination between HHV-6A and HHV-6B. At all loci iciHHV-
6A was more divergent than iciHHV-6B. There was a higher degree of nucleotide and 
amino acid homology with iciHHV-6A genomes than between iciHHV-6A genomes and the 
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HHV-6A reference strains. This was not observed in iciHHV-6B where homology was high 
between references and iciHHV-6B genomes. Examination of the CDS of all iciHHV-6 
genome revealed U83L and U83S at similar frequencies to that already reported in the 
literature. The frequency of U83S was slightly lower in iciHHV-6B genomes at 84% 
compared to 100% that has already been reported (Tweedy et al., 2015). 
Evidence for a common viral ancestor was observed in four iciHHV-6A genomes, who 
consistently grouped together in phylogenetic analysis of U46, U47, U48 and U83. In the 
analysis of U90, these subjects grouped in two different clades, subjects 1501 and 98485, 
and 20119 and LCL 7-17p13.3 were on the same branches within these clades. Due to the 
lack of diversity in iciHHV-6B and HHV-6B it was not possible to observe evidence of 
common ancestry. 
The analysis presented here only includes five viral regions due to the lack of available 
sequence from exogenous virus. To fully investigate characteristics of iciHHV-6 genomes, 
analyses of complete iciHHV-6 genomes and exogenously acquired HHV-6 genomes are 
needed.  
 
8.6 Concluding remarks 
The work in this thesis sheds light onto the complexity of iciHHV-6. As it becomes clearer 
that inheritance in the germ-line is not a dead-end for HHV-6, and that the integrated 
genome is a dynamic one, a detailed understanding of the consequences of, and the 
demographic associations with, iciHHV-6 is crucial. 
Presented in this thesis is the larger of only two population based studies of iciHHV-6 and 
its phenotypic associations. Such studies can provide a wealth of information for future 
study; allowing hypothesis generating and testing; identification of individuals and 
families positive for iciHHV-6; and determining the prevalence of iciHHV-6 in different 
populations. Due to the availability of detained pedigree information and GWAS data; 
further analysis of iciHHV-6 identified in the GS:SFHS cohort may allow for a more detailed 
understanding of the historical origins of iciHHV-6 in the Scottish, and British populations. 
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Appendix 1 
Table A1-1: Suppliers 
Supplier Address 
Agilent Technologies 
5301 Stevens Creek Boulevard, Santa Clara, California, 
95051, USA 
Bio-Rad Labortories 
Bio-Rad Laboratories Ltd., Bio-Rad House, Maxted Road, 
Hemel Hempstead, Hertfordshire, HP2 7DX 
CLC Bio Silkeborgvej 2, Prismet, 8000 Aarhus, Denmark 
Coulter Electronics Ltd. 
Oakley Court, Kingsmead Business Park, London Road, High 
Wycome, HP11 1JU 
Covaris Inc 14 Gill Street, Unit H, Woburn, Massachusetts, USA 
DNA2.0 1140 O'Brian Drive, Suite A, Menlo Park, CA 94025 
Dundee Cell Products 
James Lindsay Place, Dundee Technopole, Dundee, DD15 
5JJ 
Elkay Laboratory 
Products (UK) Ltd 
Unit E, Lutyens Industrial Centre, Bilton Road, Basingstoke, 
Hampshire, RG24 8LJ, UK  
Fisher Scientific Inc Bishop Meadow Road, Loughborough, LE11 5RG, UK  
GE Healthcare 
Amersham Place, Little Chalfont, Buckinghamshire, HP7 
9NA, UK  
Gilsons Scientific 20 Charles St. Luton, Bedfordshire, LU2 OEB, UK  
GraphPad Software Inc 7825 Fay Avenue, Suite 230 La Jolla, California, 92037, USA 
Haier Westgate House, Westgate Ealing, London, W5 1YY, UK  
IBM 
UK Head Office, PO Box 41, North Harbour, Portsmouth, 
Hampshire, PO6 3AU, UK 
Illumina 5200 Illumina Way, San Diego, California, 92122, USA 
Integrated DNA 
Technologies 
Leuven, Integrated DNA Technologies, BVBA, 
Intterleuvenlaan 12A, B-3001 Leuven, Belgium 
Integra Biosciences Tardisstrasse 201, CH-7205 Zizers, Switzerland 
KAPA Biosystems 
200 Ballardvale Street, Suite 250, Willington, Massachusetts, 
01887, USA 
Life Technologies Unit 3, Fountain Drive, Inchinnan, Renfrew PA4 9RF 
Microzone Ltd 
4 Heath Square, Boltro Road, Haywarth Heath, West Sussex, 
RH16 1BL, UK  
NCSS 329 North 1000 East Kaysville, Utah, 84037, USA 
New Brunswick 
Scientific/ Eppendorf 
Endurance House, Vision Park, Histon, Cambridge, CB24 
9ZR, UK 
Python Software 
Foundation 
9450 SW Gemini Drive, ECM~ 90772, Beaverton, OR 97008, 
USA 
Qiagen Ltd 
QIAGEN House, Fleming Way, Crawly, West Sussex, RH10 
9NQ, UK  
Sigma-Aldrich 
The Old Brickyard, New Road, Gillingham, Dorset, SP8 4XT, 
UK  
Thermo Scientific Inc 81 Wyman Street, Waltham, MA 02454, USA  
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Appendix 2 
Table A2-1: Assay primer and probe sequences 
Primer/Probe Name Sequence 
Β-globin Forward GGCAACCCTAAGGTGAAGGC 
Β-globin Reverse GGTGAGCCAGGCCATCACTA 
Β-globin Probe (TAMRA) 6-FAM-ATGGCAAGAAAGTGCTCGGTGCCT-TAMRA 
B-globin Probe (MGB) 6-FAM-GACTGCCCGCTACCA-DQ2 
U2A Forward GCACCAGCGCGGAAAC 
U2A Reverse TGCTGTCCCGGTATGGATCT 
U2 Probe 6-FAM/HEX-TCTGCGAAGATAGTGACCCCGATGACC-BHQ1 
U7 Forward AAAATTTCTCACGCCGGTATTC 
U7 Reverse CCTGCAGACCGTTCGTCAA 
U7 Probe (TAMRA) 6-FAM/VIC1-TCGGTCGACTGCCCGCTACCA-TAMRA 
U7 Probe (MGB) VIC- GACTGCCCGCTACCA-DQ2 
HHV-6B Pol Forward GGCCAGCCAGTCCTTTAGTAGA 
HHV-6B Pol Reverse GGATGAGACCCATCGGTTTGTG 
HHV-6B Pol Primer HEX-TTCCAAGCACAGACTCGCGAACACAAGG-BHQ1 
HHV-6A Pol Forward GGCCAGCCAGTCCTTTAGTAGA 
HHV-6A Pol Reverse GGATGAGACTCATCGGTTTGTG 
HHV-6A Pol Probe HEX-TCCCAAGCACAGACTCACGGATACAAGG-BHQ1 
U100A2 Forward GGCCGTCGCCATCGA 
U100A2 Reverse AGGCTGAGCGCTATGAAACC 
U100A2 Probe 6-FAM- AACGCGCACAAAAATATCAGCGCAC-BHQ1 
HHV-6 DR1 Forward GAAACTGTAACGGCCACGTT 
HHV-6 DR1 Reverse GTGCTCCGCCACGACTAC 
HHV-6 DR1 Probe HEX-CGCCGCCGCCGTTACTGTC-BHQ1 
HHV-6A DR6 Forward CGGCATCGCGGAGAAC 
HHV-6A DR6 Reverse TGTACGGATCGTGGTGGAGTT 
HHV-6A DR6 Probe HEX-CCACCTACCGTGGCCGCCGT-BHQ1 
HHV-6B DR6 Forward GCAGGCCGTCCAAACTGT 
HHV-6B DR6 Reverse ACGGTAGGTGGATCCGTTCTC 
HHV-6B DR6 Probe HEX-CGGCTATACGAGTCGGCACCGG-BHQ1 
16-FAM labelled probe used in singleplex, VIC labelled probe used in duplex, 2DQ: Dark 
Quencher 
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Appendix 3 
 
Table A3-1: RPP30 and viral component concentrations, and estimated copies per cell for each replicate, and day, for ‘in reaction’ digest ddPCRs 
Day 
U7 DR6A HHV-6A Pol DR6B HHV-6B Pol 
RPP30 U7 Copy/Cell RPP30 DR6A Copy/Cell RPP30 Pol Copy/Cell RPP30 DR6B Copy/Cell RPP30 Pol Copy/Cell 
1 1530 813 1.06 1649 1508 1.83 1600 870 1.09 1890 1570 1.66 1950 963 0.99 
1 1480 763 1.03 1559 1473 1.89 1540 830 1.08 1740 1450 1.67 1680 845 1.01 
1 1560 842 1.08 1547 1426 1.84 1510 832 1.10 1780 1510 1.70 1780 877 0.99 
1 1530 807 1.05 1525 1424 1.87 1420 800 1.12 1720 1390 1.62 1730 876 1.01 
1 1520 812 1.06 1521 1399 1.84 1520 811 1.07 1670 1390 1.67 1770 864 0.98 
1 1530 823 1.08 1499 1432 1.91 1470 818 1.11 1740 1470 1.68 1790 887 0.99 
1 1500 799 1.06 1507 1446 1.92 1530 795 1.04 1780 1450 1.63 1760 867 0.98 
1 1440 747 1.04 1488 1403 1.89 1460 802 1.10 1770 1440 1.63 1770 898 1.01 
2 1590 875 1.10 1570 1550 1.97 1590 872 1.10 3190 2790 1.75 1460 721 0.99 
2 1530 838 1.09 1520 1500 1.97 1520 842 1.11 1930 1530 1.59 2170 1060 0.98 
2 1530 832 1.09 1630 1580 1.94 1490 808 1.08 1780 1430 1.60 2830 1390 0.98 
2 1650 868 1.05 1470 1450 1.98 1530 821 1.08 1490 1140 1.53 2290 1110 0.97 
2 1610 835 1.04 1540 1530 1.98 1610 876 1.09 2160 1740 1.61 2610 1280 0.98 
2 1530 817 1.06 1520 1450 1.92 1490 820 1.10 1680 1350 1.60 2170 1100 1.01 
2 1540 833 1.08 1470 1460 1.99 1550 839 1.08 1880 1580 1.68 499 241 0.97 
2 1560 830 1.07 1520 1490 1.96 -  - - 907 697 1.54 - - - 
RPP30 and viral component concentration units are copies µl-1.  
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Table A3-2: RPP30 and viral component concentrations, and estimated copies per cell for each replicate, and day, for pre-digest ddPCRs 
Day 
U7 DR6A HHV-6A Pol DR6B  HHV-6B Pol 
RPP30 U7 Copy/Cell RPP30 DR6A Copy/Cell RPP30 Pol Copy/Cell RPP30 DR6B Copy/Cell RPP30 Pol Copy/Cell 
1 1340 684 1.02 1390 1420 2.05 1400 669 0.95 1460 1360 1.87 1530 689 0.90 
1 1310 672 1.02 1340 1350 2.02 1320 653 0.99 1390 1330 1.91 1430 642 0.90 
1 1340 673 1.00 1290 1290 2.00 1320 638 0.97 1390 1290 1.85 1450 662 0.91 
1 1370 689 1.00 1310 1340 2.04 1310 628 0.96 1390 1290 1.86 1410 634 0.90 
1 1320 657 1.00 1270 1320 2.07 1310 631 0.96 1420 1350 1.90 1350 614 0.91 
1 1290 653 1.02 1270 1300 2.05 1320 658 0.99 1390 1320 1.90 1360 634 0.93 
1 1290 660 1.02 1290 1340 2.08 1260 627 0.99 1390 1270 1.82 1410 625 0.89 
1 1300 655 1.01 1350 1360 2.01 1260 614 0.97 1370 1310 1.91 1400 625 0.89 
2 1090 544 1.00 1090 1100 2.00 1040 520 1.00 1430 1330 1.86 1430 657 0.92 
2 1050 539 1.03 1020 1070 2.09 1060 517 0.98 1370 1330 1.94 1390 644 0.93 
2 1060 525 0.99 1030 1070 2.08 1010 522 1.04 1390 1310 1.88 1390 620 0.89 
2 1070 543 1.02 1030 1060 2.07 990 493 1.00 1330 1250 1.88 1350 611 0.91 
2 1050 519 0.99 1030 1080 2.09 1030 493 0.96 1370 1310 1.91 1380 632 0.92 
2 1050 531 1.01 1050 1070 2.04 1090 552 1.01 1450 1300 1.80 1370 602 0.88 
2 1090 542 0.99 1070 1090 2.04 1030 512 1.00 1420 1360 1.92 1380 629 0.91 
2 1130 541 0.95 1070 1080 2.03 -  - - 1430 1300 1.83 - - - 
RPP30 and viral component concentration units are copies µl-1. 
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Appendix 4 
Table A4-1: Summary of categorical disease variables examined in the primary analysis 
of the GS:SHFS (totals and frequencies represent the data analysed after exclusion of 
poorly amplifying samples). 
Disease 
Positive 
N(%) 
Negative 
N(%) 
Total 
N 
Cardiovascular and respiratory disease    
Asthma 2,607 (11.3) 20,544 (88.7) 23,151 
COPD1 265 (1.1) 22,878 (98.9) 23,143 
High blood pressure  3,137 (13.7) 19,979 (86.3) 23,151 
Stroke 339 (1.5) 22,812 (98.5) 23,151 
Cancers    
Any cancer 551 (2.4) 22,600 (97.6) 23,151 
Bowel cancer 138 (0.6) 23,013 (99.4) 23,013 
Breast cancer (female only) 319 (2.3) 13,323 (97.7) 13,642 
Lung cancer 62 (0.3) 23,089 (99.7) 23,151 
Prostate cancer (male only) 86 (0.9) 9,423 (99.1) 9,503 
Degenerative disease    
Alzheimer’s disease 40 (0.2) 23,111 (99.8) 23,151 
Parkinson’s disease 54 (0.2) 23,097 (99.8) 23,151 
Joint and bone related    
Hip fracture 126 (0.5) 23,025 (99.5) 23,151 
Rheumatoid arthritis  419 (1.8) 22,732 (98.2) 23,151 
Osteoarthritis 1,731 (7.5) 21,420 (92.5) 23,151 
Other disease    
Depression 2,135 (9.2) 21,016 (90.8) 23,151 
Diabetes 776 (3.4) 22,375 (96.6) 23,151 
1Chronic obstructive pulmonary disease (COPD) 
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Table A4-2: Summary of social characteristics examined in the primary analysis of the 
GS:SFHS cohort (totals and frequencies represent the data analysed after exclusion of 
poorly amplifying samples). 
Characteristics 
Frequency 
N(%) 
Characteristics 
Frequency 
N(%) 
Ethnicity  Postcode area (continued)  
Asian 112 (0.5) Paisley 660 (3.2) 
Black 16 (0.1) Perth 3,343 (16.1) 
Mixed 108 (0.5) Galashiels 58 (0.3) 
White 22,401 (96.4) Lerwick 29 (0.1) 
Other 24 (0.1) Total: 20,823 (100) 
Not specified 566 (2.4) Years in education  
Total: 23,227 (100) 0 8 (0.1) 
Nationality  1-4 41 (0.3) 
African 9 (0.0) 5-9 415 (3.3) 
Caribbean 9 (0.0) 10-11 3,102 (25) 
Chinese 12 (0.1) 12-13 2,547 (20.5) 
English 1,528 (6.6) 14-15 1,846 (10.8) 
Indian 45 (0.2) 16-17 2,544 (20.5) 
Irish 230 (1.0) 18-19 1,338 (10.8) 
Northern Irish 54 (0.2) 20-21 379 (3.1) 
Pakistani 23 (0.1) 22-23 121 (1.0) 
Scottish 19,802 (85.3) 24+ 59 (0.5) 
Welsh 46 (0.2) Total: 12,400 
Other 404 (1.7) Qualification level  
Not specified 1,065 (4.6) No qualification 1,842 (8.4) 
Total: 23,227 (100) Standard Grade/O-level 3,529 (16.1) 
Postcode area  Higher Grade 2,412 (11.0) 
Aberdeen 1,399 (6.7) University degree 7,194 (32.8) 
Dundee 5,895 (28.3) Other professional/technical 6,324 (28.9) 
Dumfries and Galloway 48 (0.2) Other qualification 602 (2.7) 
Edinburgh 725 (3.5) Total: 21,903 (100) 
Falkirk 263 (1.3) SIMD1 Quintile  
Glasgow 7,055 (33.9) 1st 2,681 (12.9) 
Inverness 149 (0.7) 2nd 2,937 (14.1) 
Kilmarnock 307 (1.5) 3rd  3,369 (16.2) 
Kirkwell 34 (0.2) 4th 5,347 (25.7) 
Kirkaldy 538 (2.6) 5th 6,489 (31.2) 
Motherwell 289 (1.4) Total: 20,823 (100) 
Outer Hebrides 31 (0.1)   
1Scottish index of material depravation (SIMD) 
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Table A4-3: Summary of continuous variable examined in the primary analysis of the 
GS:SFHS, stratified my sex (means represent the data analysed after exclusion of poorly 
amplifying samples). 
Characteristic 
Mean (±SD1) 
Female Male 
Body measurements   
Age (years) 47.8(±15.3) 47.4(±15.5) 
BMI2 26.5(±5.7) 26.9(±4.5) 
Height (cm) 162.5(±6.6) 176.2(±7.0) 
Wight (kg) 70.0(±15.2) 83.5(±14.9) 
Cognitive, memory and reasoning   
GHQ3 score 2.6(±4.2) 2.0(±3.6) 
Likert score 16.7(±9.2) 14.9(±8.2) 
Logical memory score (immediate) 16.5(3.8) 15.4(±4.0) 
Logical memory score (delayed) 15.4(±4.2) 14.2(±4.4) 
Verbal fluency score 39.8(±11.7) 39.5(±11.8) 
Mill Hill vocabulary score 29.7(±4.7) 30.6(±4.8) 
1Standard deviation (SD) 
2Body Mass Index (BMI) 
3General health questionnaire (GHQ) 
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Table A4-4: Mean (±SD) scores of cognitive variables and iciHHV-6 status, stratified by 
sex 
 
Test 
Full cohort 
p value iciHHV-6 
negative 
iciHHV-6 
positive 
GHQ score    
Female 2.6(±4.2) 3.0(±4.2) 0.128 
Male 2.0(±3.5) 2.0 (±3.4) 0.909 
Likert score    
Female 16.7(±9.1) 17.5(±8.7) 0.124 
Male 14.9(±8.1) 14.6(±7.8) 0.606 
Logical memory score 
(immediate) 
   
Female 16.6(±3.8) 16.3(±3.9) 0.155 
Male 15.5(±4.0) 15.2(±4.2) 0.314 
Logical memory score 
(delayed) 
   
Female 15.4(±4.2) 15.2(4.3) 0306 
Male 14.2(±4.4) 14.0(±4.6) 0.453 
Verbal fluency score    
Female 39.9(±11.7)  39.3(±10.9) 0.373 
Male 39.5(±11.8) 39.3(±11.9) 0.769 
Mill Hill vocabulary score    
Female 29.8(±4.7) 29.2(±4.7) 0.039 
Male 30.5(±4.8) 30.7(±4.9) 0.609 
Italics indicate statistical significance 
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Appendix 5 
The bellow model was produced by, and is summarised below by Dr Paul Johnson 
(University of Glasgow) 
 
A statistical model for inferring linkage between two fragments from ddPCR data 
Overview 
The aim of the analysis is to infer the strength of linkage between two fragments, A and 
B, from their presence or absence in 𝑛 droplets from a ddPCR assay. The assay assigns 
each droplet to one of four classes: 
(1) Neither fragment was detected 
(2) Only A was detected 
(3) Only B was detected 
(4) Both A and B were detected. 
The data consist of the numbers of droplets counted in each class. 
 
Model 
We modelled the four ddPCR counts, 𝐲 = 𝑦1, … , 𝑦4, as drawn from a multinomial 
distribution with proportions 𝐩 = 𝑝1, … , 𝑝4: 
𝐲 ~ Multinomial(𝑛, 𝐩), 
where 𝑛 = ∑ 𝑦𝑖𝑖 . The proportions, 𝐩, are modelled as a mixture of the classes 1-4 
proportions arising from unlinked fragments, 𝐩(𝑢), with those arising from linked 
fragments, 𝐩(𝑙). The parameter governing the proportion of the fragments that come from 
the linked rather than the unlinked model is 𝜋, so that  
𝐩 = (1 − 𝜋)𝐩(𝑢) + 𝜋𝐩(𝑙). 
The parameter 𝜋 can be interpreted as a measure from 0 to 1 of the degree of linkage 
between A and B. The aim of this analysis is therefore to estimate 𝜋.  
The proportions under both the unlinked and linked models are determined by the mean 
numbers of A and B fragments per droplet, 𝛼 and 𝛽, respectively. The expected 
distribution of the 𝑛 droplets across classes 1 to 4 differs markedly between the unlinked 
and linked models, providing the signal that allows 𝜋 to be estimated. The distribution of 
fragments over droplets is assumed to be Poisson. Using the Poisson probability mass 
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function, the proportions of droplets with no A fragments is 𝑒−𝛼, and the proportion with 
no B fragments is 𝑒−𝛽. The proportions with any A and any B fragments are therefore 
1 − 𝑒−𝛼 and 1 − 𝑒−𝛽, respectively. Under the unlinked model, which assumes that the 
probabilities of observing A and B fragments are independent, the proportion with neither 
A nor B is simply the product of these marginal proportions, 𝑒−𝛼−𝛽. The expected 
proportions in the other three classes can be similarly calculated as the product of the 
margins (Table A5-1). 
 
Table A5-1. Expected proportions of droplets with none, either or both A and B fragments 
under the unlinked model. 
 B absent B present Total 
A absent 𝑝1
(𝑢)
= 𝑒−𝛼−𝛽 𝑝3
(𝑢)
= 𝑒−𝛼(1 − 𝑒−𝛽) 𝑒
−𝛼 
A present 𝑝2
(𝑢)
= 𝑒−𝛽(1 − 𝑒−𝛼) 𝑝4
(𝑢) = (1 − 𝑒−𝛼)(1 − 𝑒−𝛽) 1 − 𝑒
−𝛼 
Total 𝑒−𝛽 1 − 𝑒−𝛽 1 
 
The marginal proportions under the linked model are the same as under the unlinked 
model (Table A5-2). However, the proportion of droplets with neither fragment is now 
determined by the concentration of whichever fragment is in excess, max (𝛼, 𝛽), as 
𝑒−max (𝛼,𝛽). As with the unlinked model, the other three proportions can be calculated 
from the margins (Table A5-2).  
 
Table A5-2. Expected proportions of droplets with none, either or both A and B fragments 
under the linked model.  
 B absent B present Total 
A absent 𝑝1
(𝑙)
= 𝑒−max (𝛼,𝛽) 𝑝3
(𝑙)
= 𝑒−𝛼 − 𝑒−max (𝛼,𝛽) 𝑒
−𝛼 
A present 𝑝2
(𝑙)
= 𝑒−𝛽 − 𝑒−max (𝛼,𝛽) 𝑝4
(𝑙)
= 1 + 𝑒−max (𝛼,𝛽) − 𝑒−𝛼 − 𝑒−𝛽 1 − 𝑒
−𝛼 
Total 𝑒−𝛽 1 − 𝑒−𝛽 1 
 
The model was fitted to the data using Monte Carlo Markov Chain (MCMC) using JAGS in 
R. Three independent Markov chains were each run for 1 million iterations with a thinning 
rate of 100 and following burn-in of 1 million. The prior distributions for log(𝛼) and log(𝛽) 
were normal with means of zero and variances of 100 and the prior for 𝜋 was uniform 
from zero to one. Posterior modes and 95% credible intervals (CI) were estimated directly 
from the combined MCMC samples from the joint posterior distribution of the parameters. 
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Appendix 6 
Presented below in Table A6-1 and A6-2 are primer pairs used to amplify overlapping fragments over the complete length of the HHV-6A and HHV-6B 
genomes. Primers pairs suffixed by ‘A’ are specific to HHV-6A, those suffixed by ‘B’ are specific to HHV-6B. All primer pairs with the exception of ‘6A’ 
and ‘6B’ were designed by E Zhang (University of Leicester). Primer pairs ‘6A’ and ‘6B’ were used on subjects DNA that did not generate product with 
primer pair 6. 
 
Table A6-1: Primer pairs used to amplify overlapping fragments spanning the complete HHV-6A genome. 
Primer pair Primer name 
Primer Sequence 
(5’-3’) 
Primer first base position 
(U1102) 
TA (oC) 
Extension time 
(minutes) 
1A 
DR1F HST/KUK ACCTTGGCCCGAGCAAGAATGC 638 
62 12 
DR8RA GGATTACGGAGGTGAATGTTGC 7451 
2A 
DR8F GCAGAGACAAAAGTATGCGGAAG 7274 
52 8 
HHV6A probe 40R GCGATTCTCGTATCGGGTTA 11913 
3A 
HHV6A probe 51F GGATACACCCCACTCCACAT 11666 
60 8 
HHV6A probe 51R GAGTGCAATACAGAAGCCGG 17492 
4A 
HHV6A probe 42 F CCATTTCTTGCGAATGTTGA 17282 
58 8 
HHV6A probe 42 R GATACGTCAAGACGGGGAAA 19068 
5 
HHV6 probe 5F1(U11) TTTTTACATCACGACGCGATC 18958 
52 8 
HHV6 probe 5R ATGGTCCTCCATGGGTTCTT 24962 
6 
HHV6 probe 18 F ATGGCGCACGCTAAAAAG 22898 
56 8 
HHV6 probe 6R2 TGTAACGGAGGAATGGGAAG 30570 
6A 
HHV6 probe 18 F2 TCGACAGACGACCCCATATT 22940 
56 8 
HHV6 probe 6RA GGTCAAGTGCTTGGATATGAAG 30500 
7A 
HHV6A probe 43 F GGCAGTTGTCCAAAAATCTGA 30426 
58 8 
HHV6A probe 43 R CCTGACTGTGGTCAACAACG 37177 
8 
HHV6 probe 17 F TCGAACTAAACCCGAGACCT 37029 
56 8 
HHV6 probe 17 R GCCATGTGGTTTGAGAGGAT 43487 
9 
HHV6 probe 7F CGAAAAGCTCATGCTTACCC 43364 
56 8 
HHV6 probe 7R AACTTGAAGCTGGCGACATT 49363 
10 
HHV6 probe 13 F TCTCACTTCCGAAACTTCTATGC 49268 
62 8 
HHV6 probe 13 R CAGTTGTTGCTTCCGATTCC 52664 
11A 
HHV6A probe 52F TATCCGCTCGAACACCAACT 52047 
60 8 
HHV6A probe 52R CCAGCAAGAAAAGGAGCAGT 58242 
12 HHV6 probe 15 F CGTGACGTGTGCCAATCT 58062 62 8 
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HHV6 probe 15 R GCTCAGTTGTCGAGGGAGAC 62168 
13A 
HHV6A probe 50 F CATCAAAAAGACAGCCAGGA 62039 
56 8 
HHV6A probe 50 R GTTGGTATGGCCGAAGATCA 67338 
14 
HHV6 probe 32 F ACACGCAACATGGCAAATAA 67168 
60 8 
HHV6 probe 32 R CGTGCCATAGCGAAATGTAA 72346 
15A 
HHV6A probe 49 F CAGGAAAGGGACGGTGATAA 72178 
58 8 
HHV6A probe 49 R ATCGAAAGCACCACCTTCAC 76670 
16A 
HHV6A probe 30F2 GTGAAGGACCGTTGAGGTGT 76150 
56 8 
HHV6 probe 30 R ATGCTTGCCTTTTCTCATGG 81675 
17 
HHV6 probe 29 F TGTCTCTCCTTCTGGCACCT 81594 
62 8 
HHV6 probe 29 R GCAATCTTAGCAGCCGACTC 85341 
18A 
HHV6A probe 47 F GCTGTCGAGTCCACCATTTT 85168 
56 8 
HHV6A probe 47 R TAACGTTCGGCGGAATTAAC 90530 
19 
Probe3 C1 CGCAGATAGCTTGTTGACCA 90465 
56 8 
Probe3 C2 CACTTCAGTTCCAGGGGTGT 96597 
20 
HHV6 probe 11 F CGGAAACCATAGCTGTCCAT 96291 
52 8 
HHV6 probe 11 R GCTTATGCTTCCCAATTCCA 100877 
21 
HHV6 probe 24 F GCGGTAAACGGCATACATTT 100767 
58 8 
HHV6 probe 24 R TGTACCTGGCAGCATCTGAG 103429 
22 
HHV6 probe 25 F ATTGTTTATGCGTGCAGACG 103377 
56 8 
HHV6 probe 25 R CCGTTGCTTTCTCTTCCATC 107612 
23 
Probe4 D1 GGGTTTAACGTAGCGAACCA 107521 
58 8 
Probe4 D2 CCGGAGAATGAAATCCTTGA 113415 
24A 
HHV6A probe 41 F TCGGACGTGTAAGATGTTGAA 113343 
60 8 
HHV6A probe 41 R CGGATCACTCCCGAAATCTA 117406 
25 
HHV6A probe 44 F GGTGGATTACGCCACTGTTT 117310 
60 8 
HHV6A probe 44 R AAACTGCACGAAATCCGAAG 123286 
26 
HHV6 probe 9F GCGCAAACAATGTGCGTAGT 123087 
56 8 
HHV6 probe 9R TCTCCTCTTCCGTTGACACC 128903 
27A 
HHV6A probe 45 F TATCTTTGGTCGGGGCTCTT 128732 
58 8 
HHV6A probe 45 R TGATTGCAACAGTGATGGTACA 133181 
28 
HHV6 probe 21 F CACATCTGTATGCTAATGATTGCT 133039 
56 8 
HHV6 probe 21 R AGATTGATTGCACCCGAAAC 137011 
29 
HHV6 probe 27 F CAAGGTGGAGGTTTCTTTGG 136954 
52 8 
HHV6 probe 27 R AGGACCGTGTCCCATCATAG 141622 
30A 
HHV6A probe 48 F CTGGCCCAAAACAGAAATTG 141446 
58 8 
HHV6A probe 48 R GAGAGTTTTCCATGGCCACA 145806 
31 
HHV6 probe 26 F CATGGTGGTTCTCCTGTGTG 145628 
58 8 
HHV6 probe 26 R GAGGGTGGGCACGTATTTTA 147897 
32A 
HHV6A probe 46F GGTCAGGTCCTCACGACAGT 147806 
60 8 
DR1R GAAGAAGATGCGGTTGTCTTGTT 151965 
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Table A6-2: Primer pairs used to amplify overlapping fragments spanning the complete HHV-6B genome. 
Primer pair Primer name 
Primer Sequence 
(5’-3’) 
Primer first base position 
(HST) 
TA (oC) 
Extension time 
(minutes) 
1B 
DR1F (HST/KUK) ACCTTGGCCCGAGCAAGAATGC 638 
62 12 
DR8RB CGCCCGCGACTGCCATAGAG 8168 
2B 
Pac2F TGGGAGGCGCCGTGTTTTTC 8480 
60 8 
HHV6 probe 10 R TTGCATCGATACCGTTTCTG 12828 
3B 
Probe A1 TCACCGGATTCGACATGTAA 12518 
56 8 
Probe A2 TTAAAGTACGGGGTGCAAGG 18237 
4B 
HHV6 probe 14 F ACACTCGCATTCCGAAAGTT 18157 
56 8 
HHV6 probe 14 R AGTCGCTGAGTCCTTGGGTA 19855 
5 
HHV6 probe 5F (U11) TTTTTACATCACGACGCGATC 19793 
52 8 
HHV6 probe 5R ATGGTCCTCCATGGGTTCTT 25767 
6 
HHV6 probe 18 F ATGGCGCACGCTAAAAAG 23699 
56 8 
HHV6 probe 6R2 TGTAACGGAGGAATGGGAAG 31513 
6B 
HHV-6 Probe 18FB TCGCTCCACTCCAACTTCTATTC 25581 
52 8 
HHV-6 Probe 6RB CTGCGGCTCCGGAGAG 31487 
7B 
HHV6 probe 16 F CCAAGCACTTGACCAGTTGA 31430 
57 8 
HHV6 probe 16 R TTGTCGGGACTGATGATGAA 38065 
8 
HHV6 probe 17 F TCGAACTAAACCCGAGACCT 37990 
56 8 
HHV6 probe 17 R GCCATGTGGTTTGAGAGGAT 44442 
9 
HHV6 probe 7F CGAGAAGCTCATGCTTACCC 44319 
56 8 
HHV6 probe 7R AACTTGAAGCTGGCGACATT 50318 
10 
HHV6 probe 13 F TCTCACTTCCGAAACTTCTATGC 50223 
61 8 
HHV6 probe 13 R CAGTTGTTGCTTCCGATTCC 53624 
11B 
Probe B1 TCGGTCTGCTCATAGTCACG 53545 
56 8 
Probe B2 CAGGGCTGTTGTCGGTAAAT 59130 
12 
HHV6 probe 15 F CGTGACGTGTGCCAATCT 59016 
61 8 
HHV6 probe 15 R GCTCAGTTGTCGAGGGAGAC 63122 
13B 
HHV6 probe 33 F TCATCTTGCTCATTCTCCCTAA 63022 
54 8 
HHV6 probe 33 R TCACTTGCAGTCGTTTGAGG 68230 
14 
HHV6 probe 32 F ACACGCAACATGGCAAATAA 68122 
60 8 
HHV6 probe 32 R CGTGCCATAGCGAAATGTAA 73235 
15B 
HHV6 probe 31 F TCGGAAGCGGAGATTTCTAA 73144 
60 8 
HHV6 probe 31 R CCACCTTCGCAACAACAATA 77701 
16B 
HHV6 probe 30 F TGAATTTTGTCGTGCTCTGC 77591 
56 8 
HHV6 probe 30 R ATGCTTGCCTTTTCTCATGG 82740 
17 HHV6 probe 29 F TGTCTCTCCTTCTGGCACCT 82659 62 8 
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HHV6 probe 29 R GCAATCTTAGCAGCCGACTC 86410 
18B 
HHV6 probe 23 F AGCAGCCGAAAGTAGTTCCA 86317 
57 8 
HHV6 probe 23 R TCGGCGGAATTAACAAAAAC 91648 
19 
Probe C1 CGCAGATAGCTTGTTGACCA 91589 
56 8 
Probe C2 CACTTCAGTTCCAGGGGTGT 97721 
20 
HHV6 probe 11 F CGGAAACCATAGCTGTCCAT 97415 
52 8 
HHV6 probe 11R GCTTATGCTTCCCAATTCCA 102007 
21 
HHV6 probe 24 F GCGGTAAACGGCATACATTT 101897 
57 8 
HHV6 probe 24 R TGTACCTGGCAGCATCTGAG 104562 
22 
HHV6 probe 25 F ATTGTTTATGCGTGCAGACG 104510 
56 8 
HHV6 probe 25 R CCGTTGCTTTCTCTTCCATC 108762 
23 
Probe D1 GGGTTTAACGTAGCGAACCA 108671 
56 8 
Probe D2 CCGGAGAATGAAATCCTTGA 114565 
24B 
HHV6 probe 12 F CATGGTTCCGTCTTCCAAGT 114379 
52 8 
HHV6 probe 12 R TGTGTGGAAACACCCTTCAA 120115 
25 
HHV6 probe 19 F CGGAGATATGACAAGTAGAGAGAGG 120053 
62 8 
HHV6 probe 19 R CAATGAATTCCTCAGCGACT 124330 
26 
HHV6 probe 9F GCGCAAACAATGTGCGTAGT 124263 
56 8 
HHV6 probe 9R TCTCCTCTTCCGATGACACC 130529 
27B 
HHV6 probe 20 F GTGTGGTGGAGTTCCGAGTT 130444 
56 8 
HHV6 probe 20 R TGATCCATTCGAAGAAAATGC 134841 
28 
HHV6 probe 21 F CACATCTGTATGCTAATGATTGCT 134756 
56 8 
HHV6 probe 21 R AGATTGATTGCACCCGAAAC 139157 
29 
HHV6 probe 27 F CAAGGTGGAGGTTTCTTTGG 139099 
60 8 
HHV6 probe 27 R AGGACCGTGTCCCATCATAG 142911 
30B 
HHV6 probe 28 F TGGATATTTGAATGTACCATCGAG 142846 
56 8 
HHV6 probe 28 R TCGTGTTTAGAGTCCCGGTAA 147255 
31 
HHV6 probe 26 F CATGGTGGTTCTCCTGTGTG 147190 
57 8 
HHV6 probe 26 R GAGGGTGGGCACGTATTTTA 149441 
32B 
HHV6 probe 22 F AACGGTCAGGTTCTCACGAC 149347 
56 8 
HHV6 probe 22 R TATCTGTCTTCCAGAGCAACAG 153042 
33B 
U100Fw2 TATCTCCGAACATGATGCTG 151384 
62 13 
DR1R GAAGAAGATGCGGTTGTCTTGTT 153849 
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